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Thesis Summary 
 
This thesis addresses the mitigation of opioid-induced respiratory depression in wild African 
antelope species.  
 
Potent opioids such as etorphine or thiafentanil are often used for the immobilisation of wild 
herbivores. One disadvantage of using these potent opioids is that they can cause clinically 
significant respiratory depression which is due to their potent effect on mu-opioid receptors. 
Activation of mu-opioid receptors in the respiratory centres of animals depresses neurons 
that generate the normal respiratory rhythm. At the same time activation of mu-opioid 
receptors on chemo receptors in the brain stem, on the aortic arch and carotid bodies 
depresses the normal respiratory drive as these chemo receptors become less sensitive to 
activation by hypercapnia, hypoxaemia and acidaemia. This effect in turn leads to a reduction 
of the respiratory frequency and tidal volume. Furthermore, pulmonary vasoconstriction, 
caused by the sympathomimetic actions of etorphine, decreases pulmonary perfusion. This 
effect leads to impaired diffusion of oxygen through the alveolar membrane. Studies have 
found that serotonergic ligands, specifically 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-
DPAT), improved blood oxygenation by reducing opioid-induced respiratory depression and 
improving pulmonary perfusion through their serotonergic effects on the lungs and brain. 
More specifically, 8-OH-DPAT binds to 5-HT1A and 5-HT7 serotonin receptors in the lungs 
and brain. This binding results in smooth muscle relaxation and improved pulmonary 
perfusion without affecting catatonia and sedation caused by opioids. It was thought that the 
use of the R-enantiomer of 8-OH-DPAT (R-8-OH-DPAT) in comparison to the racemic form 
(RS-8-OH-DPAT), might produce even better results because of its high specificity at the 5-
HT1A receptors.  
 
Although some literature on the pharmacokinetic data of 8-OH-DPAT in rats and marmosets 
existed, there was no published literature available on the pharmacokinetics of 8-OH-DPAT 
in ungulates. 
 
Therefore, the investigation into the pharmacokinetics and bioavailability of R-8-OH-DPAT 
in goats served as the first step in a series of experiments to understand the viability of adding 
R-8-OH-DPAT to an opioid-based immobilisation protocol for wild antelope species in order 
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to alleviate respiratory depression. It was hypothesised that the pharmacokinetics and 
bioavailability of R-8-OH-DPAT in goats would be similar but different to that reported in 
other species. It was established that the bioavailability of R-8-OH-DPAT when injected 
intramuscularly (IM) into goats was 66%. At the dosage used in this experiment (0.1 mg kg-
1), signs of serotonin toxicity were observed in some of the goats. The bioavailability results, 
as well as the encountered side effects in goats, guided the choice of three experimental R-8-
OH-DPAT dosages for the next experiment. 
 
The second experiment aimed to determine the ability of R-8-OH-DPAT, when administered 
in combination with etorphine in a dart, to prevent opioid-induced respiratory depression in 
blesbok (Damaliscus pygargus phillipsi) and impala (Aepyceros melampus). The experiment 
also aimed to establish the most clinically effective dosage of R-8-OH-DPAT, in these 
species. 
 
Blesbok and impala were chosen for the second experiment as they were abundant and 
readily available in the study area. Both are antelope species commonly immobilised with 
potent opioids. Impala are regularly used in immobilisation experiments. It was hypothesised 
that R-8-OH-DPAT would mitigate opioid-induced respiratory depression in wild ungulates 
without affecting the quality of immobilisation. R-8-OH-DPAT did not influence induction, 
immobilisation or recovery scores in either of the species. However, this experiment revealed 
that there were substantial differences between the two antelope species and their 
physiological changes after the administration of etorphine alone as well as etorphine in 
combination with 0.005, 0.02 and 0.07 mg kg-1 R-8-OH-DPAT respectively. Surprisingly, 
opioid-induced hypoxia was substantially more severe in impala compared to blesbok. 
Respiratory rate in blesbok, but not impala, increased with an increasing dosage of R-8-OH-
DPAT but this did not translate into clinically relevant improvements in partial arterial 
oxygen pressure (PaO2) values in blesbok. 
 
In impala, the medium and higher dosages of R-8-OH-DPAT combined with etorphine led 
to an improved PaO2 and decreased opioid-induced tachycardia during the first ten minutes 
of immobilisation.  
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It was concluded that species-specific effects and the possibility of serotonin toxicity at 
higher dosages, which seemed most effective, might not allow the routine use of R-8-OH-
DPAT at appropriate dosages for wildlife immobilisation.  
 
These results lead to the third experiment which aimed at comparing physiological effects of 
two commonly used potent opioids, namely etorphine and thiafentanil, in both antelope 
species. It was hypothesised that the time to recumbence, immobilisation quality and 
physiological variables during immobilisation of blesbok and impala respectively would 
differ between the two potent opioids.  
 
The results of this experiment demonstrate that both opioids used in high dosages are suitable 
for immobilisation of blesbok and impala without the addition of any sedative or 
tranquillisers. Both, blesbok and impala developed hypertension with either of the opioids. 
The thiafentanil treated animals of both species developed higher systemic blood pressure 
compared to the etorphine treated animals. The healthy animals used for these experiments 
recovered from hypertension without apparent adverse consequences.  
 
Thiafentanil in impala achieved a faster time to recumbence compared to etorphine but 
thiafentanil also was responsible for more incidences of prolonged apnoea during the 
beginning of the monitoring period in impala. Overall, there were large differences in the 
reaction of individual impalas to the opioid immobilisation, which seemed to result in 
unpredictable immobilisation.  
 
In blesbok, opioid-induced respiratory depression, hypoxia and hypercapnia were much less 
pronounced than in impala. Thiafentanil treated blesbok had higher respiratory rates, higher 
PaO2 and lower partial arterial carbon dioxide pressure (PaCO2) compared to etorphine 
treated blesbok. There was no difference in time to recumbence between the two opioids in 
blesbok.  
 
In conclusion, for short term management procedures of impala and blesbok, both opioids 
are suitable. No matter which opioid is used, both cause hypoxaemia to a greater or lesser 
degree and oxygen supplementation should be considered for both species. 
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Veterinarians should also be aware that in some species, such as impala, thiafentanil can 
achieve a faster time to recumbence than etorphine. However, this statement cannot be 
applied across all species as in blesbok there was no significant difference between both 
drugs with regards to time to recumbence. In addition, time to recumbence has to be weighed 
against potential negative respiratory, pulmonary and cardiovascular side-effects of the drug. 
 
While these experiments did not give the desired positive results with regards to the use of 
R-8-OH-DPAT to alleviate opioid-induced respiratory depression, they led to insights into 
differences between the two opioids which will enable veterinarians to make a more educated 
decision as to which opioid should be used preferentially.  
 
New insights into the differences between blesbok and impala with respect to reaction and 
physiological changes caused by opioids will also enable researchers to make decisions with 
regards to species selection for wildlife trials. It may also explain some of the difficulties 
encountered when immobilising impala. 
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Introduction 
 
This thesis is focused on the physiology and mitigation of opioid-induced respiratory 
depression in wild African antelope species.  
 
Two opioids, etorphine hydrochloride and thiafentanil oxalate, are currently registered and 
widely used for the immobilisation of wild herbivores in South Africa and the USA (Haigh 
1990; Kock and Burroughs 2012). Wild antelope in South Africa are immobilised on a 
regular basis for translocation and management purposes and opioid-based immobilisation 
mixtures are mostly used for this purpose (Kock and Burroughs 2012). One of the 
disadvantages reported when immobilising with potent opioids is that they can cause 
clinically significant respiratory depression (Haigh 1990; Kock and Burroughs 2012).  
 
Potent opioids have a potent effect on mu-opioid receptors. Activation of mu-opioid receptors 
in the respiratory centres of animals depresses neurons that generate the normal respiratory 
rhythm. At the same time activation of mu-opioid receptors on chemo receptors in the brain 
stem, on the aortic arch and carotid bodies depresses the normal respiratory drive as these 
chemo receptors become less sensitive to activation by hypercapnia, hypoxaemia and 
acidaemia. This effect in turn leads to a reduction of the respiratory frequency and tidal 
volume (Buss and Meltzer 2001; McCrimmon and Alheid 2003). Furthermore, pulmonary 
vasoconstriction, caused by the sympathomimetic actions of etorphine, decreases pulmonary 
perfusion. This effect leads to impaired diffusion of oxygen through the alveolar membrane 
(Meyer et al. 2015).  
 
Studies have found that serotonergic ligands, specifically 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT), improve blood oxygenation by reducing opioid-
induced respiratory depression and increase pulmonary perfusion through their serotonergic 
effects on 5-HT1A and 5-HT7 serotonin receptors in lungs and brain. This results in smooth 
muscle relaxation and improved pulmonary perfusion without affecting catatonia and 
sedation caused by opioids (Lalley et al. 1994; Sahibzada et al. 2000; Meyer et al. 2006; 
Meyer et al. 2010). It is thought that the use of the R-enantiomer of 8-OH-DPAT (R-8-OH-
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DPAT) in comparison to the racemic form (RS-8-OH-DPAT), might produce even better 
results because of its high specificity at the 5-HT1A receptors (Hadrava et al. 1996; Yu et al. 
1996a; Lejeune et al. 1997; Christoffersen and Meltzer 1998).  
 
Further, differences of opioid receptor affinity of etorphine and thiafentanil seem to elicit 
different effects in antelope species with regards to immobilisation properties and respiratory 
physiology (Meyer et al. 2008a; Zeiler and Meyer 2017a and b). However in-depth 
investigation of those differences in different species have not been reported as opioids were 
usually combined with various sedatives or tranquillisers (Meyer et al. 2008a; Zeiler and 
Meyer 2017a).  
 
Most investigations so far have been carried out in impala, which are known for being 
especially difficult and also vary phylogenetically from most other antelope species 
(Hernandez Fernandez and Vrba 2005; Zeiler and Meyer 2017a).  
 
In this thesis, we investigated the feasibility of the chemical R-8-OH-DPAT to be used as an 
adjunct to etorphine-based immobilisation mixtures in order to alleviate opioid-induced 
respiratory depression.  
 
We also investigated if there was a significant difference with regards to the changes elicited 
by the two opioids (etorphine and thiafentanil) on immobilisation quality and respiratory 
physiological variables and thus, if one opioid should be used preferentially over the other. 
Finally, we compared physiological changes as a result of the opioid-based immobilisation 
between impala and blesbok and discovered species-specific differences. 
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Chapter 1: Literature Review 
1.1 Management of wildlife in South Africa 
South Africa has large, well known national parks where wildlife conservation is practiced 
such as Kruger National Park, Hluhluwe – iUmfolozi Park and many others. In addition to 
these parks, an estimated twenty percent of South Africa’s agricultural land has been 
converted into private game farms. Wildlife can be owned privately (Higginbottom and King 
2006; Cousins et al. 2008) and an estimated 20 million head of game roam South Africa (Gert 
Dry, personal communication, 2015). 
 
In South Africa commercial trade of wildlife is similar to the trade of domestic livestock. 
Over 150 000 wild animals are chemically immobilised with opioids each year, for clinical, 
translocation and management purposes such as ear tagging and rotation of breeding males 
between camps (unpublished data, Wildlife Pharmaceuticals SA 15/1/2018). Neighbouring 
countries such as Swaziland, Namibia and Zambia are also following the South African 
example. With privatisation of wildlife, the incidence of chemical immobilisations is ever 
increasing. The increase in wildlife farming and sustainable utilisation of wildlife, which also 
includes locally as well as globally endangered and vulnerable antelope species such as roan 
antelope (Hippotragus equinus), Tsessebe (Damaliscus lunatus) and bontebok (Damaliscus 
pygargus ssp. pygargus) (South African Department of environmental affairs and Tourism 
2007; Radloff et al. 2017), has led to a high demand for pharmaceuticals and instruments that 
can facilitate safe wildlife immobilisation. It also means that there is a vast pool of semi 
captive wildlife species in South Africa that lend themselves to scientific studies of wildlife, 
including the development and improvement of immobilisation techniques. 
1.2 Chemical immobilisation of wildlife 
Apart from trapping, net-capture and mass-capture of herds of wildlife, chemical 
immobilisation is an important method to capture wild animals for translocation, diagnostic 
testing or medical treatment (Laubscher et al. 2015). In zoos and intensive breeding facilities, 
chemical immobilisation is usually carried out from the ground. In contrast, wild animals 
roaming in wildlife reserves and farms often have to be located and darted from a helicopter. 
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This method can cause additional stress and trauma to these animals (Kock and Burroughs 
2012). 
 
Chemical immobilisation is usually carried out by licensed veterinarians. A remote drug 
delivery system is used for this purpose; usually a dart gun or blowpipe. The drug is injected 
by means of a dart syringe which is fired from the dart gun at a distance of between five and 
80 meters (Kock and Burroughs 2012). Laws governing the possession of darting equipment 
and immobilisation drugs differ in each country. In South Africa, dart guns are freely 
available and do not need to be licensed. However, most drugs for the immobilisation of 
wildlife are scheduled (South African Department of Health, Medicines and Related 
Substances control act 101 of 1965) and immobilisation of wildlife is considered a veterinary 
procedure and therefore must be undertaken by a licenced veterinarian (South African 
Department of Agriculture Forestry and Fisheries, Veterinary and Para-Veterinary 
Professions act 1982). 
 
As dart volume is often a limiting factor, immobilising drugs need to be highly potent and 
concentrated. They must also have a wide safety margin as wild animals cannot be examined 
and weighed prior to immobilisation (Kreeger et al. 2002). The ideal drug is fast-acting to 
limit stress and the likelihood of escape following darting (Kock and Burroughs 2012). In 
addition, the ideal drug should be reversible as animals are often released straight back into 
the wild and have complex social structures when released back into groups (Haigh 1990). 
Social species need to be integrated as soon as possible to minimise hierarchy disturbances 
and alterations in group dynamics. Not only is animal welfare of concern but often, these 
animals are also very valuable or endangered species and therefore of high monetary as well 
as conservation value. It is therefore of paramount importance that any immobilisation 
mixture has a wide margin of safety and minimal side effects. Safety of the drug for humans 
would also be a desirable attribute as accidental injections of humans during wildlife 
immobilisations are known to occur which can have severe consequences (Kreeger et al. 
2002; Kock and Burroughs 2012).  
 
Highly potent opioids such as etorphine hydrochloride, carfentanil and thiafentanil oxalate 
are widely used for the chemical immobilisation of wild ruminants as these drugs fulfil most 
of the basic characteristics of a good immobilisation drug (Haigh 1990; Kreeger et al. 2002; 
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Kock and Burroughs 2012). These highly concentrated opioids are also considered extremely 
dangerous for humans and can lead to intoxication, respiratory failure and death. The 
availability of the full antagonist naltrexone and naloxone contributes to safety of these drugs 
as human drug exposure can be treated immediately and effectively by administration of 
opioid antagonists (Haigh 1990; Kock and Burroughs 2012). Naltrexone is also used to fully 
reverse opioid-based immobilisation of wildlife species after capture, especially if the animal 
is released back into the wild and needs to be fully alert. If a residual analgesic or sedative 
effect is required, partial opioid antagonists or mixed agonists/antagonists can be used for the 
reversal of opioids such as diprenorphine, nalorphine or butorphanol (Kock and Burroughs 
2012).  
 
Drug combinations used for darting are usually not commercially available as pre-mixed 
solutions and are rarely registered in this form. Immobilisation drugs are usually combined 
to be species and situation specific prior to darting by the wildlife veterinarian (Kock and 
Burroughs 2012). Drugs for immobilisation such as opioids and alpha-2 agonist are usually 
purchased as highly concentrated drugs for this purpose or compounded by a compounding 
pharmacy according to the prescription of the wildlife veterinarian (Kock and Burroughs 
2012).  
1.2.1 Effects of capture on wildlife 
Chemical immobilisation of wildlife is often associated with high risks to the animal. Wild 
animals cannot be examined with regards to their nutritional and health status beforehand 
and they often cannot be monitored or receive adequate supportive treatment during 
immobilisation in the field. In addition, they are often highly stressed and run long distances 
before they are immobilised and can be approached. Most immobilisation drugs also have 
severe side effects as they not only cause sedation by influencing the central nervous system, 
but usually also influence cardiovascular, respiratory and thermoregulatory functions of the 
body. The most common problems encountered during wildlife immobilisation include 
respiratory depression, cardiovascular disturbances, bloat, impaired thermoregulation and 
stress, all of which can contribute to hypoxia and ultimately result in the development of 
capture myopathy (Arnemo et al. 2014; Breed et al. 2019). 
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1.2.2 Capture myopathy (CM) 
CM is a metabolic disease of wild and domestic animals. CM is often associated with stress, 
pursuit or transport of animals (Paterson 2014; Breed et al. 2019). Certain species, especially 
wild ungulates have a predisposition to CM but other factors such as nutritional deficiencies, 
especially of vitamin E or selenium also play an important role in the development of CM 
(Flueck et al. 2012; Paterson 2014). Drugs, such as opioids, which are commonly used for 
wildlife capture possibly also contribute heavily to the development of CM due to negative 
physiological effects of these drugs on the already stressed animal, such as opioid-induced 
excitability, muscle rigidity, hyperthermia, hypoventilation and hypoxaemia (Haigh 1990; 
Paterson 2014; Fitte 2016). Altered blood flow and hypoxia of muscle tissue lead to anaerobic 
metabolism, increased lactic acid and inadequate removal of waste products. As a result, 
skeletal and cardiac muscles undergo necrosis of varying degrees. Tissue waste products and 
myoglobin released from necrotic muscles tissue cause tubular necrosis and renal failure. 
Clinical signs vary according to the localisation and severity of disease. Acute death can 
occur during the so-called capture-shock syndrome. The disease can also be protracted over 
several hours or days and manifest in ataxia and myoglobinuria. It can also manifest as 
ruptured-muscle syndrome where muscles rupture one or two days after capture as a result 
of necrosis. Usually muscles of the hind quarters are involved in this manifestation. The rare 
delayed per-acute CM syndrome can develop suddenly and up to several days post capture. 
Animals seem fine initially and then suddenly die from heart failure (Paterson 2014; Breed 
et al. 2019). 
 
CM can be diagnosed on post-mortem examination. In live animals the history and typical 
clinical symptoms as well as severe elevation of creatinine kinase (CK), aspartate 
aminotransferase (AST) and lactate dehydrogenase (LDH) are indicative of CM (Paterson 
2014). 
 
Preventative measures such as minimising stress and handling during capture, the use of 
tranquillisers, the use of capture drugs with short induction times and less respiratory 
depressive side effects, cooling of animals and capture of only healthy animals all contribute 
towards minimising the risks of CM. By monitoring the body temperature, lactate, blood pH, 
blood gases as well as enzymes with a point of care analyser one can assess parameters that 
 7 
could indicate the initial health status of the animal and potential development of CM and 
therefore give an idea of the prognosis for the animal for recovery (Fitte 2016). 
1.2.3 Bloat and regurgitation 
If animals are anesthetised under controlled conditions, they are usually starved, and water 
is withheld for several hours before the planned immobilisation. This precaution minimises 
the risk of bloat and regurgitation in ruminants and the risk of vomiting in carnivores (Kock 
and Burroughs 2012). 
 
In wild animals immobilised under field conditions, this is often not possible, and animals 
have to be monitored closely for any signs of regurgitation or bloat and action has to be taken 
accordingly. In the event of regurgitation intubation of the animal and maintenance of an 
airway is imperative. In the case of bloat, gas can be relieved by inserting a trocar or stomach 
tube. Correct positioning in sternal recumbence, especially of ruminants as soon as the animal 
can be approached, helps to prevent these situations. Drugs that are known to contribute to 
gastrointestinal tract stasis and bloat in ruminants, and induce vomiting in carnivores, such 
as alpha-2 agonists, should be avoided if possible. Side effects should be reversed with a 
partial or full antagonist (Arnemo et al. 2014). 
1.2.4 Thermoregulation 
Most drugs used for immobilisation as well as tranquillisers influence the ability of animals 
to thermoregulate adequately. The consequence is either hypothermia or hyperthermia and it 
is important to measure the animal’s rectal temperature during immobilisation. Hypothermia 
is usually of concern in cold climates and in small species owing to their large surface area 
to volume ratio. Hypothermia can be successfully treated by keeping animals warm and dry. 
Hyperthermia can be more challenging to treat and can ultimately lead to the death of the 
animal. Body temperatures of 41 ⁰C and rising are of immediate concern in ungulates 
(Arnemo et al. 2014). 
 
Hyperthermia can be prevented, by using drugs that minimise the induction time and 
therefore the excitement phase. Stress at the time of capture plays the most important role in 
the development of hyperthermia in impala (Aepyceros melampus) and therefore minimising 
handling or using techniques known to minimise stress before and during the immobilisation 
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is of importance (Meyer et al. 2008a and b). To allow for animals suffering from stress-
induced hyperthermia to cool down easily, captures should be carried out during the cooler 
parts of the day. Once animals are immobilised various cooling methods can be applied. 
Sawicka et al. (2015) reported that pouring large amounts of cool water over the animal was 
the best method to conduct excess heat away from the body. If the body temperature 
continues to rise, it is best to reverse the immobilisation (Arnemo et al. 2014). 
1.2.5 Respiratory depression and cardiovascular disturbance 
Most immobilisation drugs and anaesthetics influence the respiratory and cardiovascular 
system of the immobilised animal. Opioids generally cause hypertension and respiratory 
depression which leads to hypoxaemia and tissue hypoxia (Boom et al. 2012; Haw et al. 
2014; Meyer et al. 2015) while alpha-2 agonists cause reflex bradycardia and hypotension, 
leading to a ventilation-perfusion (V/Q) mismatch and thus also to hypoxaemia and tissue 
hypoxia (Bryant et al. 1996; Celly et al. 1997; Paddleford and Harvey 1999). Hypoxia can 
lead to acidaemia, tissue necrosis, CM and ultimately to cardiac arrest and death. 
 
It is of importance to monitor the immobilised patient and to start oxygen therapy or 
administer a partial or full reversal drugs if necessary (Fahlman 2014). 
1.2.6 Monitoring of immobilised wildlife 
1.2.6.1 Respiration and ventilation 
Respiration can be monitored by hand and with a stethoscope for frequency and depth. This 
kind of monitoring can be done in any field situation. In addition, capnography can be used 
to monitor end tidal carbon dioxide (ETCO2) and respiratory rate. ETCO2 indicates if 
ventilation and thus the gas exchange in the lungs is adequate. Sudden low ETCO2 values 
can also indicate a drop in cardiac output and blood pressure and imminent cardiovascular 
collapse. High ETCO2 values are termed hypercapnia and a sign of hypoventilation. ETCO2 
and partial arterial carbon dioxide pressure (PaCO2), as determined by blood gas analysis, 
are closely related, and values of between 35 and 45 mmHg are considered normal in most 
mammal species (Kheng and Rahman 2012; Ozeki and Caulkett 2014; Fahlman 2014; Mehta 
et al. 2017). However, capnography can be an unreliable tool, if patients cannot be intubated 
and are breathing spontaneously (Mehta et al. 2017). A recent publication by Mehta et al. 
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(2017) suggested that the measurement of respiratory minute volume by a respiratory volume 
monitor should be added as a monitoring tool for changes in ventilation in humans. 
 
The haemoglobin oxygen saturation in arterial blood (SPO2) can be measured with a pulse 
oximeter, which also monitors heart rate. The SPO2 should be > 95% for an animal to be 
considered within normal limits. In the context of immobilisation, a SPO2 of less than 95% 
could indicate inadequate ventilation and oxygen intake due to respiratory depression but it 
could also indicate decreased diffusion of oxygen in the lungs due to a V/Q mismatch or 
increased use of oxygen due to an increase in metabolism (Haw et al. 2014). Pulse oximetry 
has limitations and is influenced by many external factors which have to be taken into account 
when interpreting SPO2 readings (Sinex 1999; Kamat 2002). Usually pulse oximeters are 
calibrated on healthy human volunteers and do not allow for physiological difference that 
might exist between humans and various animal species. Calibration is only accurate to an 
SPO2 of 75% in veterinary species, and values below this have to be interpreted with caution. 
Pulse oximeters do not reflect adequate ventilation or hypercapnia which might occur without 
a decrease of haemoglobin oxygen saturation, especially if the patient receives oxygen 
supplementation. Therefore, pulse oximetry should be combined with capnography for 
anaesthetic monitoring (Kamat 2002). Pulse oximetry is based on different light absorbance 
of oxygenated versus reduced haemoglobin by red and near infrared light. Pulse oximeters 
cannot differentiate between oxygenised haemoglobin and methaemoglobin or 
carboxyhaemoglobin and thus these compounds will lead to an error by overestimating the 
actual oxygen saturation. The use of a co-oximeter can be employed if either 
methaemoglobin or carboxyhaemoglobin are suspected (Sinex 1999; Kamat 2002). 
 
Another common source of error is ambient light which leads to signal artefacts which can 
be corrected by placing a cloth over the probe. Optical shunting occurs when the probe is not 
connected properly and light from the light emitting diode source reaches the photodetector 
without passing through an arterial bed which can lead to over and underestimation of the 
actual SPO2. This issue can be corrected by repositioning of the probe. Motion artefacts are 
a further common challenge especially when dealing with immobilised animals which often 
still show a degree of muscle movement (Sinex 1999; Kamat 2002). A low signal to noise 
ratio and failure to detect signal can result from various causes including, hypotension, 
peripheral vasoconstriction (as is often caused by commonly used drugs such as alpha-2 
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agonists) hypovolemia and peripheral vascular disease (Sinex 1999; Kamat 2002). A further 
limitation to pulse oximetry is skin pigmentation. Dark pigmentation seems to make light 
penetration more difficult. Thus, it is important to preferably connect the pulse oximeter to 
the unpigmented skin of an animal (Sinex 1999; Kamat 2002). 
 
With the aid of a point of a care blood gas analyser, the arterial oxygen pressure (PaO2) can 
be determined. The PaO2 is a more sensitive indicator of hypoxaemia when compared to 
SPO2. The relationship between PaO2 and SPO2 is correlated. If SPO2 is > 95%, the PaO2 at 
sea level is usually > 75 mmHg as can be easily ascertained with the haemoglobin oxygen 
saturation curve. PaO2 of less than 75 mmHg has to be interpreted as hypoxaemia, while less 
than 60 mmHg has to be treated as severe hypoxaemia. Clinical signs of hypoxaemia include 
dyspnoea, cyanosis, tachycardia, elevated blood pressure and arrhythmias. Hypoxaemia and 
hypoxia due to hypoventilation could be treated with oxygen insufflation but this treatment 
method also requires further investigation (Haw et al. 2014; Fahlman 2014) (Figure 1).  
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Figure 1: Haemoglobin Oxygen Saturation Curve (commons.wikimedia.org, accessed 
8/1/2019) 
 
Blood gas analysis not only gives information about the patient’s ventilation and gas 
exchange in the lungs but also about the acid-base status. 
 
Pre-analytical errors with blood gas analysis often stem from inaccurate sample collection or 
storage. It is important to ascertain that the blood collected is indeed arterial blood which on 
occasion can be challenging. Preferably blood gas specific syringes should be used which 
contain lyophilized lithium heparin as anti-coagulant and have an arterial self-filling 
function. Using these syringes, instead of heparinised syringes, minimizes errors in specific 
analyte (ionized calcium readings) which could result from the use of liquid sodium heparin. 
Furthermore, if blood gases are not analysed immediately after collection, the sample should 
be stored anaerobically on ice. All bubbles should be expelled within 30 seconds after 
collection and the sample should be corked. It should also be noted that within 30 minutes to 
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two hours of collection an increase in the oxygen tension can be expected even if the sample 
is stored correctly (Bateman 2008; McGrotty and Bilbrough 2013). 
 
Blood gas analysers measure PaO2, PaCO2 and the pH of the sample. From these values the 
other variables such as bicarbonate (HCO3-), total carbon dioxide (TCO2), base excess (BE) 
and oxygen saturation (SaO2) as well as the Alveolar – arterial oxygen gradient (A-a gradient) 
can then be calculated (McGrotty and Bilbrough 2013). 
 
External factors such as temperature and barometric pressure can influence gas solubility and 
this should be taken into account, especially if samples are taken at high altitude (McGrotty 
and Bilbrough 2013). 
 
1.2.6.2 Heart rate (HR) and blood pressure (BP) 
Opioids have been reported to cause bradycardia as well as tachycardia – depending on the 
circumstances, species as well as the opioid used (Blane et al. 1967; Harthoorn 1967; Heard 
et al. 1990; Haigh 1990; Janssen et al. 1993; Zeiler and Meyer 2017a; Izwan et al. 2018). 
Heart rate can be ascertained directly by using a stethoscope. Heart rate monitoring can be 
done in any field situation and would also facilitate the identification of irregular heartbeats 
and murmurs. In addition, the pulse can be measured and indicated by pulse oximeters as 
well as by intra-arterial and high definition oscillometric (HDO) blood pressure monitors 
(Iyriboz et al. 1991).  
 
Many drugs used for immobilisation influence blood pressure due to their influence on 
systemic vascular resistance and on cardiac output (Buss et al. 2016). If blood pressure is too 
high it can cause oedema, especially lung and brain oedema, retinal damage and petechiae 
(Hattingh et al. 1994a and b). Low blood pressure (a mean arterial pressure (MAP) of less 
than 60 mmHg) will lead to inadequate tissue perfusion and hypoxia. A sudden rise in blood 
pressure could indicate either that the animal is suffering from hypoxaemia or that the animal 
has been stimulated and the plane of anaesthesia is light (Ozeki and Caulkett 2014). Blood 
pressure can be measured non-invasively with either doppler ultrasound or oscillometric 
methods or it can be measured invasively with an intra-arterial blood pressure monitor 
(Hattingh et al. 1994a; Bosiack et al. 2010; Ozeki and Caulkett 2014; Cassia et al. 2015). 
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Currently the intra-arterial blood pressure monitoring method is considered the gold standard. 
It is important to consider that there might be differences in blood pressure measurements 
when measurements are carried out on different arteries. Thus, if different arteries are used 
for blood pressure measurements in different individuals, there might be a degree of error 
arising in the results (Dorman et al. 1998; Wang et al. 2013; Bass et al. 2009; Tearney et al. 
2016).  
1.3 Opioids 
An opioid is any agent, regardless of structure, that has the functional and pharmacological 
properties of an opiate. An opiate refers to compounds structurally related to products found 
in opium. Natural opiates are derived from the resin of the opium poppy (Papaver 
somniferum). Opiates include the natural plant alkaloids such as morphine, codeine, thebaine 
as well as many semi-synthetic derivatives (Yaksh and Wallace 2011).  
 
Opium contains more than 20 distinct alkaloids, amongst them morphine which was 
discovered in 1806 by Frederich Sertuermer (Yaksh and Wallace 2011). Opioids were widely 
used as analgesics but due to the addictive potential, and other side effects of natural opioids, 
the search for potent synthetic opioids with fewer side effects continued. This search not only 
led to the discovery of new synthetic opioids, such as fentanyl, but also led to the discovery 
of opioid antagonists and compounds with agonist as well as antagonist properties (Yaksh 
and Wallace 2011; Stanley 2014). 
 
Currently four major opioid receptor classes are described: mu-, kappa-, delta- and 
nociception- receptors (Dietis et al. 2011). Endogenous ligands for these receptors consist of 
endorphins (mu-receptor ligand), enkephalins (delta- and mu-receptor ligand) and 
dynorphins (kappa-receptor ligand) (Pattinson 2008). Through this opioid system, various 
endogenous processes are regulated such as pain control, respiratory control, stress response, 
appetite and thermoregulation (Pattinson 2008). 
 
Not all opioids and opioid antagonists work on all opioid receptors (Table 1). The potent 
capture opioid etorphine is a strong agonist for mu-, kappa- and delta- receptors. Fentanyl 
and the more potent thiafentanil are also used for chemical immobilisation and are mostly 
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mu-receptor agonists (Vardanya and Hruby 2014; Zeiler and Meyer 2017a). Sufentanil, a 
potent human analgesic is a strong mu- but a moderate kappa- and delta-agonist (Yaksh and 
Wallace 2011). It is believed that the mu-receptor is responsible for most of the clinically 
relevant effects such as analgesia, sedation and catatonia, however, at the same time this 
receptor also seems to be responsible for opioid side effects such as respiratory depression 
(Lamont and Grimm 2014).  
 
Most opioids are eliminated from the body through metabolism by the liver followed by 
glomerular filtration (Smith 2009). In humans there can be very different individual 
responses to various opioids, caused by different factors. Amongst those factors are 
individual differences in opioid metabolism (Smith 2009). However, not many studies are 
available on the metabolism and elimination of such opioids in animals. In race horses for 
example etorphine was still detectable in urine for up to 72 hours after IM injection (Smith 
et al. 1996). Carfentanil in goats (Capra hircus) was investigated by Mutlow et al. (2004) 
and was still detectable in plasma 48 hours after injection with a half-life of 5.5 hours. The 
only pharmacokinetic study on opioids in wild animals was carried out by Cole et al. (2006). 
Carfentanil in common Eland (Taurotragus oryx) in this study had a plasma half-life of 7.7 
hours and after 48 hours was still detectable in plasma of two of six eland. 
 
Clinical effects of opioids include analgesia which constitutes the primary use of opioids in 
human medicine (Lamont and Grimm 2014). However, opioids also affect the central 
nervous system (CNS) where they lead to sedation in some species and excitation in other 
species (Blane et al. 1967). The sedative and catatonic properties of opioids play an important 
role when opioids are used for immobilisation of wildlife while the possible excitation is one 
of the negative side effects. Opioids also affect thermoregulation which can result in 
hypothermia and hyperthermia of animals that were treated with opioids (Lamont and Grimm 
2014).  
 
One of the most important negative side effects of opioids however, especially during 
immobilisation of wildlife, is respiratory depression, or better termed respiratory compromise 
(McCrimmon and Alheid 2003; Haw et al. 2014; Meyer et al. 2015). Currently, two potent 
opioids are registered in South Africa and the USA for the capture of wild ungulates, namely 
etorphine hydrochloride and thiafentanil oxalate. 
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Table 1: Activity of some opioid receptor ligands at various opioid receptors (modified from 
Gutstein and Akil 2006). 
Agonists mu kappa delta 
Etorphine +++ +++ +++ 
Fentanyl +++   
Thiafentanil +++   
Morphine +++ +  
Sufentanil +++ + + 
Antagonists mu kappa delta 
Naltrexone --- --- - 
Diprenorphine --- --- -- 
Partial Agonists/antagonists mu kappa delta 
Butorphanol --(+) +++  
Nalorphine --- +  
Nalbuphine -- ++  
 
1.3.1 Etorphine 
Etorphine hydrochloride is generically named as M99. Its chemical name is 7-alpha-(1-(R)-
hydroxy-1-methylbutyl)-6,14-endoethenotetrahydro-oripavine hydrochloride (Blane et al. 
1967). This morphine derivative is said to be 3000 to 4000 times more potent than morphine 
(KuKanich and Papich 2009; Lamont and Grimm 2014) and attaches to mu-, kappa- and 
delta-opioid receptors (Gutstein and Akil 2006). Etorphine is currently available in a 
concentration of 9.8 mg mL-1 as Captivon (Wildlife Pharmaceuticals (Pty) Ltd., South Africa) 
and as M99 (Novartis, South Africa). This opioid is used to immobilise a wide variety of zoo 
and wildlife species worldwide. Numerous published data are available on etorphine dosage 
suggestions for immobilisation of various wildlife species, including African ungulates, 
ostriches (Struthio camelus) and spotted hyena (Crocuta crocuta) (Kock and Burroughs 
2012).  
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Post etorphine treatment a decrease in respiratory rate (fR) and resulting hypoxia have been 
reported in ruminants (Heard et al. 1996; Meyer et al. 2010; Meyer et al. 2015; Izwan et al. 
2018). Hypoxia caused by respiratory depression is possibly compounded by the effects of 
etorphine on the pulmonary blood pressure. Independently from its effect on systemic blood 
pressure, etorphine seems to change pulmonary vascular resistance and pressures, and thus 
could affect gas exchange through causing pulmonary congestion and, or, oedema and V/Q 
mismatching (Heard et al. 1996; Meyer et al. 2006; Meyer et al. 2010; Meyer et al. 2015; 
Izwan et al. 2018). 
 
Multiple reports on physiological changes in impala (Aepycerus melampus) following 
etorphine immobilisation exist. However most of these report on mixtures of etorphine in 
combination with various sedatives or tranquillisers and thus, the actual physiological 
response could have been altered (Meyer et al. 2008a; Meyer et al. 2010; Zeiler and Meyer 
2017a). Only two reports of the use of etorphine as sole immobilisation agent in impala are 
currently available (Cheney and Hattingh 1987; Meyer et al. 2010). Cheney and Hattingh 
(1987) administered a dosage of ± 0.02 mg kg-1 to six impala. The mean time to recumbence 
was 12.9 minutes following this treatment. The animals showed an elevated body 
temperature (over 40 ºC), elevated heart rates (HR) and elevated fR. Meyer et al. (2010) darted 
impala with a dosage of 0.07 mg kg-1 etorphine. Impala became recumbent within 3.7 minutes 
and a decreased fR (13 breaths minute-1), hypoxia (PaO2 = 40 mmHg) and hypercapnia 
(PaCO2 = 51 mmHg) with an elevated A-a gradient was recorded. Over the 18-minute 
monitoring period the fR increased, the PaO2 increased gradually and the A-a gradient also 
improved. Effects of etorphine on heart rate or blood pressure were not reported. 
 
Species differences of cardiovascular effects of etorphine in sheep and goats were first 
recognised by Harthoorn (1967) and also recently by Izwan et al. (2018). While the HR of 
goats after IM etorphine treatment (etorphine dosage: 0.05 and 0.1 mg kg-1) did not change, 
sheep (etorphine dosage: 0.05 mg kg-1) developed tachycardia (Meyer et al. 2015; Izwan et 
al. 2018). However, when the drug was given IV to goats (etorphine dosage: 0.02 mg kg-1) 
by Heard et al. (1990) physiologically wide individual variation in HR was reported. Some 
goats became bradycardic while others became tachycardic. These results indicate that the 
administration route and speed of absorption could potentially influence the HR.  
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Other parameters studies included blood pressure. This was found to vary between 
individuals and did not seem much affected by etorphine in sheep (Harthoorn 1967) but it 
decreased in goats (Meyer et al. 2015). No published data are currently available on 
physiological values of blesbok, or any other antelope species, for that matter after 
immobilisation with etorphine alone.  
 
In conclusion, while there is a vast array of knowledge with regards to dosage suggestions 
and drug combinations for etorphine, very little is actually known about the physiological 
and species-specific effects of this drug in antelopes. 
 
1.3.2 Thiafentanil 
Thiafentanil oxalate was previously known as A3080 and now is generically named Thianil. 
Its chemical name is: 1-(2-(2-thienyl) ethyl)-4-methoxycarbonyl-4-(N-phenylmethoxy-
acetamidol)-piperidinium oxalate (Stanley et al. 1988). The drug is currently available for 
the immobilisation of wildlife in a concentration of 10 mg mL-1 (Wildlife Pharmaceuticals 
(Pty) Ltd., South Africa). 
 
Thiafentanil, a phenylpiperidine-opioid, is a synthetic fentanyl derivative and structurally 
very similar to the human anaesthetic drug sufentanil. It binds exclusively to the mu-opioid 
receptor (Lance and Kenny 2011). 
 
Thiafentanil is a pure opioid agonist that produces analgesia, immobilisation and anaesthesia 
in laboratory animals (Stanley and McJames 1986 cited by Stanley et al. 1988). The drug has 
a wide safety margin in domestic ferrets (Stanley and Mc James 1986 cited by (Stanley et al. 
1988)). 
 
First reports on thiafentanil were published by Stanley et al. (1988) who evaluated reliability 
and safety of the drug in immobilised elk (Cervus elaphus). The induction time after IM 
injection in elk was about minutes if the drug was injected at a dosage of 0.006 mg kg-1. 
Higher dosages could lead to immobilisation in less than two minutes. Thiafentanil was 
estimated to be twice as potent in elk when compared to etorphine hydrochloride (Stanley et 
al. 1988).  
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The half-life of thiafentanil has not been investigated. However, Stanley et al. (1988) 
reported that the recovery time in elk strongly depends on the initial dosage of the drug. Elk 
that received 0.0005 mg kg-1 body weight recovered within ten minutes without receiving an 
opioid antagonist. When elk received 0.004 mg kg-1 thiafentanil, they stood 56 minutes post 
administration whereas elk that receiving an initial dosage of 0.01 mg kg-1 took 122 minutes 
to recover post administration (Bailey et al. 1985).  
 
Janssen et al. (1993) reported that impala need a much higher thiafentanil dosages compared 
to reports in elk. Ninety percent of impala could be immobilised within three minutes by 
using a dosage of 0.08 mg kg-1 without the combination of any other drugs. The fact that 
impala needed significantly higher drug dosages per kg bodyweight is not surprising as elk 
are generally more sensitive to narcotics than most antelope (Haigh 1990).  
 
Immobilisation of impala with thiafentanil caused respiratory depression, hypoxia, 
tachycardia and hypertension at all dosages ranging from 0.03 mg kg-1 to 0.08 mg kg-1. These 
conditions improved over the 25-minute monitoring period. Initial apnoea was observed in 
some animals. Some of the impala responded to stimulation by wild jerking movements or 
by flexion of the limbs (Janssen et al. 1993). Janssen et al. (1993) published the only report 
in antelope on the physiological response to immobilisation with thiafentanil alone. While 
there is abundant literature available regarding dosage suggestions for various African 
species, very little work has been done to investigate the physiological effects of this drug 
(Kock and Burroughs 2012; Kilgallon et al. 2010; Citino et al. 2002; Cooper et al. 2005; 
Meyer et al. 2008a). 
 
1.3.3 Thiafentanil compared to etorphine 
In his report on thiafentanil Raath (2009) describes the immobilisation of two comparable 
buffalo bulls (Syncerus caffer) with 8 mg of thiafentanil and 8 mg of etorphine respectively. 
The bull darted with thiafentanil started to recover after 24 minutes post administration while 
the bull darted with etorphine took 45 minutes to recover post administration. This is nearly 
double the recovery time. Raath (2009) further elaborates that most species darted with 
thiafentanil start to recover after 20 to 25 minutes, which is faster than with other potent 
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opioids (Lance and Kenny 2011). After a treatment with 0.07 mg kg-1 of etorphine, it took 
goats between 93 to 208 minutes to recover spontaneously (O’Dell et al. 2017). 
 
In antelope species thiafentanil and etorphine have similar potency with regards to achieving 
immobilisation. A similar dosage of thiafentanil and etorphine would be used to immobilise 
most antelope species. However, higher dosages of thiafentanil seem to be better tolerated 
than higher dosages of etorphine (Raath 2009). 
 
Meyer et al. (2008a) compared impala darted with 0.031 mg kg-1 thiafentanil and 0.039 mg 
kg-1 etorphine respectively. Both immobilisation drugs were combined with either the 
tranquiliser azaperone (40 mg) or the alpha-2 agonist medetomidine (2 mg) which possibly 
explains the successful immobilisation of the impala with comparatively low dosages of 
opioids. It was apparent that impala darted with the thiafentanil combinations had faster times 
to recumbence than those darted with etorphine combinations. Faster times to recumbence 
with thiafentanil in ungulates have also been reported by Lance and Kenny (2011) but could 
not be verified in a second impala experiment when 2 mg of thiafentanil and etorphine 
respectively (0.05 mg kg-1) were combined with 2.2 mg of medetomidine (Zeiler and Meyer 
2017a). Both impala reports however describe that the animals darted with the thiafentanil 
combination initially developed apnoea and suffered from more severe hypoxia compared to 
impala darted with the etorphine combination. At the beginning of this experiment, impala 
darted with thiafentanil plus azaperone had lower SPO2 values (60%) than impala darted with 
etorphine plus azaperone (75%). Ten to sixteen minutes after measurements had commenced, 
thiafentanil treated impala had SPO2 values of 85%, which was higher than that of impala 
darted with etorphine (75%) (Meyer et al. 2008a). The thiafentanil treated impala also 
developed slightly less hypoxia (PaO2 = 47 mmHg) compared to the etorphine treated impala 
(PaO2 = 41 mmHg) in the study by Zeiler and Meyer (2017a). Heart rate was initially elevated 
with both opioids to between 140 and 180 beats minute-1 and dropped to around 120 beats 
minute-1 within ten minutes but the HR of thiafentanil immobilised impala was slightly higher 
than that of etorphine darted animals (Meyer et al. 2008a, Zeiler and Meyer 2017a). 
Respiration rates with both treatments were similar at around ten breaths minute-1 (Meyer, et 
al. 2008a; Zeiler and Meyer 2017a). Impala immobilised with etorphine did not suffer from 
induction apnoea in contrast to thiafentanil immobilised impala. However, they took longer 
to become immobile and had higher body temperatures and cortisol levels (Meyer et al. 
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2008a and b). It is claimed by many wildlife veterinarians that thiafentanil is the superior 
drug for wild impala. It is also claimed that thiafentanil used on its own seems to work best, 
despite concerns in the literature about high blood pressure caused by opioids if they are used 
in high dosages without a sedative or tranquiliser (Hattingh et al. 1994a; Haigh 1990; Buss 
et al. 2016). Thus, it was of great interest to investigate this immobilisation protocol further. 
 
Etorphine as well as thiafentanil are widely used but have rarely been compared objectively, 
thus, it is of importance to determine if one of these two potent opioids causes less respiratory 
depression and should indeed be preferentially used in antelopes in general. 
 
1.3.4 Potent opioids as health hazards for humans 
Stanley et al. (1988) warned that the accidental injection of a human with thiafentanil would 
produce the same severe respiratory depression as carfentanil or etorphine and therefore 
anybody handling these drugs should be trained in the necessary first aid procedures and have 
full opioid antagonists on hand for emergency procedures (Kock and Burroughs 2012). 
 
The potent opioids etorphine and thiafentanil are absorbed through mucous membranes and 
exposure to a drop of these highly potent opioids can lead to intoxication and death in 
humans. Humans are far more prone to respiratory depression caused by opioids than most 
other animals. Wildlife veterinarians are usually well trained in the prevention and treatment 
of any human opioid exposures and any helpers and staff are briefed before capture 
operations on the dangers of opioids. When animals are immobilised with potent opioids, 
usually there is at least one more person present who is versed in first aid procedures 
especially with regards to potent opioid exposure. The full opioid reversal drug naltrexone 
or naloxone and sterile syringes and needles should always be present in case of human 
exposure. Potent opioids have to be transported and handled with care. Needles and syringes 
used to handle opioids are usually kept separately from those used for other less hazardous 
drugs. Gloves and protective glasses can be worn to prevent exposure. Water should always 
be available to wash off any drug splash straight away. Dealing with dart syringes and dart 
guns means that all equipment has to be handled in a safe manner and gun safety is even 
more important with dart guns than with firearms as a dart can easily kill a human, no matter 
where it injects. 
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Likewise, should animals die after potent opioid immobilisation, carcasses have to be 
disposed of safely so that they do not enter the food chain (Kock and Burroughs 2012). 
 
1.3.5 Opioid-induced respiratory depression 
Opioid-induced respiratory depression is not just a concern during wildlife immobilisation 
with highly potent opioids but also in human medicine. Opioid analgesics can induce severe 
respiratory depression in often already compromised human patients and the abuse of opioids 
commonly leads to respiratory depression and deaths (McCrimmon and Alheid 2003; 
Pattinson 2008; Dahan et al. 2010). 
1.3.5.1 Regulation of breathing and ventilation 
Breathing is a very complex procedure which involves not only the lungs, diaphragm and 
intercostal muscles but also involves several respiratory centres in the brain that regulate the 
respiratory pattern and constantly react to feedback with regards to lung volume, blood gas 
tensions, acid-base balance, exercise and many other factors. In addition, breathing can also 
be consciously influenced, and can, to a certain extent, be willingly and temporarily 
overridden, for example during conscious hyperventilation or breath holding, singing or 
speaking (Czick et al. 2014). 
 
One of the most important pacemaker sites that control breathing is the PreBötzinger complex 
(PreBOTc) which is situated in the ventrolateral medulla of the brain stem and controls the 
inspiratory drive after the neonatal period (Czick et al. 2014). The PreBOTc is considered to 
be the main pacemaker of the respiratory rhythm.  
 
The PreBOTc receives input from central chemoreceptors situated in the brain stem to 
increase ventilation in response to a decrease of pH or increase in partial pressure of CO2 in 
the cerebrospinal fluid, which is in equilibrium with capillary blood. Peripheral 
chemoreceptors in the carotid bodies also contribute to mediation of ventilation in response 
to acidosis and hypercapnia but to a lesser extent than the central chemoreceptors. In humans, 
peripheral chemoreceptors for O2 are only activated during severe hypoxaemia, once the 
PaO2 falls below 60 mmHg (Czick et al. 2014). 
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The PreBOTc generates the breathing rhythm by sending signals via the ventral respiratory 
complex (VRC) and via the dorsal respiratory complex (DRC) along the spinal cord to the 
diaphragm and intercostal muscles. While the VRC modulates inspiration as well as 
expiration, the DRC only controls inspiration (Sjaastad et al. 2016). Pulmonary stretch 
sensors further influence ventilation. If lungs get distended during inspiration, these sensors 
activate the Hering-Breuer-reflex which inhibits the inspiratory neurons and thus prevents 
excessive lung distension (Sjaastad et al. 2016). 
 
Stretch receptors in the carotid sinus and aortic arch react to an increase in blood pressure 
with a signal to decrease breathing frequency. As a consequence, venous return to the heart 
is affected and this helps to stabilise arterial blood pressure (Sjaastad et al. 2016). Peripheral 
sensors in joints and muscles further influence breathing during exercise (Sjaastad et al. 
2016). Signals from the higher brain centres affect breathing, but are not essential for normal 
breath modulation (Sjaastad et al. 2016).  
 
Regulation of breathing and ventilation is thus very complex and influenced by many 
different signals of central and peripheral origin. It becomes even more complex as within 
the respiratory centres of the brain, different neurotransmitters are active. Various 
neurotransmitters act on multiple receptors and can affect different voltage-gated channels 
within the same neuron or affect the same second messenger system in different ways (Doi 
and Ramirez 2008) (Figure 2).  
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Figure 2: The respiratory network receives excitatory and inhibitory input from multiple 
sources that are integrated to generate breathing behaviour [A5: Ventrolateral pons; A6: 
Locus coerulus; Ach: Acetylcholine receptors; ATP: Adenosine triphosphate; CCK: 
Cholecystokinin receptors; DA: Dopamine receptors; NA: Nucleus of ambiguous; NE: 
Norepinephrine; NK: Neurokinin receptors; NTS: Nucleus of solitary tract; PAG: 
Periaqueductal gray; SP: Substance P; SST: Cyclid polypeptide somatostatin; TM: 
Tuberomammillary nucleus; VM: Ventral medulla; VRC: Ventral respiratory column (Doi 
and Ramirez 2008). 
1.3.5.2 Opioids and respiratory depression 
Opioid receptors are G-protein coupled receptors. Opioids binding to these receptors activate 
inhibitory pathways that ultimately reduce cyclic adenosine monophosphate (cAMP) 
production and thus reduce neuronal excitability (Doi and Ramirez 2008). 
 
From experiments with mice, it is now clear that the mu-receptor is the predominant mediator 
of morphine induced analgesia, catatonia as well as of respiratory depression (Czick et al. 
2014). Mu-opioid receptors are present in large concentrations in the respiratory control 
centres of the brain stem such as in the PreBOTc and in other areas such as in the lungs, 
carotid bodies and vagus nerve (Pattinson 2008; Czick et al. 2014). Activation of these 
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receptors changes the respiratory rhythm generation in the PreBOTc. It also reduces 
sensitivity of the central and peripheral chemoreceptors to CO2 and pH changes and thus, 
breathing frequency and tidal volume get reduced (McCrimmon and Alheid 2003; Buss and 
Meltzer 2001). Furthermore, opioids cause a decrease in pulmonary perfusion and impaired 
alveolar oxygen exchange due to pulmonary vasoconstriction and hypertension (Meyer et al. 
2015).  
1.3.5.3 Reversal of opioid-induced respiratory depression 
Thanks to the complexity and involvement of many different neuromodulator substances, 
there are also several approaches possible to combat opioid-induced respiratory depression 
(Dahan et al. 2010). While simple assisted ventilation and oxygen insufflation could combat 
hypoxia (Fahlman 2014), pharmacological agents such as opioid antagonists or partial 
antagonists could also be used but would at the same time abolish or reduce desirable effects 
such as immobilisation, sedation and analgesia (Kock and Burroughs 2012; van der Schier et 
al. 2014). 
 
Respiration could also be manipulated by respiratory stimulants which act on non-opioid 
receptor systems such as potassium channel blockers, ampakines and serotonin receptor 
agonists (van der Schier et al. 2014). 
1.3.5.3.1 Oxygen insufflation 
The routine use of oxygen is recommended during wildlife immobilisation and can be 
combined with a partial opioid reversal to better alleviate hypoxia (Fahlman 2014; Haw et 
al. 2014). However, it is not always practical to carry an oxygen flask or an oxygen 
concentrator. Some animals, such as the African elephant (Loxodonta africana) are simply 
too large to achieve an adequate oxygen flow in field conditions (Fahlman et al. 2012). In 
addition, oxygen insufflation can only be started once the capture team has reached the 
immobilised animal. The team might reach the animal only after several minutes which might 
be too late as hypoxia is worst during the first ten minutes of opioid immobilisation (Heard 
et al. 1990; Buss and Meltzer 2001; Meyer et al. 2006; Meyer et al. 2008a; Meyer et al. 
2015). Oxygen therapy might also have to be combined with a partial reversal of the opioid 
in order to be effective (Haw et al. 2014). 
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1.3.5.3.2 Full opioid receptor antagonists 
Two full opioid antagonists are currently available for clinical use (Table 1). Naloxone is a 
non-selective competitive antagonist for mu-, kappa- and delta-opioid receptors and 
approved for therapeutic use in humans for the purpose of reversing opioid-induced adverse 
reactions, including respiratory depression. The biologic half-life of naloxone is 33 minutes. 
This is short and re-narcotisation has to be expected after this amount of time as the biological 
half-life of most opioids is longer (Kock and Burroughs 2012). 
 
Naltrexone hydrochloride is registered for the use in animals as formulation called Trexonil 
in a concentration of 50 mg ml-1 (Wildlife Pharmaceuticals (Pty) Ltd., South Africa). 
Naltrexone is derived from the basic phenanthrene structure which is similar to thebaine 
(Haigh 1990). Due to its longer biological half-life, naltrexone is commonly used to 
antagonise opioid immobilisation in wildlife (Haigh 1990; Mutlow et al. 2004; Cole et al. 
2006). The current recommendations in wild ruminants for the dose of naltrexone in order to 
antagonise thiafentanil and etorphine are 10 mg and 20 mg of naltrexone per milligram of 
thiafentanil and etorphine respectively. At these doses, no re-narcotisation has been reported 
(Kock and Burroughs 2012; O’Dell et al. 2017). 
 
Signs of recovery after naltrexone administration consist of an increased fR and respiratory 
depth, followed by movement of areas of the head such as ear twitching, eye movement and 
lifting of the head. Animals then stand up (Haigh 1990; O’Dell et al. 2017).  
 
While full opioid antagonists such as naloxone and naltrexone reverse respiratory depression 
caused by opioids, they also reverse all other desirable effects such as analgesia, sedation and 
catatonia of the patient and thus their use is limited in the context of wildlife immobilisation 
or pain management unless the situation permits the complete reversal of all opioid effects. 
 
1.3.5.3.3 Partial opioid receptor antagonists 
Partial mu-receptor antagonists (also called opioid agonist-antagonist drugs) such as 
butorphanol, nalbuphine and nalorphine can be used to alleviate respiratory depression 
caused by strong mu-agonistic immobilisation drugs such as etorphine (Kock et al. 1995; 
Boardman et al. 2014; Lamont and Grimm 2014). However, some of these partial antagonists 
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also reduce the immobilisation effects of opioids. Thus, their use and efficacy are limited 
(Haw et al. 2016a and b).  
1.3.5.3.4 Potassium channel blockers 
Doxapram is the oldest potassium channel blocker used to stimulate breathing by its action 
on the carotid bodies (van der Schier et al. 2014). Doxapram is commonly used as a 
respiratory stimulant by veterinarians (Kock and Burroughs 2012). Doxapram when 
administered to impala that were immobilised with etorphine increased the minute ventilation 
during the first three minutes after immobilisation, but it did not achieve a decrease in PaCO2. 
The respiratory effects of doxapram were short lived (Meyer et al. 2010). 
 
A novel potassium channel blocker, GAL-021, is currently being studied and has been shown 
to counter-act respiratory depression caused by alfentanil without reducing analgesia or 
sedation in human volunteers. GAL-021 also has a rapid onset of effect and could be used 
concomitantly with an opioid (van der Schier et al. 2014; Roozekrans et al. 2014; Roozekrans 
et al. 2015). 
1.3.5.3.5 Ampakines 
Ampakines are modulators of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic 
acid (AMPA) receptors. Within the PreBOTc, AMPA receptors are important for the 
maintenance of the respiratory rhythm and their activation leads to an increase in respiratory 
frequency. Pre-treatment with the ampakine CX717 reduced alfentanil induced respiratory 
depression in humans without antagonising analgesia or sedation (Dahan et al. 2010; van der 
Schier et al. 2014). Treatment of etorphine immobilised goats with an IV injection of the 
ampakine CX1942 attenuated opioid-induced respiratory depression in these animals (Haw 
et al. 2016a). 
1.3.5.3.6 Serotonin (5-HT) receptor ligands 
Although only discovered in the mid-twentieth century, serotonin, or 5-Hyrdoxytryptamine 
(5-HT) is a biochemical which can be found in plants as well as animals. In mammals it is 
utilised as a neurotransmitter within the central and peripheral nervous system. Serotonin 
also serves as a hormone in many tissues where it is involved in the regulation of numerous 
physiological processes. Amongst others it regulates smooth muscles in the cardiovascular 
system and gastrointestinal tract and stimulates platelet aggregation. The exact sites and 
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modes of action of serotonin are still under investigation and so far fourteen 5-HT receptor 
subtypes have been identified, most of which are G-protein coupled receptors (Sanders-Bush 
and Mayer 2006; Barnes and Neumaier 2011). 
 
5-HT1A, 5-HT7 and 5-HT4A receptors are all involved in respiratory rhythm generation and 
are expressed in the PreBOTc, but not on pain neurons. Thus, drugs acting on these receptors 
might have potential to be used in conjunction with opioids to alleviate opioid-induced 
respiratory depression without influencing analgesia and sedation (Richter et al. 2003; 
Pattinson 2008). 
1.3.5.3.6.1 5-HT4A receptors 
5-HT4A receptors are strongly co-expressed together with mu-opioid receptors on inspiratory 
neurons of the PreBOTc (Manzke et al. 2003). The 5-HT4A and mu-receptors interact in an 
antagonistic manner. While mu-receptors decrease cAMP and thus lead to inhibition of 
neuronal activity, 5-HT4A receptors raise the cAMP concentration and thus facilitate neuronal 
signal transmission. In rats, the application of a 5-HT4A agonist increased minute ventilation. 
When rats were treated with the opioid fentanyl apnoea resulted and stable respiratory 
activity was re-established by subsequent treatment of these rats with the 5-HT4A agonist 
BIMU8. Analgesia was maintained (Manzke et al. 2003). In etorphine treated goats, 
administration of the 5-HT4A agonist zacopride increased ventilation and thus improved 
hypercapnia while maintaining opioid-induced immobilisation (Meyer et al. 2006).  
 
Lötsch et al. (2005) investigated if the 5-HT4 receptor agonist mosapride would alleviate 
morphine induced respiratory depression in humans and rats. Respiratory depression was 
assessed by means of breathing frequency, carbon dioxide rebreathing and spirometry. The 
assessment, based on these variables, did not indicate that mosapride could prevent 
respiratory depression in these species. Unfortunately, blood gas analysis was not reported 
in these experiments. 
 
Subsequently Meyer et al. (2010) administered the 5-HT4A agonist metoclopramide to 
etorphine immobilised impalas. In accordance with Lötsch et al. (2005) there was no 
improvement of minute ventilation. However, on examination of blood gases, an increase in 
PaO2 was observed within three minutes after injection which was coupled to a decreased A-
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a gradient. Meyer et al. (2010) thus concluded that the improvement of blood oxygenation 
most possibly was due to an improvement of V/Q ratios caused by metoclopramide via its 
vasodilatory action on pulmonary blood vessels. Unfortunately this drug also caused arousal 
of the impala several minutes after injection (Meyer et al. 2010). 
 
Dutschmann et al. (2009) compared the difference between the 5-HT1A receptor agonist 8-
OH-DPAT and the 5-HT4 agonist RS 67333 in their ability to counteract cardiorespiratory 
disturbances caused by remifentanyl in rats. It was established that in contrast to 8-OH-
DPAT, which restored breathing, the 5-HT4 agonist RS 67333 further suppressed 
cardiovascular functions. 5-HT1A receptors were more densely expressed in brainstem areas 
responsible for the cardiorespiratory control such as the PreBOTc and others. The authors 
concluded that, despite earlier reports by Manzke et al. (2003), 5-HT1A agonists might be 
better suited than 5-HT4 agonists to counteract opioid-induced respiratory depression.  
1.3.5.3.6.2 5-HT7 receptors 
Like the 5-HT4A receptor, the 5-HT7 receptor stimulates cAMP production (Richter et al. 
2003). 5-HT7 receptors might influence respiration as they are expressed in the PreBOTc, but 
in low numbers (Richter et al. 2003). The 5-HT7 agonist pimozide was administered to 
etorphine immobilised impala but the drug did not attenuate the etorphine-induced hypoxia 
in this experiment (Meyer et al. 2010). 5-HT7 receptors are implicated in various behavioural 
and psychological processes such as processes affecting the circadian rhythm, sleep 
induction, behaviour and gastro intestinal and vascular smooth muscle relaxation (Richter et 
al. 2003; Pithadia and Jain 2009). 
1.3.5.3.6.3 5-HT1A receptors 
5-HT1A receptors are broadly distributed in the CNS. They are expressed by all serotonin 
neurons as auto-receptors as well as by many non-serotonergic neurons as hetero-receptors. 
The activation of 5-HT1A receptors is usually inhibitory as they reduce the neuron firing rate. 
Apart from influencing the central respiratory centres, 5-HT1A receptors are therapeutic 
targets for several neuropsychiatric disorders. For clinical treatment of various disorders such 
as schizophrenia, depression and anxiety, various 5-HT1A ligands that act as partial agonists 
or antagonists have been developed and partial 5-HT1A agonists such as buspirone and 
gepirone are effective anxiolytics used in human medicine (Richter et al. 2003). 5-HT1A 
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receptor activation can also lead to hypothermia, hyperphagia and serotonin syndrome 
(Goodwin et al. 1985; Prow et al. 1996; Christoffersen and Meltzer 1998; Barnes and 
Neumaier 2011). 
 
5-HT1A receptors are the most abundant 5-HT receptors in the central respiratory network. 
While it is established that 5-HT1A receptor agonists prevent respiratory depression caused 
by opioids and establish normal respiratory patterns after disturbance (Sahibzada et al. 2000; 
Richter et al. 2003; Dutschmann et al. 2009; Dahan et al. 2010; van der Schier et al. 2014; 
Kimura and Haji 2014), the exact mechanisms how this is achieved are still an enigma. 5-
HT1A receptor activation leads to inhibition of neuronal transmission along the same 
inhibiting pathway that is activated by mu-opioid receptors (Richter et al. 2003; Manzke 
2004). The effects of 5-HT1A agonists are possibly based on a mixed action of 5-HT1A 
receptors at the spinal cord and in the respiratory centres of the brain stem as well as 
interaction with the opioid mechanism (Kimura and Haji 2014).  
 
It is proposed that activation of post-synaptic 5-HT1A receptors inhibits nerve impulses in the 
inspiratory centres which, under the influence of opioids cause a prolonged inspiratory phase 
and thus lead to apnoea (Lalley et al. 2014). As a consequence of further inhibition, 
respiratory patterns are shifted, the prolonged inspiratory phase (caused by opioids) is 
decreased and respiratory rate increased (Lalley et al. 1994; Sahibzada et al. 2000; Manzke 
2004). Another proposal is that 5-HT1A receptor activation increases excitability of neurons 
in the spinal cord (Teng et al. 2003). And yet a further proposal involves pre-synaptic 5-HT1A 
auto-receptors that might reduce serotonin release (Oertel et al. 2007). 
 
The 5-HT1A receptor agonist buspirone has already been successfully used in the treatment 
of severe surgery related apnoea in a child (Wilken et al. 1997). This case report is however 
in contrast to experimental results reported by Oertel et al. (2007) where the 5-HT1A receptor 
agonist buspirone did not reduce morphine induced respiratory depression in humans but 
rather increased nausea. Methods of Oertel et al. (2007) were the same as reported for 
mosapride by Lötsch et al. (2005) and respiratory depression was assessed by means of 
breathing frequency, carbon dioxide rebreathing and spirometry. Unfortunately blood gas 
analysis was not reported in these experiments and based on results of Meyer et al. (2006) 
and Meyer et al. (2010), an improvement of blood gas values might have been detected due 
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to the possible influence of 5-HT1A agonists on improving the opioid-induced V/Q mismatch. 
Buspirone is currently the only registered 5-HT1A agonist available for human use but is only 
a weak respiratory stimulant when administered with opioids and a different agonist such as 
the 5-HT1A agonist 8-OH-DPAT might have produced a different outcome (Guenther et al. 
2009). The 5-HT1A receptor agonist 8-OH-DPAT improved opioid-induced respiratory 
depression in goats without affecting immobilisation (Meyer et al. 2006). 
 
Based on the above-mentioned publications the 5-HT1A agonist, 8-OH-DPAT seemed the 
best candidate to further analyse for its suitability to be used in an opioid-based 
immobilisation mixture for wild animals. 
 
1.4 8-OH-DPAT 
The experimental drug 8-OH-DPAT was first synthesised and reported by Arvidsson et al. 
(1981). 8-OH-DPAT is a highly selective agonistic ligand for the 5-HT1A receptor with some 
action on the 5-HT7 receptor (Pithadia and Jain 2009; Barnes and Neumaier 2011) . The drug 
was mostly used in experiments to characterise 5-HT1A receptor actions (Goodwin et al. 
1985; Löscher et al. 1990; Eison and Wright 1992; Zuideveld et al. 2000; Guenther et al. 
2009; Zhuang et al. 2012). 
 
The racemic mixture of 8-OH-DPAT contains two enantiomers: the slightly more potent R–
enantiomer and the S-enantiomer (Hadrava et al. 1996; Lejeune et al. 1997; Christoffersen 
and Meltzer 1998). 
 
1.4.1 8-OH-DPAT and the treatment of respiratory depression 
Both 5-HT1A receptor agonists, 8-OH-DPAT and buspirone, have been investigated within 
the context of treatment of opioid-induced apnoea and spontaneous central apnoea. In human 
medicine, this would have valuable applications in conjunction with respiratory depression 
caused by opioid-based analgesia. (Wilken et al. 1997; Teng et al. 2003; Pattinson 2008). 
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Both, 8-OH-DPAT as well as buspirone, were found to be able to restore normal respiratory 
activity in rats without affecting analgesia after a state of severe respiratory depression or 
apnoea was provoked by treatment with the opioid morphine (Sahibzada et al. 2000; 
Guenther et al. 2009). At high dosages of 0.01 mg kg-1, 8-OH-DPAT seemed to increase 
spontaneous minute ventilation and even complement the analgesic effect of morphine 
(Guenther et al. 2009). In mice 0.01 mg kg-1 8-OH-DPAT administered intraperitoneal (IP) 
decreased central apnoea. 8-OH-DPAT administered IV at 0.1 mg kg-1 also increased 
breathing frequency in hypoxic goats (Herman et al. 2001). A dosage of 0.5 mg kg-1 8-OH-
DPAT injected IV together with the opioid etorphine attenuated the respiratory depressive 
effects of etorphine without reversing the catatonic immobilisation (Meyer et al. 2006). 
However, this effect seemed to stem from an altered pulmonary perfusion leading to 
improved gas exchange rather than from an increased respiratory rate (Meyer et al. 2006). In 
impala, the partial 5-HT1A agonist buspirone injected IV at 0.05 mg kg-1 also improved the 
respiratory state of etorphine-immobilised animals presumably by its positive influence on 
the alveolar gas exchange as none of the drugs achieved improved minute ventilation (Meyer 
et al. 2010). Unfortunately, 8-OH-DPAT in the context of respiration was either used in 
laboratory animals or administered IV and thus it cannot be concluded that it would have the 
same affects when it is used IM in wild animals in an immobilisation mixture together with 
an opioid. In addition, the ideal 8-OH-DPAT dosage in this context has yet to be established. 
 
1.4.2 8-OH-DPAT dosages 
The literature mostly describes dose–effect studies on laboratory animals such as rats, mice 
and gerbils which include the IV administration of 8-OH-DPAT or of its slightly more potent 
active enantiomer R-8-OH-DPAT (Lejeune et al. 1997; Sahibzada et al. 2000; Guenther et 
al. 2009) (Table 2). Although most reports are in a different context, it is important to 
extrapolate from the available literature to propose dosages to be used in combination with 
etorphine to immobilise an animal. 
 
There are species-specific differences in laboratory animals with regards to their 
susceptibility to 8-OH-DPAT (Eison and Wright 1992). Species-specific differences possibly 
also exist between other mammals, such as between goats and various antelope species. 
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Mostly behavioural serotonergic effects were measured in laboratory animals and termed 
serotonin syndrome (SS). 
 
Serotonin syndrome (SS), purposefully elicited, is used in laboratory animals to characterise 
drug activity and activation of serotonin receptors and therefore numerous reports on SS are 
available in this context (Table 2). Serotonin syndrome in laboratory animals is divided in 
the following signs: forepaw treading, flat body posture, hindlimb abduction, head weaving, 
straub tail and tremors (Tricklebank et al. 1985; Haberzettl et al. 2013). Pupillary dilation 
has also been reported as a sign of 5-HT1A receptor activation (Yu et al. 2004). 
 
Rats were the most susceptible and 0.033 mg kg-1 R-8-OH-DPAT injected SC elicited 
behavioural effects such as forepaw treading and cessation of cage leaving response (Yu and 
Lewander 1997). Hence, possibly lower dosages can be used in rats to elicit effects on the 5-
HT1A receptors. Pupillary dilation in rats started from about 0.01 mg kg-1 of R-8-OH-DPAT 
injected IV and was dosage dependent (Yu et al. 2004). Carey et al. (2004) found that rats 
injected with 0.025 mg kg-1 8-OH-DPAT show behavioural differences when compared to 
saline treated rats. These differences were not visible when rats were treated with 0.01 mg 
kg-1 8-OH-DPAT (Carey et al. 2004). A dosage of 0.1mg kg-1 8-OH-DPAT was used in rats 
by Kline et al. (2010) in an attempt to facilitate faster healing of traumatic brain injury. 
 
In most experiments on the ability of 8-OH-DPAT to alleviate respiratory disturbance, 
laboratory animals were possibly treated with a much higher dosage of 8-OH-DPAT than 
necessary. For example, in the experiment of Dutschmann et al. (2009) rats were injected 
with 1 mg kg-1 IV in conjunction with remifentanil. While Sahibzada et al. (2000) as well as 
Guenther et al. (2009), restored normal breathing in rats by IV injection of just 0.01 mg kg-1 
8-OH-DPAT after causing a morphine-induced apnoea. No behavioural side effects were 
reported in these studies as the animals were under opioid influence which might have 
suppressed behavioural responses to the serotonin agonist. 
 
In an attempt to decrease central apnoea in mice, Stettner et al. (2008) injected 0.01 mg kg-1 
8-OH-DPAT into mice. Mice are less susceptible to behavioural responses than rats. Mice 
treated IP with 8-OH-DPAT showed dilation of the pupils from a dosage of 1 mg kg-1 (Prow 
et al. 1996). 
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Darmani and Zhao (1998) produced behavioural effects in the least shrew (Cryptotis parva) 
with 1.25 mg kg-1 of 8-OH-DPAT injected IP. This was also the lowest dosage used in the 
experiment. Effects in shrews increased with increasing dosages up to 20 mg kg-1. These 
dosage rates could possibly have been a lot lower as the least shrew is more susceptible than 
the mouse to 8-OH-DPAT (Darmani and Zhao 1998). In Mongolian gerbil (Meriones 
unguiculatus), behavioural effects were induced by 8-OH-DPAT after SC injection of 0.125 
mg kg-1 (Eison and Wright 1992). 
 
Lalley et al. (1994) treated apnoea in cats with an IV administration of 0.01 to 0.05 mg kg-1 
8-OH-DPAT. Kotani et al. (2016) decreased pupil size of marmosets (Callithrix jacchus) 
with a dosage of 0.1 mg kg-1 8-OH-DPAT injected IM. In experiments with rhesus monkeys 
(Macaca mulatta) McMahon (2016) managed to elicit a 9-tetrahydrocanabiol (THC) 
discrimination response with 0.056 mg kg-1 8-OH-DPAT injected SC. After injecting 8-OH-
DPAT 0.5 mg kg-1 IM Löscher et al. (1990) observed head shakes in pigs. Head shaking in 
pigs was in contrast to the behavioural effects usually observed in laboratory animals where 
“head weaving” is listed as one of the symptoms but at the end of the severity scale 
(Tricklebank et al. 1985). There are two reports of 8-OH-DPAT use in ruminants, both in 
goats. Herman et al. (2001) administered 0.1 mg kg-1 IV 8-OH-DPAT into goats and achieved 
an increase in breathing frequency and improved minute ventilation. Meyer et al. (2006) 
examined if the use of 0.5 mg kg-1 8-OH-DPAT injected IV together with etorphine would 
improve opioid-induced hypoxia. These studies in goats did not report any side effects or 
behavioural effects caused by 8-OH-DPAT despite the fact that the dosages were 
comparatively high. However any behavioural changes could have been masked by the 
sedative effect of etorphine (Meyer et al. 2006). Altered behaviour and SS occurred within 
15 minutes after SC injection of 8-OH-DPAT in mice, rats and marmosets and coincided 
with its highest plasma concentrations (Prow et al. 1996; Yu and Lewander 1997; Kotani et 
al. 2016). Following this literature study, it became clear that a bioavailability study of 8-
OH-DPAT followed by a dose-response study in various species would be of value as 8-OH-
DPAT could be potentially used in wildlife immobilisation to alleviate opioid-induced 
respiratory depression. 
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Goats, being small ruminants, predominantly browsers, and easy to handle without 
immobilisation are commonly used as a model for studies of pharmaceuticals to be used in 
wild ungulates (Buss and Meltzer 2001). Thus, a bioavailability study of 8-OH-DPAT to 
compare absorption of the drug after IM and IV administration was elected to be undertaken 
in goats. 
1.4.3 Serotonin syndrome (SS) and serotonin toxicity (ST) 
Serotonin syndrome (SS) can be caused by the use of serotonergic drugs which result in over 
activation of the peripheral and post-synaptic 5-HT1A and 5-HT2A receptors (Volpi-Abadie 
et al. 2013). When SS appears as a side effects of patents, treated with serotonergic drugs, it 
is termed serotonin toxicity (ST). Serotonin toxicity can also develop due to drug interactions. 
Hall et al. (2008) mention that phenylpiperidine opiates such as fentanyl, sufentanil and 
alfentanil by themselves significantly elevate central serotonin levels. Thus, when these 
opioids are combined with serotonin agonists, they could potentially lead to ST. In contrast, 
morphine and morphine analogues such as etorphine, do not affect serotonin levels (Hall et 
al. 2008). The importance of this information lies in the fact that various potent opioids are 
used for capture of wildlife and while etorphine is a morphine derivative, thiafentanil, another 
potent opioid which is popular for wildlife capture is a phenylpiperidine opioid and closely 
resembles sufentanil in its structure (Kock and Burroughs 2012).  
 
Serotonin toxicity has to be taken seriously. In the context of the attempted improvement of 
respiration, ST would obviously have to be considered as a negative and undesirable side 
effect. Serotonin toxicity can potentially be life threatening. Serotonin toxicity in humans is 
characterised by a triad of symptoms consisting of altered mental status, neuromuscular 
abnormalities and autonomic hyperactivity (Boyer 2005; Volpi-Abadie et al. 2013). The 
altered mental state can include agitation, anxiety, restlessness and excitement. 
Neuromuscular abnormalities can manifest in tremors, hyperreflexia, muscle rigidity and 
autonomic hyperactivity can include hypertension, tachycardia, arrhythmias, tachypnoea, 
hyperthermia, mydriasis, shivering, diarrhoea and vomiting. Serotonin toxicity can involve 
vital sign abnormalities such as tachycardia, hypertension and hyperthermia which can 
become severe and terminate in shock (Boyer 2005). Clinical pathological disturbances 
observed in conjunction with ST can be metabolic acidosis, rhabdomyolysis, elevated levels 
of creatinine, lactate and certain enzymes, disseminated intravascular coagulopathy and signs 
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of renal failure. Most of these symptoms would develop as a consequence of untreated 
hyperthermia (Boyer 2005) and would be difficult to differentiate in wildlife from signs of 
CM which would be very similar (Paterson 2014). Thus, ST in humans, as well as in animals, 
is actually not easy to diagnose and diagnosis is often based on history of serotonergic drug 
use and clinical symptoms. Toxicology would be the gold standard for the diagnosis of ST 
(Volpi-Abadie et al. 2013). 
 
Serotonin toxicity can be treated by stopping the serotonergic agent and by providing 
supportive care and stabilising the patient, which might include sedation with 
benzodiazepines and cooling in case of hyperthermia. Serotonin antagonists can also be 
included in the therapy. If untreated, mild STs can resolve within 24 hours (Volpi-Abadie et 
al. 2013). Pharmacologically, ST can be treated with the 5-HT2A receptor antagonist 
cyproheptadine. The 5-HT2A receptor is thought to be mostly implicated in the development 
of hyperthermia in humans (Hall et al. 2008). However, our study would be dealing with the 
5-HT1A agonist 8-OH-DPAT and therefore cyproheptadine would be contra-indicated as 
potential treatment for ST in our experiments. 
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Table 2: 8-OH-DPAT dosages reported in various species 
8-OH-DPAT 
dosage in mg 
kg-1 
Administra-
tion method 
Species Reference Context 
0.01  IV rats (Yu et al. 2004) Pupillary dilation  
0.033  
 
SC rats (Yu and Lewander 1997) SS 
0.025  SC rats (Carey et al. 2004) Locomotor activity 
0.1  IP rats (Kline et al. 2010) Traumatic brain 
injury 
1.0  IV rats Dutschmann et al. 2009) With remifentanyl 
0.01  IV rats (Sahibzada et al. 2000) With morphine 
0.01  IV rats (Guenther et al. 2009) With morphine 
0.01  IP mice (Stettner et al. 2008) Treat spontaneous 
apnoea 
1.0  IP mice (Prow et al. 1996) Pupillary dilation 
1.25  IP least 
shrews 
(Darmani and Zhao 1998) SS 
0.125  SC mongolian 
gerbils 
(Eison and Wright 1992) SS 
0.01  IV cats (Lalley et al. 1994) Treat apnoea 
0.1  IM marmosets (Kotani et al. 2016) Pupillary dilation 
0.056  SC rhesus 
monkeys 
(McMahon 2016) THC response 
0.5  IM pigs (Löscher et al. 1990) SS 
0.1  IV goats (Herman et al. 2001) With hypoxia 
0.5  IV goats (Meyer et al. 2006) With etorphine 
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1.5 The choice of species to conduct wildlife research 
There is a vast number of wildlife species and every species cannot be covered individually 
when carrying out pharmacological or anaesthesiology research. Investigators have to 
carefully choose the species best suited for the research questions to be answered. Small 
domestic ruminant species like sheep (Ovis aries) and goats (Capra hircus) are commonly 
used as a model for antelope species as serial blood samples can be collected for 
pharmacological research and monitoring devices can be attached before immobilisation 
without causing undue stress to domestic animals (Heard et al. 1990; Heard et al. 1996; Buss 
and Meltzer 2001; Meyer et al. 2006; Meyer et al. 2015; O’Dell et al. 2017; Izwan et al. 
2018). In contrast, to undertake pharmacological investigations into immobilisation, wildlife 
species should ideally be used to properly reflect the interaction between the stress induced 
by human presence and the drug effects (Meyer et al. 2008a and b). It is important however, 
to choose a wildlife species which is easy to keep in captivity and easy to handle as well as 
abundantly available in the study area. Furthermore, the species of choice should be 
phylogenetically, physiologically and in their behaviour, representative of as many wildlife 
species as possible.  
 
1.5.1 Goats (Capra hircus) 
Goats (Figure 3) are often used as a model for wild ungulates as they are easily available 
small domestic ruminants and can be handled without immobilisation. Venous and arterial 
blood can be collected over a period of time without causing unnecessary stress or the risk 
of prolonged anaesthesia to the animals. For these reasons, goats have been previously used 
as models for wild ungulates on many occasions (Heard et al. 1990; Heard et al. 1996; Buss 
and Meltzer 2001; Mutlow et al. 2004; Meyer et al. 2006; Meyer et al. 2015; Haw et al. 
2016a and b; Izwan et al. 2018). Goats are closest related to the antelope subfamilies 
Alcelaphinae as well as Hippotraginae (Hernandez Fernandez and Vrba 2005) (Figure 4). 
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Figure 3: Indigenous goats (Capra hircus) used for this experiment. 
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Figure 4: Phylogenetic relationships in the suborder of Ruminatia (Hernandez Fernandez and 
Vrba 2005). Marked with red boxes are the subfamilies relevant to this study: Aepycerotinae 
(Impala), Alcelaphinae (blesbok) and Caprinae (goats, sheep). 
 
1.5.2 Blesbok (Damaliscus pygargus phillipsi) 
Blesbok (Figure 5) fall into the subfamily of Alcelaphinae. They are medium sized antelopes 
and weigh around 60 kg. Males as well as females have horns. Blesbok live in herds of two 
to 25 ewes and lambs. Adult males live as bachelor groups or as territorial rams. Blesbok are 
seasonal breeders. After a gestation period of approximately eight months, they give birth 
during the summer months of December to February. They prefer the grassland habitat of 
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southern Africa and are very popular animals to be kept on game farms where they are utilised 
for ecotourism, meat production and hunting. Colour variations of blesbok are used for stud 
breeding in South Africa and fetch very high auction prices (Furstenburg 2016a). Blesbok 
have to be captured and kept in temporary confinement regularly for translocation and trade 
purposes. Drug combinations commonly used for the immobilisation of blesbok contain a 
potent opioid such as etorphine or thiafentanil in combination with the butyrophenone 
derivative azaperone or with an alpha-2 agonist (Kock and Burroughs 2012). Blesbok are 
listed on the IUCN red list as least concern (Lloyd and David 2008). 
 
When these animals are kept in temporary captivity, it is important to protect their sharp 
horns with plastic pipes to prevent injuries during social interactions (Kock and Burroughs 
2012). 
 
 
Figure 5: Blesbok (Damaliscus pygargus phillipsi) in the enclosure – note that pipes are on 
the horns to prevent injuries. 
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1.5.3 Impala (Aepyceros melampus) 
Impala (Figure 6) are small to medium sized antelopes of the savannah woodlands of the 
southern African subregion, with adult ewes weighing around 40 kg. This species is sexually 
dimorphic with only male animals having horns. During mating season from January to May, 
males become very territorial and vocal. Most rams spend their time in bachelor herds while 
females live in breeding herds. Impala lamb during the summer months from November to 
February. Impala are widespread and an important source of game meat in southern Africa 
and are captured regularly for trade and translocation purposes. In South Africa, black, 
saddleback and white impala are now bred as colour variations, which makes some of the 
animals very valuable as stud animals (Furstenburg 2016b). 
 
Impala are one of the most challenging species to dart. The reason for this is because they 
are a comparatively small and mobile target but also because they suffer from severe 
respiratory depression when darted with potent opioids and tend to be easily affected by CM 
if they are stressed (Zeiler and Meyer 2017a and b). Common drugs used for darting of impala 
are the potent opioids etorphine and thiafentanil, sometimes combined with ketamine. 
Veterinarians usually have the opioid reversal naltrexone or the partial opioid reversal 
butorphanol on hand to alleviate respiratory depression as soon as possible if required (Meyer 
et al. 2010; Kock and Burroughs 2012; Zeiler and Meyer 2017a and b) . Impala are listed on 
the IUCN red list as least concern (IUCN 2016). Impala, from a phylogenetic point of view 
are not closely related to other antelope species (Hernandez Fernandez and Vrba 2005) 
(Figure 4).However, because of their abundance and because they are easy to keep in 
temporary confinement and a popular zoo species, numerous anaesthesia and immobilisation 
experiments have been conducted with impala (Cheney and Hattingh 1987; Janssen et al. 
1993; Meyer et al. 2008a and b; Meyer et al. 2010; Zeiler et al. 2015; Perrin et al. 2015; 
Zeiler and Meyer 2017a)  
 
 42 
 
Figure 6: Impala (Aepyceros melampus) ram and ewes in their natural habitat. 
 
1.6 Summary 
Adverse anaesthetic events and deaths are common in wildlife anaesthesia. Wild animals 
cannot be clinically examined beforehand and may have underlying disease or physiological 
conditions that can lead to complications during immobilisation. Body weight is difficult to 
determine in the field as animals in most cases cannot be weighed neither can food and water 
be withdrawn. Following immobilisation wild animals have to be located and are often not 
examined for the first 15 to 20 minutes until a ground team can reach them. It is therefore 
imperative to constantly look for improvement of methods of wildlife immobilisation and 
anaesthesia (Breed et al. 2019). Improvement includes but is not limited to immobilising 
drugs and combinations. One of the major current concerns is respiratory depression caused 
by the opioids used for immobilisation of wild ungulates. In this context, the first minutes 
post immobilisation are especially critical as often animals have not yet been reached to 
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administer any further medication in order to treat respiratory depression. This topic was 
chosen to be the focus of this thesis. 
 
Our research explored the use of the serotonergic drug R-8-OH-DPAT that could potentially 
improve the safety of immobilisation of a vast variety of wildlife species. Following these 
experiments, the potent opioid immobilisation drugs etorphine and thiafentanil were 
compared in two antelope species. The two drugs were compared with regards to 
immobilisation quality, safety as well as physiological changes. Special emphasis was placed 
on respiratory depression.  
 
1.7 Aims  
The general aims of this thesis were as follows: 
 
1) Determine the bioavailability and pharmacokinetic parameters of R-8-OH-DPAT injected 
IM compared to IV in goats. 
 
2a) Characterise the ability of R-8-OH-DPAT, when administered in combination with 
etorphine in a dart, to alleviate or prevent opioid-induced respiratory depression in impala 
and blesbok. 
2b) Establish the most clinically effective dosage of R-8-OH-DPAT, when mixed with the 
opioid etorphine in a dart, for immobilisation of wild ungulates to improve respiration. 
2c) Determine if there are species-specific differences in the effect of R-8-OH-DPAT on 
respiration during etorphine immobilisation. 
 
3) Compare physiological effects of two commonly used potent opioids, namely etorphine 
and thiafentanil, on impala and blesbok, and ascertain if there are species-specific effects, 
especially with regards to the drug influence on their respiratory physiology. 
 
1.8 General Hypothesis 
The following hypotheses guided the research: 
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1) The pharmacokinetics and bioavailability of R- 8-OH-DPAT in goats will be similar but 
different to that reported in other species. 
 
2) R-8-OH-DPAT will mitigate opioid-induced respiratory depression in impala and blesbok 
without affecting the quality of immobilisation. 
 
3) The time to recumbence, immobilisation quality and physiological variables, during 
immobilisation of blesbok and impala respectively, will differ between the two potent opioids 
etorphine and thiafentanil.  
 
4) There will be species-specific differences with regards to immobilisation quality and the 
effects of both opioids on respiratory physiology of the two antelope species. 
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Chapter 2: General Materials and Methods 
2.1 Study location 
All animals used in experiments were housed on Ngongoni Game Farm near Nelspruit, 
Mpumalanga Province, South Africa, approximately 713 m above sea level (25°31’25.2” S, 
31°06’50.8” E) (Figure 7). 
 
This research has particular relevance for South African wildlife conservation and 
production. South Africa has vast conservation areas and a large private wildlife industry and 
as such there is a high demand for safe wildlife anaesthesia. Wildlife immobilisations are 
carried out daily for management, scientific and clinical purposes. Many endangered species 
breeding projects are privately managed. The semi-controlled environments of captive 
breeding programmes and translocation enclosures, referred to as bomas, create an ideal 
situation where new drug combinations can be tested under controlled conditions (Semjonov 
et al. 2016). The quarantine and research bomas of Wildlife Pharmaceuticals (Pty) Ltd., the 
manufacturer of etorphine, thiafentanil and other wildlife immobilisation drugs, were used 
for these experiments. 
 
In addition, one of the initial lead investigators for the potential use for 8-OH-DPAT during 
opioid-based anaesthesia, Dr Leith Meyer, as well as the PhD student were based in South 
Africa near Nelspruit.  
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Figure 7: Map of South Africa displaying various provinces, the province Mpumalanga was 
the study area (Wikitravel.org). 
 
2.2 Drugs 
2.2.1 The R-enantiomer of 8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-
DPAT) 
8-OH-DPAT is a highly selective agonistic ligand for the 5-HT1A receptor with some action 
on the 5-HT7 receptor (Pithadia and Jain 2009; Barnes and Neumaier 2011).  
 
The racemic mixture of 8-OH-DPAT contains two enantiomers: the slightly more potent R-
enantiomer and the S-enantiomer (Hadrava et al. 1996; Lejeune et al. 1997; Christoffersen 
and Meltzer 1998). The R-enantiomer of 8-OH-DPAT (R-8-OH-DPAT hydrobromide; 
C16H25NO.HBr) was purchased from TOCRIS Bioscience, United Kingdom; catalogue 
number 1080. The chemical was stored frozen in desiccated form at -20 ºC. A stock solution 
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of 5 mg mL-1 in sterile water was prepared in a laboratory under aseptic conditions for the 
experiments within 24 hours before each trial. The solution was kept cold in vials at +4 ºC 
until it was used. 
 
For the immobilisation experiments, in addition to the stock solution, a 1 mg mL-1 solution 
was prepared fresh for each trial from the 5 mg mL-1 stock solution. 
Stability of the chemical in solution and in serum under frozen storage conditions was 
confirmed by laboratory analysis. 
 
2.2.2 Immobilisation drugs 
Immobilisation drugs were manufactured and supplied by Wildlife Pharmaceuticals (Pty) 
Ltd., South Africa. 
 
The following drugs were used: 
• Thiafentanil 10 mg mL-1 (Thianil, Wildlife Pharmaceuticals (Pty) Ltd., South Africa), 
a potent opioid commonly used to immobilise wild ungulates. 
• Etorphine 9.8 mg mL1 (Captivon, Wildlife Pharmaceuticals (Pty) Ltd., South Africa) 
a potent opioid commonly used to immobilise wild ungulates. 
• Azaperone 100 mg mL-1 (Zapnil, Wildlife Pharmaceuticals (Pty) Ltd., South Africa) 
a butyrophenones derivative tranquiliser that is commonly used in combination with 
opioids to combat hypertension caused by opioids, reduce induction time and reduce 
involuntary and voluntary movements during immobilisation. 
• Naltrexone 50 mg mL-1 (Trexonil, Wildlife Pharmaceuticals (Pty) Ltd., South Africa), 
a full opioid antagonist commonly used to reverse opioid-based immobilisation. 
Naltrexone is also used in the case of any accidental human opioid exposure during 
immobilisation procedures. 
• Butorphanol 50 mg mL-1 (Butonil, Wildlife Pharmaceuticals (Pty) Ltd., South 
Africa), a mu-opioid receptor antagonist and kappa-opioid receptor agonist which is 
used to combat respiratory depression that might arise during opioid-based 
immobilisation. Butorphanol was kept on stand-bye for potential emergencies. 
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• Midazolam 50 mg mL-1 (Dazonil, Wildlife Pharmaceuticals (Pty) Ltd., South Africa) 
was on stand-bye for the treatment of any potential severe serotonergic effects caused 
by R-8-OH-DPAT. 
 
2.2.3 Additional drugs 
• Adrenalin 1:1000: was available for treatment of acute cardiac emergencies (Kyron 
Laboratories, South Africa) 
• Doramectin 1 % (Dectomax®, Zoetis, South Africa) was used as injectable 
anthelmintic.. 
• Doxapram hydrochloride 20 mg mL-1 (Dopram, Fresenius Kabi, South Africa) was 
available for treatment of acute respiratory depression. 
• Procaine penicillin 150,000 IU ml-1 Benzathine penicillin 150,000 IU ml-1 
(Duplocillin ®, MSD Animal Health, South Africa) was used if animals had a deep 
dart wound or other injuries where antibiotic treatment was indicated. 
• Flumethrin 1 % (Drastic Deadline, Bayer Animal Health, South Africa) was used as 
pour-on dip for goats and wildlife species to eliminate ticks. 
• Vitamin / Amino acid / Mineral injection (Kyroligo, Kyron Laboratories, South 
Africa) was used for wildlife species shortly after delivery as a supportive drug. 
• Medical oxygen: Medical oxygen was supplied by Ecomed (South Africa) and was 
kept on stand-bye for potential emergencies. 
• Meloxicam 20 mg mL-1 (Metacam®, Boehringer Ingelheim, South Africa) is a non-
steroidal anti-inflammatory (NSAID) and was used as a once-off treatment in selected 
case of potentially painful trauma, such as when animals developed a haematoma or 
had a very deep dart wound. Meloxicam was chosen as NSAID of choice as it is not 
toxic for vultures (Naidoo et al. 2008) and other scavengers. 
• Oxytetracycline hydrochloride 40 mg, gentian violet 4 mg spray (Necrospray NT, 
Bayer Animal Health) was used to treat the dart wounds and other minor wounds 
when indicated. 
• Fenbendazol 5 % (Panacur® BS, MSD Animal Health, South Africa) was used as 
oral anthelmintic for goats. 
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2.3 Research animal numbers and ethical clearance 
A total of six female goats were used for the bioavailability experiment described in chapter 
3. Goats of similar weight and age were chosen. This study was approved by the Murdoch 
University Animal Ethics Committee (R2922/17) and the animal ethics committee of 
Wildlife Pharmaceuticals (WPAEC-2016-DPATGOAT-09-C) 
 
A total of six female impala and six female blesbok were necessary to carry out the clinical 
experiment with the serotonin agonist 8-OH-DPAT described in chapter 4. The study was 
approved by the Murdoch University Animal Ethics committee (R2923/17) as well as by the 
Wildlife Pharmaceuticals Animal Ethics Committee (WPAEC-DPATBLES-11-B). 
 
A total of eight female impala and eight female blesbok were used to carry out the 
experiments described in chapter 5 and 6. These animals were different from the animals 
described in chapter 4. The study was approved by Murdoch University’s Animal Ethics 
Committee (R3039/18) as well as Wildlife Pharmaceutical’s Animal Ethics Committee 
(WPAEC-2017-DPATBLES-11-B). 
 
No additional experiments were carried out for chapter 7, which describes the species 
differences if etorphine or thiafentanil are used for immobilisation. For this chapter, data 
collected in chapter 5 and 6 were evaluated. 
 
2.3.1 Health examinations 
Before experiments began all animals were weighed and physically examined by the 
veterinarian to ensure they were in good health. A faecal sample was collected from the 
rectum and a full blood, serum and plasma sample was collected from the jugular vein in 10 
ml vacutainer tubes by means of phlebotomy with a 18 G 25.4 mm vacutainer needle. All 
animals received a full blood cell count (IDEXX Lasercyte DX with a LaserCyte ® CBC5R 
cartridge) and a blood smear was examined. Animals received a liver and kidney function 
test using the IDEXX Catalyst DX with Catalyst ® Chem 10 CLIP cartridge. This cartridge 
provided information on the following parameters: Glucose (GLU), urea, creatinine (CREA), 
blood urea nitrogen / creatinine ratio, total protein, albumin (ALB), globulin (GLOB), 
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albumin / globulin ratio, alanine aminotransferase (ALT) and alanine alkaline phosphatase 
(ALP). 
Haematology and blood chemistry were carried out in the laboratory of West Acres Animal 
Hospital, Nelspruit. Faecal worm egg counts were carried out initially by West Acres Animal 
Hospital and again at one monthly interval by the veterinary research practice of Wildlife 
Pharmaceuticals SA to monitor the worm burden of goats and wildlife species. 
 
Impala and blesbok were weighed again after the second trial in order to adjust drug dosages 
where weights had changed. Goats were weighed by a handler lifting the animals on a 
bathroom scale and subtracting the weight of the handler. Weighing of blesbok and impala 
was carried out under immobilisation and animals were weighed while lying in a stretcher in 
sternal position and lifted with a hand-held precision scale which was attached to a pole 
(Anyload OCSL Mini Crane Scale, Anyload Transducer Co. Ltd. Canada). 
 
2.3.2 Pregnancy diagnosis 
Transabdominal ultrasound scan for pregnancy was carried out to ensure animals were not in 
advanced stage of pregnancy using a hand-held portable SIUI 800 ultrasound. 
 
2.4 Housing of wildlife species for the experiments 
Female impala and female blesbok for this study originated from private game farms and 
were purchased from a professional game capture operator (Capture@Wildlifevets). Impala 
and blesbok were held in the quarantine and research enclosures (bomas) of Wildlife 
Pharmaceuticals (Pty) Ltd. on Ngongoni Game Farm, Mpumalanga Province, South Africa 
(Figure 8), approximately 713 m above sea level. 
 
The enclosures consisted of several compartments of six by eight metres in size and were 
constructed from sturdy wooden poles. Impala and blesbok were held separately in groups 
of four to six animals. One third of each boma was covered with shade netting and the bomas 
were built on a slight slope to provide proper drainage. The bomas were connected to a 1.2 
m wide passageway that allowed for easy movement of the animals between boma 
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compartments and when they were off-loaded from the delivering truck. The enclosures were 
located on an open site that was easily accessed by game capture trucks but far away enough 
from any commercial roads so that the animals were not disturbed by the resulting noises. A 
fully equipped veterinary laboratory was available within 100 m from the enclosures.  
 
Solid feed containers along the boma wall were used, with smooth edges to prevent injury to 
the animals. Cement water troughs that were sunk into the ground and which extended to the 
outside of the bomas could contain more than 50 litres of water each. Water and feed were 
supplied ad libitum. Animals were fed game pellets (Boskos TM, WES enterprises, South 
Africa), A-grade lucerne (Medicago sativa) hay as well as Eragrostis hay. 
 
 
Figure 8: Wildlife enclosures (bomas) where animals were held for the experiments. 
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2.5 Housing and preparation of goats for the experiment 
Six healthy domestic female goats weighing between 29 and 43 kilograms (kg) were used in 
one of the studies (Figure 3). The goats were individually identified by means of ear tags and 
maintained in a suitably fenced outdoor enclosure of 15 x 10 meter which contained a covered 
shed and crush area for easy handling. Feed comprised of game pellets (BoskosTM, WES 
enterprises, South Africa) lucerne (Medicago sativa) hay and a salt lick. Feed as well as fresh 
water was available ad libitum. Natural trees and rocks served as enrichment. Before the 
experiment all goats were ear tagged and subjected to a health examination as described 
above. 
2.5 Preparation of wildlife species for the experiments 
After an initial adjustment period of two weeks after delivery, the animals were immobilised 
by means of darting with a CO2 gas powered dart projector (X-Caliber, Pneu-Dart, Inc., PA 
17701) with 1ml type P Pneu-darts with a 1.9 cm barbed needle (Pneu-Dart, Inc.PA, USA). 
For this operation water was withdrawn at least three hours prior to immobilisation. All 
animals that were housed together within one boma compartment were immobilised and 
handled at the same time. All animals were individually examined and identified by means 
of numbered and colour coded ear tags. Plastic pipes were secured on horns of the blesbok 
to prevent injury. Blood and faecal samples were collected to carry out a health screen as 
described above. All animals were weighed and were treated at dosages recommended for 
small ruminants with the following drugs: pour on dip containing flumethrin 1% (Drastic 
Deadline, Bayer Animal Health), injectable dewormer containing doramectin 1% (Dectomax 
®, Zoetis) and an injectable vitamin / mineral supplement (Kyroligo, Kyron Laboratories, 
South Africa). 
 
All blesbok were immobilised with 3 mg etorphine (Captivon, Wildlife Pharmaceuticals 
(Pty) Ltd., South Africa) and 20 mg azaperone (Zapnil, Wildlife Pharmaceuticals (Pty) Ltd., 
South Africa). Reversal of the immobilisation was achieved by IV injection into the ear vein 
of 60 mg naltrexone (Trexonil, Wildlife Pharmaceuticals (Pty) Ltd., South Africa). 
 
All impala were immobilised with 1.5 mg thiafentanil (Thianil, Wildlife Pharmaceuticals 
(Pty) Ltd., South Africa). Reversal of the immobilisation was achieved by an IV injection 
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into the ear vein of 20 mg of naltrexone (Trexonil, Wildlife Pharmaceuticals (Pty) Ltd., South 
Africa). 
 
As soon as all animals were immobilised, handlers entered the compartment and positioned 
animals sternal in a shaded area so that they could be worked on safely (Figure 9). Breathing 
and reflexes were monitored constantly. Once the animals had been examined and weighed, 
the horns were piped (blesbok only), medicines were injected, ear tags applied and blood and 
faecal sample collected, the immobilisations of all animals in one boma were reversed with 
an IV injection of naltrexone into the ear vein and animals were all up within two to three 
minutes.  
 
Once experiments were completed, all goats and antelopes were sold to private goat- and 
wildlife farms in the area. 
 
 
Figure 9: Mass immobilisation and handling of animals within one boma compartment. 
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Chapter 3: Pharmacokinetics and bioavailability of the 5-HT1A 
serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-
DPAT) in domestic goats (Capra hircus) 
 
This chapter is a modified version of the following publication: 
Pfitzer S.; Woodward A.P.; Laubscher L.; Warren K.; Vaughan-Higgins R.; Raath J.P., 
Laurence M. 2019. Pharmacokinetics and bioavailability after intramuscular injection of the 
5-HT1A serotonin agonist R-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in 
domestic goats (Capra hircus). Journal of Veterinary Pharmacology and Therapeutics. DOI: 
10.1111/jvp.12741. 
 
3.1 Introduction 
Opioids are commonly used for the immobilisation of wildlife. Stable immobilisation allows 
veterinarians opportunities for safe medical treatment, routine examination, emergency care 
and relocation of free-ranging species (Haigh 1990; Kock and Burroughs 2012). Opioid 
immobilisation of wildlife is associated with certain risks. Respiratory depression and 
hypoxia are well-known side effects of opioids and are caused predominantly by the 
activation of mu-opioid receptors. Activation of mu-opioid receptors causes a reduced 
respiratory rate and minute volume and reduces the sensitivity of chemoreceptors to elevation 
of carbon dioxide (McCrimmon and Alheid 2003; Lalley 2003; Buss and Meltzer 2001; 
Lalley et al. 2014; Meyer et al. 2015).  
 
The opioid etorphine is used for immobilisation of wild herbivores and can lead to a V/Q 
mismatch (Meyer et al. 2015). This mismatch is caused by pulmonary vasoconstriction and 
hypertension which is postulated to result from the sympathomimetic action of etorphine 
(Meyer et al. 2015). Studies have found that serotonergic ligands, specifically 8-OH-DPAT, 
through its serotonergic effects on the 5-HT1A receptors, alleviate opioid-induced hypoxia by 
reducing respiratory depression and V/Q mismatch (Sahibzada et al. 2000; Richter et al. 
2003; Meyer et al. 2006; Stettner 2008; Kimura and Haji 2014). Importantly, 8-OH-DPAT 
did not affect analgesia, catatonia or sedation caused by opioids (Manzke et al. 2003; Meyer 
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et al. 2006; Guenther et al. 2009). It is thought that the use of the R-enantiomer of 8-OH-
DPAT may produce even more pronounced results in comparison to the previously-studied 
racemic form because of its high specificity at the 5-HT1A receptors (Hadrava et al. 1996; 
Yu, et al. 1996a and b; Lejeune et al. 1997).  
 
Although some literature on the pharmacokinetic data of 8-OH-DPAT in rats and marmosets 
exists, there is currently no published literature available on the pharmacokinetics of 8-OH-
DPAT in ungulates (Yu and Lewander 1997; Zuideveld et al. 2002; Kotani et al. 2016). 
 
It was hypothesised that the pharmacokinetics and bioavailability of R-8-OH-DPAT in goats 
would be similar but different to that reported in other species. This investigation into the 
pharmacokinetics and bioavailability of R-8-OH-DPAT in goats serves as the first step in a 
series of experiments to elucidate the viability of adding R-8-OH-DPAT to an opioid-based 
immobilisation protocol for wild antelope species in order to alleviate respiratory depression. 
 
3.2 Material and Methods 
3.2.1 Animal use and care 
This study was approved by the Murdoch University Animal Ethics Committee (R2922/17) 
and the animal ethics committee of Wildlife Pharmaceuticals (WPAEC-2016-DPATGOAT-
09-C). Six healthy domestic female indigenous goats weighing between 29 and 43 kg were 
used for this project. Each goat was considered healthy after a physical examination, 
complete blood cell count and serum biochemical analysis. The goats were maintained in a 
suitably fenced outdoor enclosure which contained a covered shed and crush area. Food and 
water were available ad libitum.  
 
A two-way cross-over experiment was undertaken with a 14-day rest period. Animals were 
assigned randomly to one of the two groups. Goats were treated with alternating IM or IV 
injections in the order of their ear tag numbers and the first treatment was determined via 
coin toss. 
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Each goat was injected with 0.1 mg kg-1 (0.23 µmol kg-1) R-8-OH-DPAT hydrobromide 
(Tocris Bioscience, Bristol, UK, catalogue number 1080), equivalent to approximately 0.075 
mg kg-1 R-8-OH-DPAT (pubchem.ncbi.nlm.nih.gov) dissolved in sterile water to a 
concentration of 5 mg mL-1. The dosage of 0.1 mg kg-1 was based on previous literature 
(Herman et al. 2001; Meyer et al. 2006). 
 
Group one was injected IV during the first experiment and IM with the same dosage during 
the second experiment, while group two were injected IM during the first experiment and IV 
during the second experiment with the same dosage as group one. Intra-venous injection was 
administered with a 21 G 25.4 mm needle as a bolus into the jugular vein opposite to the 
catheterised jugular vein. 
 
After the IV injection, blood was drawn back into the syringe and reinjected to ensure that 
the full dose of R-8-OH-DPAT was administered. The IM injection was given into the lateral 
femoral muscle group with a 21 G 25.4 mm needle. As this experiment was carried out with 
an aim of improving wildlife immobilisation methods, the chosen IM injection site was a 
commonly used site for long distance dart immobilisation of wildlife. 
 
The neck of each goat was shaved before the experiment and a central venous catheter (18G, 
45 mm) was placed in the jugular vein and secured with three layers of adhesive tape 
(Vetband, 10 cm, Midlands veterinary Wholesaler, South Africa). One millilitre of 
heparinised saline was injected into the catheter to prevent blood clotting. Goats were 
manually restrained for the duration of catheterisation and blood sample collection. On each 
occasion the first 1 mL of blood was discarded to remove any blood or flush fluid that 
remained in the extension set. Serial serum samples were collected at 2, 5, 10, 15, 20, 30, 40, 
60 minutes following treatment. Blood was collected in 20 mL syringes and immediately 
transferred to serum tubes and stored on ice. Within two hours post collection, the blood was 
centrifuged, and serum decanted into cryovials and stored at -20 ⁰C until further analysis 
within two weeks after collection. 
  
 57 
3.2.2 Laboratory analysis 
Laboratory analysis of the serum was performed by means of liquid chromatography tandem 
mass spectrometry (LC-MS/MS) by FDA Laboratories, Pretoria, South Africa similar to 
methods published (Yu et al. 1996b; Kotani et al. 2016). The serum (20 µL) was diluted with 
methanol. The mixture was then centrifuged for protein precipitation. The supernatant was 
collected and then subjected to analysis against a reference standard prepared by dissolving 
R-8-OH-DPAT powder in methanol. Chromatographic separation was achieved using a 
Phenomenex Luna® 5µm C18 150 x 2mm analytical column maintained at 40 ˚ C. The mobile 
phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) the 
gradient elution program was as follows: 0-1 min, 90% A; 1-2 min, 90-10% A; 2-5 min, 10% 
A; 5-6 min, 10-90% A; 6-10 min, 90% A.  
 
The LC-MS/MS system consisted of an Agilent 1200 high pressure liquid chromatography 
system coupled to an AB Sciex triple-quadrupole 3500 mass spectrometer. Positive 
electrospray ionization was used, and the analysis was performed in the multiple electron 
monitoring mode (MRM). The turbo ion spray source was set with the following settings: 
capillary voltage 5500 V, nebuliser gas (N2) 10 (arbitrary units), curtain gas (N2) 20 (arbitrary 
units) and source temperature of 400 ˚C. Two MRM transitions were selected, the most 
intense (248.105 m/z:147.000 m/z) being used for quantification and the other (248.105 
m/z:107.000 m/z) for confirmation.  
 
Limit of quantification (LOQ) can be defined as the amount of the analyte, expressed in an 
appropriate mass unit (e.g. ng, μg), brought into the measuring equipment as an amount of 
standard in a standard solution, and giving a signal at least ten times larger than that of the 
observed noise (Shabir 2003). The limit of quantification was set at 20 µg L-1 according to 
the methods described by Shabir (2003). The Limit of detection (LOD) was estimated to be 
5 µg L-1 as the lowest non-zero observation in the dataset was 5.7 µg L-1. The inter-assay 
variation was 12.53 % and the intra-assay variation was 10.35 %. 
 
Matrix-matched calibration curve and control samples were prepared by spiking on serum, 
collected from goats that had not been treated with the drug, at different concentrations from 
20 µg L-1 to 500 µg L-1. Serum concentrations of R-8-OH-DPAT were obtained by the use 
of peak area and slope-intercept from linear matrix matched calibration curves. 
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3.2.3 Data analysis 
Data management was conducted in Microsoft Excel 2016. Analysis and visualisation of data 
and definition of models was performed in MATLAB 2015 (The Mathworks, Inc.). Coding 
for the study was developed based on the author’s previous work (Sebbag et al. 2016). 
Though the experiment was a conventional two-stage, cross-over design, the dataset was 
characterised by numerous observations that were below the analytical method detection 
limit (BLD; n = 6/88), or below the quantification limit but above the detection limit (BLQ; 
n = 40/88).  
 
3.2.4 Pharmacokinetic Modelling 
A typical data analysis scheme for the two-stage setting was used for pharmacokinetic 
modelling. For the compartmental analysis, after viewing the intravenous data on log10 scale, 
a one-compartment model (Toutain and Bousquet-Mélou 2004a and b) was chosen. The 
model for IV administration was implemented as the ordinary differential equation (ODE) 
(Equation 1), where DX1/dt is the rate of change of drug mass in the central compartment, 
X1 is the drug mass (µg) in the central compartment, Vc is the central compartment volume 
of distribution (L kg-1), and ClP is the plasma clearance (L kg-1 min-1). 
 
Equation 1:   ;<=;> = 	−	(<=?@) 	∗ 	-./ 
 
Numeric solutions of the ODE were obtained for this model using the numeric differentiation 
formulas as implemented in MATLAB’s ‘ode15s’ (Shampine and Reichelt 1997).  
 
For the IM model (Equation 2; Equation 3) we defined first-order absorption, where Xa is the 
drug mass in the absorption compartment (µg) and ka is the first-order absorption rate 
constant (hr-1). 
 
Equation 2:  ;<=;> = 	−(A<=?@B ∗ 	-.0) + (Xa ∗ 34) 
 
Equation 3:   ;<C;> = 	−(Xa	 ∗ 	34) 
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This model includes IM bioavailability FIM (%), implemented in the ODE initial conditions. 
The model therefore includes four primary pharmacokinetic parameters to be estimated from 
the data; total body clearance (CLT), volume of distribution of the central compartment (Vc), 
first-order absorption rate constant (ka), and intramuscular bioavailability (FIM). The error 
standard deviation (σε2) is also estimated in this model. 
 
Parameter estimation was governed by the following principles: 
 
1: all BLQ data points were included as scalar observations, as for the observations above 
the quantification limit (LOQ) (i.e. the LOQ was ignored). 
 
2: the BLD data points were defined as censored observations (i.e. < 5 µg L-1). 
 
3: a censored non-linear regression model was defined, and instead of minimising the sum-
of-squares of the weighted residuals, we implemented maximum likelihood estimation of the 
pharmacokinetic parameters, first for the IV phase only, then for the IV and IM phases 
simultaneously. 
 
For step 3 the censored (Tobit) regression was implemented by direct definition of the log-
likelihood function (Lynn 2001), with optimization using the MATLAB functions ‘fmincon’ 
(constrained function minimisation), an implementation of an interior-point algorithm, and 
‘patternsearch’, an adaptive mesh algorithm. For the BLQ, this censored regression method 
is equivalent to Beal’s ‘method 3’ (Beal 2001). For the maximum likelihood estimation, we 
assumed the distribution of residual errors was normal, with standard deviation as a 
parameter to be estimated (σε2). To accommodate heteroscedasticity the residuals were 
weighted (1/Y). We estimated simultaneous parameters for the IV and IM phase for each 
subject, to improve the robustness of the IM parameter estimates. The goodness-of-fit of the 
models was assessed by plots of the observed and predicted concentrations vs time for each 
subject, and identity (observed vs predicted concentrations) and residuals plots across 
subjects. Secondary parameters were estimated from the final models.  
 
The area-under-the-curve (AUC) was determined by numeric integration of the final models. 
The AUCinf was obtained as the improper integral (integration from time zero to infinity).  
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The elimination and absorption half-lives were obtained from Equation 4. 
 
Equation 4:   5 =D = 	 EFGH DI  
 
Where k is the rate constant. As the model was parameterised using clearance, the elimination 
rate constant was obtained as clearance divided by the volume of distribution. 
3.3 Results 
3.3.1 Serotonin Toxicity 
All goats injected IV displayed clear clinical signs of serotonin toxicity (Boyer 2005; Isbister 
et al. 2007; Volpi-Abadie et al. 2013), while two of six goats injected IM displayed mild 
signs of serotonin toxicity. The clinical behavioural effects of the R-8-OH-DPAT manifested 
within two minutes and five minutes after injection in goats that were injected IV and IM 
respectively. These clinical signs consisted of head shaking, chewing and licking, moderate 
to severe shivering of the entire body, vocalisation, urination and hypersensitivity to external 
stimulation (hyperaesthesia). Behavioural effects lasted between 10 to 20 minutes and 
coincided with the serum peak (Figure 10, Figure 11). All goats fully recovered within 20 
minutes after onset of the symptoms.  
 
No signs of a localised adverse reaction could be observed at the injection sites. 
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Figure 10: Predicted serum concentrations in goats after IV injection of 0.1 mg kg-1 R-8-OH-
DPAT hydrobromide. 
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Figure 11: Predicted serum concentrations in goats after IM injection of 0.1 mg kg-1 R-8-OH-
DPAT hydrobromide. 
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3.3.2 Pharmacokinetic analysis 
The IM data series from one subject was excluded from analysis as it contained no useful 
information and was probably indicative of drug administration error (numerous BLD 
observations). The final analysed dataset included 88 observations, from six IV subject-
occasions and five IM subject-occasions. 
 
Though the experiment was a conventional two-stage cross-over design, the dataset was 
characterized by observations that were below the analytical method of detection limit (n = 
6/88) or below the quantification limit but above the detection limit (n = 40/88). 
 
The final compartmental model was an acceptable fit, to both the IV and the IM data. The 
goodness-of-fit visualisation indicated that the fit of the IV model across subjects (Figure 12) 
was similar to that of the IM model across subjects (Figure 13). For all the modelled subject-
occasions the quality of the model fit was similar; none stood out as being indicative of model 
failure. 
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Figure 12: Observed versus predicted concentrations of R-8-OH-DPAT in serum of goats 
after IV injection of 0.1 mg kg-1 R-8-OH-DPAT hydrobromide. The solid line is the line of 
identity (y = x). 
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Figure 13: Observed versus predicted concentrations of R-8-OH-DPAT in serum of goats 
after IM injection of 0.1 mg kg-1 R-8-OH-DPAT hydrobromide. The solid line is the line of 
identity (y = x). 
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3.3.3 Pharmacokinetic parameters 
According to the compartmental analysis, the mean bioavailability after IM injection of R-8-
OH DPAT in goats was 0.66 with a coefficient of variation of 28.5 % (Table 3). The mean 
volume of distribution in the central compartment was 1.47 L kg-1 with a coefficient of 
variation of 34.48 % (Table 3).The mean serum body clearance was 0.06 L kg-1 min-1 with a 
coefficient of variation of 23.91 % (Table 3).The mean standard deviation of the residual 
error distribution was 0.31 with a coefficient of variation of 35.83 % (Table 3). The mean 
first order IM absorption rate constant is 0.14 hours with a coefficient of variation of 43.69 
% (Table 3). 
 
The mean absorption half-life according to calculations based on the compartmental analysis 
after IM in injection of R-8-OH-DPAT in goats was 6 minutes with a coefficient of variation 
of 44.25 % (Table 4). The mean elimination half-life according to calculations based on the 
compartmental analysis after IM injection of R-8-OH-DPAT in goats was 18 minutes with a 
coefficient of variation of 16.94 % (Table 4).The maximum plasma concentration during IM 
injection had a mean of 29.5 µg L-1 and was achieved at a mean time of 15 minutes after 
injection (CV % = 17.77).  
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Table 3: Estimated primary parameters from compartmental analysis for subjects 1-6. 
 
Vc ClP σε2 ka FIM 
1 1.049 0.03991 0.2331 0.1013 0.6448 
2 1.962 0.06594 0.4216 0.1436 0.9769 
3 0.7193 0.03987 0.4762 0.07038 0.5007 
4 1.416 0.05617 0.2171 0.23015 0.5376 
5 1.7486 0.07031 0.2393 0.1427 0.6393 
6 1.94845 0.06496 0.2680 .* .* 
MEAN 1.474 0.0562 0.3092 0.1376 0.6599 
MEDIAN 1.582 0.0606 0.2536 0.1427 0.6393 
CV% 34.489 23.91 35.83 43.69 28.5 
MEAN is the arithmetic mean.  
MEDIAN is the sample median.  
CV % is the coefficient of variation (STD / MEAN*100). STD is the sample standard 
deviation.  
VC is the central compartment volume of distribution (L kg-1). 
ClP is the plasma body clearance (L kg-1 min-1). 
σε2 Is the standard deviation of the residual error distribution. 
ka is the first-order absorption rate constant after intramuscular administration (min-1). 
FIM is the bioavailability after intramuscular administration (as proportion). 
* Not estimated as the available IM data for this subject were excluded. 
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Table 4: Estimated secondary parameters from the compartmental analysis for subjects 1-6. 
 Tmax Cmax t1/2 ka t1/2 ke AUCinf IV AUCinf 
IM 
1 17.48 27.03 6.841 18.23 1889.2 1220.7 
2 15.20 47.35 4.827 20.62 1143.4 1119.2 
3 17.97 15.61 9.848 12.51 1895.7 949.0 
4 11.23 28.16 3.011 17.47 1342.5 723.0 
5 14.36 29.38 4.857 17.24 1072.7 686.8 
6 .* .* .* 20.79 1160.8 .* 
MEAN 15.25 29.51 5.877 17.81 1417.4 939.7 
MEDIAN 15.20 28.16 4.857 17.85 1251.6 949.0 
CV% 17.77 38.63 44.25 16.94 26.71 25.08 
MEAN is the arithmetic mean.  
MEDIAN is the sample median.  
CV % is the coefficient of variation (sample standard deviation /MEAN*100). 
Tmax is the time of maximum plasma concentration for the IM phase (minutes). 
Cmax is the maximum serum concentration achieved during the IM phase (µg L-1). 
t1/2 ka is the absorption half-life (minutes). 
t1/2 ke is the elimination half-life (minutes).  
AUC inf is the area under curve estimated for the time range 0 to Infinity (improper integral) 
(µg hr-1 L-1) 
* Not estimated as the available IM data for this subject were excluded. 
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3.4 Discussion 
The use of serotonin agonists can be associated with serotonin toxicity, also called serotonin 
syndrome (Boyer 2005; Isbister et al. 2007; Volpi-Abadie et al. 2013). Serotonin toxicity has 
been described in humans and animals. It is characterised by a triad of symptoms consisting 
of altered mental status, neuromuscular abnormalities and autonomic hyperactivity (Boyer 
2005; Isbister and Buckley 2005; Volpi-Abadie et al. 2013). The altered mental state can 
include agitation, anxiety, restlessness and excitement. Neuromuscular abnormalities can 
manifest in tremors, hyperreflexia, muscle rigidity and autonomic hyperactivity can include 
hypertension, tachycardia, arrhythmias, tachypnoea, hyperthermia, mydriasis, shivering, 
diarrhoea and vomiting. Because serotonin toxicity can involve vital sign abnormalities such 
as tachycardia, hypertension and hyperthermia, these symptoms on occasion can become 
severe and terminate in shock (Boyer 2005).  
 
Serotonin toxicity observed in this experiment came unexpected. Herman et al. (2001) 
described the effects of 8-OH-DPAT (0.1 mg kg-1) on hypoxic goats and reported an increase 
in breathing frequency. This report did not mention any signs of serotonin toxicity or other 
adverse effects. Meyer et al. (2006) described the used of 0.5 mg kg-1 of the racemic form of 
8-OH-DPAT in goats during immobilisation with the potent opioid etorphine. Goats were 
injected IV with the serotonin agonist while under etorphine immobilisation and the 
immobilisation was reversed 30 minutes later. The serotonin agonist seemed to improve the 
respiratory function of goats immobilised with etorphine. No adverse effects of 8-OH-DPAT 
were reported. Herman et al. (2001) and Meyer et al. (2006) both used the racemic form of 
8-OH-DPAT. It is therefore postulated that the onset of serotonin toxicity in the current 
experimental goats at a dosage of 0.1 mg kg-1 was associated with the use of the R-enantiomer 
of 8-OH-DPAT. The R-enantiomer has been shown to have more specific action on the 5-
HT1A receptors (Hadrava et al. 1996; Yu et al. 1996a; Lejeune et al. 1997) which could be a 
likely reason for the toxicity clinical signs described here. 
 
The lower limit of quantification in this study coincided with biologically relevant drug 
concentrations. Because the number of BLQ observations was large (40 / 88) and more 
prevalent in the IM phase, the reported concentrations of the BLQ observations were used 
directly rather than deleting them from the dataset. Despite widespread use in analytical 
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method validation, quantification limits depend on arbitrary selection of an acceptable 
relative error limit, ignoring the fact that measurement error is present in all the data (Guo et 
al. 2010; Jelliffe et al. 2015). Simply discarding the BLQ data would result in complete 
failure of the IM phase, even though it contains valuable information. The presence of BLQ 
data required careful consideration of appropriate methodology to limit bias in parameter 
estimation while retaining information (Jusko 2012). Recent observations using population 
analysis suggest that simply ignoring the limit of quantification is a viable approach, where 
numeric values for the BLQ data are available and superior to deletion or substitution (Byon 
et al. 2008; Keizer et al. 2015). In this study, the BLQ observations were retained, combined 
with the popular maximum likelihood approach (Bergstrand and Karlsson 2009) for the BLD 
observations. However, the precise impact of measurement error associated with BLQ 
observations on the parameter estimates in this study is not known and there is a specific risk 
of inaccuracy in the estimated bioavailability due to the greater number of BLQ observations 
in the IM phase. This is possibly reflected in the high coefficient of variation values. The 
interference of the limit of quantification with plasma concentrations achieved after a 
therapeutically relevant dose suggests that optimisation of analytical methods is a key priority 
for further investigations of this drug. 
 
Establishing bioavailability estimates for R-8-OH-DPAT administered via the IM route has 
significant practical value. This knowledge can be used to ascertain the practicality and a 
dose estimate for adding the serotonin agonist to an opioid-based immobilisation dart 
mixture. The lowest individual bioavailability being 50 % in goat 3 and the highest 
bioavailability of 98 % in goat 2 shows wide variability between the five subjects. This could 
just be due to inaccuracy of analytical methods but another possible reason to explain this 
could be the fact that the injection site was not well defined in this study. The injection site 
for this study was chosen to be equal to a commonly used dart site and thus was just defined 
as the lateral femoral muscle group and not as a specific muscle of this group. This muscle 
group consists of various portions of the M. tensor fasciae latae, M. gluteobiceps, M. gluteus 
medius and M. semitendinosus (Nickel et al. 1984). Variation in bioavailability thus could 
potentially stem from different properties of different muscles or parts of muscles within this 
muscle group which might have variation of vascularisation and blood flow that could 
influence drug absorption (Buxton 2006). In addition, other anatomical features such as 
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poorly perfused fat or fasciae could prevent drug absorption (Buxton 2006; Rutgers et al. 
1980). 
 
Although there was a large variability (range 50 % to 98 %), the mean bioavailability (F) was 
66 % after IM injection. Therefore R-8-OH-DPAT was well absorbed from the injection site. 
At the chosen concentration of 5 mg of R-8-OH-DPAT hydrobromide, dissolved in one 
millilitre of sterile water, the total drug volume per animal was low. This means that the drug 
could also be mixed with other aqueous preparations of drugs commonly used for wild animal 
immobilisation and still fit into a low volume immobilisation dart.  
 
With an absorption half-life of six minutes, the highest serum concentrations of R-8-OH-
DPAT were reached in all goats between 11 and 17.5 minutes after IM injection. The mean 
elimination half-life of R-8-OH-DPAT in goats was 18 minutes (CV = 17 %) according to 
the compartmental analysis in our experiment. This result is similar to that reported by Yu 
and Lewander (1997). These researchers showed that in rats the plasma half-life of R-OH-
DPAT reached 27 minutes. As it was the goal of the current experiment to ascertain if R-8-
OH-DPAT could be used in conjunction with etorphine, it is appropriate to compare 
pharmacokinetic values of these drugs. 
 
Although etorphine is widely used and its effects well documented, to the authors’ 
knowledge, there is currently no published pharmacokinetic study on etorphine in ungulates 
available. In a non-compartmental analysis of pharmacokinetics of etorphine in juvenile 
African elephants of 240 to 500 kg bodyweight, the highest serum concentration of etorphine 
after IM injection of a dosage of about 2 µg kg-1 was reached at 30 minutes after injection. 
Therefore, the highest serum concentrations of both drugs would be reached at similar time 
points post IM injection: at between 11 and 17.5 minutes for R-8-OH DPAT and at about 30 
minutes for etorphine. 
 
Serum concentration of etorphine declined steadily and displayed an elimination half-life of 
66 minutes in juvenile elephants (Jacobson et al. 1986) and less than 60 minutes in a human 
(Friedrich et al. 1991). With an elimination half-life of 18 minutes for R-8-OH-DPAT, the 
plasma concentrations of both drugs after IM injection are comparable. 
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The volume of distribution for etorphine in juvenile elephants at steady state was 1.316 L kg-
1 (Jacobson et al. 1986). The mean volume of distribution of R-8-OH-DPAT in goats was 
very similar at 1.474 L kg-1 with a coefficient of variation of 34.5 %. This indicates that R-
8-OH-DPAT, as well as etorphine, are well distributed and distribution possibly includes 
various tissues throughout the body. 
 
There is always a possibility that drugs influence each other’s pharmacokinetic parameters. 
This has been reported for the peripheral alpha-2 agonist MK 467 when it was injected 
together with medetomidine and dexmedetomidine in cats and dogs (Bennett et al. 2016; 
Pypendop et al. 2016). 
 
3.5 Conclusions 
According to pharmacokinetic analysis, R-8-OH-DPAT was readily absorbed with a mean 
bioavailability of 66 % after IM injection. These results are also supported by clinical signs 
observed post injection. Following the observation of clinical signs of serotonin toxicity in 
the goats at a dosage of R-8-OH-DPAT hydrobromide of 0.1 mg kg-1, it is concluded that the 
dosage used in conjunction with opioids should possibly be lower in order to achieve the 
desired clinical effect without causing serotonin toxicity. Although serotonin toxicity may be 
masked during opioid immobilisation, sometimes the immobilisation is reversed within a few 
minutes with the full opioid reversal naltrexone and in this case, the animals could suffer 
from serotonin toxicity due to R-8-OH-DPAT’s activity which would not be reversed. 
 
Following the promising results of this bioavailability experiment, further research using R-
8-OH-DPAT was warranted. An experiment that investigated the clinical effects of various 
dosages of this serotonin agonist in combination with the opioid etorphine to immobilise 
antelope was considered to be a useful addition to this field of study.  
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Chapter 4: Dose-effect study of the serotonin agonist R-8-OH-
DPAT on opioid-induced respiratory depression in blesbok 
(Damaliscus pygargus phillipsi) and impala (Aepyceros melampus) 
 
This chapter is a modified version of the following publication: 
 
Pfitzer S, Laubscher L, Meyer L, Warren K, Vaughan-Higgins R, Raath JP, Laurence M. 
2019. Dose-effect study of the serotonin agonist R-8-OH-DPAT on opioid-induced 
respiratory depression in blesbok (Damaliscus pygargus phillipsi) and impala (Aepyceros 
melampus), Veterinary Anaesthesia and Analgesia 46, pp. 796-806. 
https://doi.org/10.1016/j.vaa.2019.06.006.  
 
4.1 Introduction 
Sales of potent opioids in 2016 suggest that over 150 000 wild animals, mostly herbivores, 
were chemically immobilised in South Africa for various clinical, management or research 
purposes (unpublished data, Wildlife Pharmaceuticals SA 15/1/2018). Chemical 
immobilisation is the only way to safely capture and treat or relocate most wildlife species 
and veterinarians have a responsibility to use the safest combinations of chemicals to prevent 
adverse events like injury or death of the animals. 
 
Immobilising wild animals under field conditions is associated with significant challenges. 
The age, health- and pregnancy status is often unknown, and the animals are sometimes 
chased over long distances before the dart can be administered. Feed and water intake prior 
to darting is usually uncontrolled and immediate approach after the immobilising drugs take 
effect is often not possible because of terrain constraints and the distance the animals run 
after darting. At times, an animal may be unattended for up to 30 minutes after darting before 
it can be safely re-positioned, and basic anaesthetic monitoring can commence. It is only 
from this time that actions to combat negative side effects of the immobilisation can be taken.  
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Potent opioids such as etorphine or thiafentanil are often used for the immobilisation of wild 
herbivores (Haigh, 1990; Kock and Burroughs, 2012). One disadvantage of using these 
potent opioids is that they often cause clinically significant respiratory depression which is 
mostly associated with their mu-opioid receptor activity (Haigh, 1990; Kock and Burroughs, 
2012). Activation of mu-opioid receptors in the respiratory centres of animals depresses 
neurons that generate the normal respiratory rhythm. At the same time activation of mu-
opioid receptors on chemo receptors in the brain stem, on the aortic arch and carotid bodies 
depress the normal respiratory drive as these chemo receptors become less sensitive to 
activation by hypercapnia, hypoxaemia and acidaemia. This decreased sensitivity in turn 
leads to a reduction of the respiratory frequency and tidal volume (Buss and Meltzer 2001; 
McCrimmon and Alheid 2003). Furthermore, it has been suggested that pulmonary 
vasoconstriction, caused by the sympathomimetic actions of etorphine, decreases pulmonary 
perfusion. This effect leads to impaired diffusion of oxygen through the alveolar membrane 
(Meyer et al., 2015). Studies have found that serotonergic ligands, specifically the racemic 
form of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), reverse respiratory 
depression through their effects on the brainstem respiratory neurons (Lalley et al., 1994; 
Sahibzada et al., 2000). In addition, 8-OH-DPAT improved alveolar oxygen diffusion in 
goats without affecting catatonia and sedation caused by opioids (Meyer et al. 2006). The R-
enantiomer of 8-OH-DPAT (R-8-OH-DPAT), compared to the racemic form, has a higher 
specificity at the 5-HT1A receptors and thus possibly greater effects. It is postulated that 
because of this, the R-enantiomer may produce a more effective reversal of opioid-induced 
respiratory depression (Hadrava et al. 1996; Yu et al. 1996a; Lejeune et al. 1997; 
Christoffersen and Meltzer 1998).  
 
Impala (Aepyceros melampus) and blesbok (Damaliscus pygargus phillipsi) were chosen for 
this experiment as they are abundant and readily available in the study area. They are also 
two species commonly immobilised with potent opioids. This study aimed to determine the 
ability of R-8-OH-DPAT, when administered in combination with etorphine in a dart, to 
prevent opioid-induced respiratory depression in blesbok and impala. The experiment also 
aimed to establish whether effects of R-8-OH-DPAT might be species specific and to 
determine the most clinically effective dosage of R-8-OH-DPAT. It was hypothesised that 
R-8-OH-DPAT would mitigate opioid-induced respiratory depression in both wild ungulate 
species without affecting the quality of immobilisation.  
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4.2 Materials and Methods 
The study was approved by the Murdoch University Animal Ethics committee (R2923/17) 
as well as by the Wildlife Pharmaceuticals Animal Ethics Committee (WPAEC-
DPATBLES-11-B). 
 
Six female impala (34.5 ± 4.6 kg) and six female blesbok (56.6 ± 6.5 kg) were used for this 
experiment and held at the research enclosures of Wildlife Pharmaceuticals (Pty) Ltd. on 
Ngongoni Game Farm, Mpumalanga Province, South Africa (25°31’25.2”S, 31°06’50.8”E). 
 
Research animals were chosen to be of same sex, similar size and in good health to reduce 
confounding variables. Males were excluded from this study for practical (housing) reasons. 
The enclosures consisted of several compartments that were approximately six by eight 
metres in size and were constructed from sturdy gum tree poles. The impala and blesbok 
were held separately in groups of six animals per enclosure.  
 
Animals were wild captured. After an initial adjustment period of two weeks after delivery, 
the animals were immobilised, marked and subjected to a veterinary health examination 
which included a full blood cell count, a blood smear and a liver and kidney function test. At 
this occasion, the animals under immobilisation were weighed while lying in sternal position 
in a stretcher and lifted with a hand-held precision scale which was attached to a pole 
(Anyload OCSL Mini Crane Scale, Anyload Transducer Co. Ltd. Canada). 
 
The immobilising drug etorphine, as well as the R-8-OH-DPAT, were administered IM via 
remote injection by darting. Each animal was darted by means of a CO2 gas powered dart 
projector (X-Caliber, Pneu-Dart. Inc., PA, USA). The darts used were 1 ml (impala) and 1.5 
ml (blesbok) P-type Pneudarts with 1.9 cm barbed needles (Pneu-Dart. Inc., PA, USA). 
Animals were darted on four separate occasions with a wash-out period of two weeks 
between each occasion. Six animals were processed on each trial day. Each animal was 
weighed again during the second occasion and drug dosages adjusted according to weight for 
the following occasions. The drug dosage of etorphine (Captivon, 9.8 mg mL-1, Wildlife 
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Pharmaceuticals SA (Pty) Ltd, South Africa) was 0.09 mg kg-1 in all animals. Etorphine was 
combined with various dosages of R-8-OH-DPAT hydrobromide (Tocris Bioscience, Bristol, 
UK, catalogue number 1080). R-8-OH-DPAT treatments were as follows: a low dosage at 
0.005 mg kg-1, a medium dosage at 0.02 mg kg-1 and a high dosage at 0.07 mg kg-1. Etorphine 
on its own was used as control treatment. The darts were filled to capacity with sterile water. 
R-8-OH-DPAT was dissolved in a pharmaceutical laboratory under aseptic conditions in 
water for injection to 1 mg ml-1 and 5 mg ml-1 within 24 hours before each trial. Stability of 
the chemical in solution was confirmed during a previous bioavailability experiment (Pfitzer 
et al. 2019a). The highest dosage of 0.07 mg kg-1 was chosen based on literature on goats 
according to which 0.1 and 0.5 mg kg-1 of the racemic form were injected IV (Herman et al. 
2001; Meyer et al. 2006). Dosages were also determined based on the results of a 
bioavailability study in goats (Pfitzer et al. 2019a). During the latter study, the IV 
administration of 0.1 mg kg-1 R-8-OH-DPAT led to serotonergic side effects in goats (Pfitzer 
et al. 2019a). As a result, the R-8-OH-DPAT dosages for this wildlife study were chosen to 
be lower than 0.1 mg kg-1. The lowest dosage of 0.005 mg kg-1 was chosen based on literature 
on rats where effects on respiratory depression of racemic 8-OH-DPAT were found from 
0.01 mg kg-1 (Sahibzada et al. 2000). Due to its higher specificity at the 5-HT1A receptors, 
R-8-OH-DPAT was predicted to be more potent than the racemic form (Hadrava et al. 1996; 
Yu et al. 1996a; Lejeune et al. 1997). Therefore, the lowest dosage was chosen at 0.005 mg 
kg-1 and the medium dosage double that of the first effective dosage reported in rats, namely 
0.02 mg kg-1. 
 
The trial was carried out as a four-way cross-over dose-response study on four trial occasions. 
Each animal was treated once on each trial occasion. On the first trial date animals were 
allocated to a treatment dose schedule at random. All treatments were allocated once or twice 
on each trial date. Care was taken that treatments were spread out over various times of the 
day. The sample size of six animals was small but considered to be sufficient. As it is 
logistically difficult to hold large numbers of wild animals, studies of this kind are often 
conducted using small number of animals (Huber et al. 2001; Howard et al. 2004; Sawicka 
et al. 2015). 
 
Time to recumbence was the time from darting to when the animal became immobile in 
sternal or lateral position and could be approached and handled without physical restraint. 
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As soon as the animal was recumbent, it was blind-folded and cotton wool inserted into the 
ears to minimise external stimuli. The animal was then loaded onto a stretcher and carried 
out of the enclosure to an experimental monitoring table where it was placed in sternal 
position with the head elevated.  
 
Recording of physiological variables began at five minutes after an animal became 
recumbent. Physiological variables were recorded every five minutes until 35 minutes after 
recumbence. Rectal temperature was measured by means of a modified hand-held digital 
thermometer (Hanna Checktemp 1, Hanna Instruments (Pty) Ltd., USA). The environmental 
temperature and barometric pressure were recorded during each immobilisation. Barometric 
pressure was measured by the EPOC portable blood gas analyser (EPOC Blood Analysis 
System, Epocal; USA) and the environmental temperature was measured by the Weather+ 
Bluetooth Sensor (Oregon Scientific, USA). Respiratory rate as measured by means of visual 
observation of chest expansions and auscultation with a stethoscope for one minute (Littman 
Classic II SE; USA). The auricular (Arteria auricularis) or pedal arteries (A. digitalis) were 
catheterised using a 21 Gauge (G) catheter (Jelco IV catheter radiopaque; Smith Medical 
International, UK) to measure intra-arterial blood pressure using the Deltran II pressure 
transducer (Utah Medical, UT, USA) connected to an IntraTorr blood pressure monitor 
(IntraTorr, IntraVitals, Teddington, UK). This device also measured pulse rate. Arterial blood 
was also drawn from these catheters for blood gas analysis. Arterial blood samples were 
collected anaerobically in a heparinised blood gas syringe (BD A-Line; Becton Dickinson & 
Co, Plymouth, UK) at times 5, 10, 15, 20 and 30 minutes after recumbence. The first 2 mL 
were always discarded to avoid blood contamination of blood pooled in the catheter. Arterial 
blood was analysed by a portable blood gas analyser using EPOC BGEM test cards (BGEM 
smart cards; Epocal; USA) to determine blood gases within five minutes after sampling. 
Measurements on the test cards included blood gases as well as lactate, glucose, creatinine, 
sodium, potassium, calcium, and haematocrit. The alveolar-arterial oxygen (A-a) gradient 
corrected to rectal temperature was calculated as described by Meyer et al. (2010). 
 
All measurements were made outdoors in a shaded area between 08:00 to 12:00 and 14:00 
to 17:00 respectively to avoid hot temperatures at midday.  
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The immobilisation of all animals was reversed with intravenous naltrexone (Trexonil 50 mg 
mL-1 Wildlife Pharmaceuticals SA (Pty) Ltd, South Africa) injected at a ratio of 20 mg 
naltrexone to 1 mg etorphine as soon as the 35-minute monitoring period was over (O’Dell 
et al. 2017). Induction and recovery were monitored, and each animal was subjected to an 
induction score (referring to speed and quality), immobilisation score (referring to motor 
responses during the monitoring period) and recovery score (referring to speed and 
smoothness of recovery after the IV administration of naltrexone) (Table 5).  
 
4.2.1 Data analysis 
Analyses were performed with Genstat Version 19 to determine whether there was an effect 
of the various R-8-OH-DPAT dosage rates on the physiological variables of interest. A linear 
mixed model was fitted to the data. Since the R-8-OH-DPAT dose rate effect could be 
expected to show a linear trend, the R-8-OH-DPAT dose rate effect was sub-divided into a 
linear trend and a non-linear trend. The effect of time after recumbence was not expected to 
be linear so a random slope model was not considered. The fixed model included a linear 
effect of R-8-OH-DPAT, a non-linear effect of R-8-OH-DPAT, the effect of time after 
recumbence and interactions between treatment and time effects. The random model included 
terms for animal, trial date, animal by trial date and animal by trial date by minutes after 
recumbence. The residual variance/covariance model included correlations between 
measurements made on the same animal on the same trial date and different variances for 
each animal. Non-significant random effects and co-variances were removed from the model 
before the significance of fixed effects was assessed. A p-value < 0.05 was considered 
significant. 
 
For the evaluation of the ƒR the data were transformed logarithmically prior to analysis. This 
transformation was required due to the increase in residual variance as the respiratory rate 
increased more than ten-fold. 
 
Heart rate, ƒR, systolic arterial pressure (SAP), diastolic arterial pressure (DAP), MAP, 
arterial blood pH, PaCO2, PaO2, and A-a gradient corrected to rectal temperature were 
statistically evaluated. 
 
 79 
Standard errors of differences (SEDs) are shown with means so that the reader can assess 
whether differences between means are statistically significant. They can be used to calculate 
a t-value (least significant difference (LSD) to compare the difference between means to zero 
at the 5 % level of significance.  
 
Time to final recumbence, induction-, immobilisation- and recovery scores were analysed 
for normality using the Shapiro-Wilk test. If the data were parametric, repeated measures 
ANOVA was used to compare the repeated measurements in each R-8-OH-DPAT 
anaesthetic regime (0, 0.005, 0.02, and 0.07 mg kg-1). If the data were non-parametric the 
Friedman’s ANOVA test was used. Values of p < 0.05 were considered statistically 
significant. Data were summarised and presented as median and interquartile range (IQR). 
Statistical analysis was carried out on IBM SPSS for Windows, version 24 (IBM Corp., 
Armonk, N.Y., USA). 
 
 
Table 5: Induction, immobilisation and recovery scores 
Score 1 2 3 4 5 
Induction Slight ataxia, animal 
goes into recumbence 
within 5 minutes and 
does not get up again 
Ataxia, animal might go 
down twice before final 
recumbence 
Longer ataxic phase (15 min). 
Repeated recumbence before approach 
is possible.  
Animal is ataxic but does 
not go down and needs to 
be physically captured or 
darted again 
No signs of drug taking 
effect 
Immobilisation Animal attempts to 
stand and needs to be 
re-dosed, risk to 
handlers  
Tongue movement, 
chewing, Spontaneous 
motor activity, struggling 
during manipulation 
(sedated) 
 
Tongue is relaxed, but reactive to 
touch and thus intubation not possible, 
muscular rigidity, can be handled 
safely (light anaesthesia) 
Smooth, complete 
relaxation, extractable 
tongue, loss of pedal 
reflex, no involuntary tail 
movements, (moderate to 
deep anaesthesia) 
 
Too deep, no reflexes, severe 
cardiorespiratory depression 
Recovery Smooth and rapid 
transition from 
assisted sternal 
recumbence to 
unassisted sternal 
recumbence. Animal 
stands in one attempt 
and is sufficiently 
recovered to walk with 
only slight ataxia 
within 3 minutes after 
administration of drug 
antagonists (excellent) 
Some imbalance in 
unassisted sternal 
recumbence. Animal 
displays moderate ataxic 
movements and may take 
one or two attempts to get 
up. Walks with moderate 
ataxia and lack of co-
ordination. Recovery to 
walking occurs within 15 
minutes following 
administration of drug 
antagonists (good) 
Animal needs assistance to stay in 
sternal recumbence. Makes numerous 
attempts to stand but frequently falls 
before being successful and displays 
marked ataxia when walking. 
Recovery to walking in excess of 15 
minutes following administration of 
drug antagonists (fair) 
Animal needs to be 
assisted in sternal 
recumbence for more than 
15 minutes following the 
administration of drug 
antagonists, is not 
responsive to stimuli and 
makes no attempt to stand 
up for over 30 minutes. 
(poor) 
Animal does not recover and 
dies or has to be euthanised 
 
4.3 Results  
Environmental temperatures during the blesbok experiment were 23.3 ± 5.9 ºC and during 
the impala experiments 23.8 ± 4.2 °C. The animals’ rectal temperatures varied but were all 
within physiologically acceptable limits (Table 7).  
 
Significant treatment effect and treatment and time interactions could be identified in some 
of the physiological variables. In both species, the majority of variables were affected by 
time (Table 6). A summary of measured physiological variables of the treatments for both 
species with SED is given in Table 7. 
 
There were no statistically significant differences between treatment group medians for time 
to recumbence and induction-, immobilisation- and recovery-scores, in blesbok or impala as 
determined by Friedman’s ANOVA (Table 8). 
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Table 6: Significance of treatment effects of R-8-OH-DPAT on certain physiological 
variables when used in conjunction with etorphine immobilisation in blesbok (n = 6) and 
impala (n = 6). Significant results of R-8-OH-DPAT treatment effects, effect of time and 
interaction of time and treatment (p < 0.05) are given in bold. 
Fixed term 
Treatment effect 
(Combined linear and nonlinear 
effects of R-8-OH DPAT dosage) 
Time effect 
(minutes after 
recumbence) 
Interaction 
(treatment x time) 
Blesbok 
   
HR 0.308 <0.001   0.635 
Log fR 0.007 <0.001   0.016 
SAP 0.420   0.003   0.168 
DAP 0.658 <0.001   0.014 
MAP 0.197 <0.001   0.739 
PaCO2 0.017 <0.001 <0.001 
PaO2 0.065 <0.001   0.385 
A-a gradient 0.230   0.218   0.085 
pH 0.198 <0.001   0.002 
Impala 
   
HR 0.005 <0.001   0.435 
Log fR 0.422 <0.001   0.952 
SAP 0.311   0.028   0.198 
DAP 0.998 <0.001   0.032 
MAP 0.973   0.007   0.237 
PaCO2 0.598   0.001   0.586 
PaO2 0.657 <0.001   0.187 
A-a gradient 0.693 <0.001   0.474 
pH 0.901 <0.001   0.013 
Footnote: Physiological values evaluated were heart rate (HR), logarithmic values of the respiratory rate (Log 
fR), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), arterial 
blood pH (pH), arterial partial pressure of carbon dioxide (PaCO2), arterial pressure of oxygen (PaO2) and 
the alveolar-arterial oxygen gradient (A-a gradient). 
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Table 7: Physiological values (means) for times 5, 10, 20 and 30 minutes after recumbence 
in blesbok and impala immobilised with 0.09 mg kg-1 etorphine and three dosages of R-8-
OH-DPAT, namely low (0.005), medium (0.02) and high (0.07) mg kg-1. 
  Time after recumbence of blesbok 
 Treatment 
 
5min 10min 20min 30min 
HR Control 54 46 46 44 
(beats  
minute-1) 
Low 45 44 41 38 
 Medium 54 49 45 41 
 High 52 49 47 41 
SED within treatment 2.9 SED within time 3.9 
      
loge fR Control 2.7 (14) 2.7 (15) 2.4 (11) 2.3 (10) 
(breaths 
minute -1) 
Low 3.2 (24) 2.8 (16) 2.7 (14) 2.4 (11) 
 Medium 3.8 (45) 3.6 (37) 3.1 (23) 3.0 (21) 
 High 3.2 (24) 3.0 (21) 2.9 (19) 2.9 (19) 
SED within treatment 0.13 SED within time 0.27 
      
SAP Control 151 152 142 137 
(mmHg) Low 144 148 140 139 
 Medium 161 158 152 151 
 High 147 152 147 148 
SED within treatment 3.0 SED within time 7.6 
      
DAP Control 118 118 109 107 
(mmHg) Low 116 115 104 101 
 Medium 115 119 118 112 
 High 113 120 114 111 
SED within treatment 2.3 SED within time 7.3 
      
MAP Control 134 128 122 121 
(mmHg) Low 127 129 125 118 
 Medium 137 135 130 129 
 High 130 131 126 125 
SED within treatment 3.0 SED within time 5.2 
      
PaCO2 Control 42 43 44 46 
(mmHg) Low 42 43 45 45 
 Medium 39 40 45 47 
 High 40 44 52 53 
SED within treatment 1.5 SED within time 1.8 
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PaO2 Control 77 75 74 70 
(mmHg) Low 74 73 71 66 
 Medium 78 79 69 66 
 High 79 67 65 65 
SED within treatment 4.2 SED within time 4.4 
      
A-a gradient Control 17 17 18 19 
(mmHg) Low 21 21 24 20 
 Medium 20 17 20 24 
 High 16 23 21 18 
SED within treatment 2.5 SED within time 2.8 
      
pH Control 7.44 7.43 7.43 7.42 
 Low 7.44 7.44 7.43 7.44 
 Medium 7.48 7.46 7.43 7.42 
 High 7.49 7.45 7.42 7.40 
SED within treatment 0.013 SED within time 0.014 
      
Temperature Control 38.6 38.9 39.0 39.0 
(ºC) Low 38.8 39.3 39.2 39.1 
 Medium 39.1 39.3 39.4 39.3 
 High 38.8 39.2 39.2 39.0 
SED within treatment 0.11 SED with time 0.21 
      
Lactate Control 2.33 1.79 1.53 1.34 
(mmol L-1) Low 1.46 1.20 0.97 0.91 
 Medium 1.16 0.99 0.83 0.80 
 High 1.45 1.15 1.01 0.86 
SED within treatment 0.182 SED with time 0.443 
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Table 7 continued 
  Time after recumbence of impala 
 R-8-OH-
DPAT level 
5min 10min 20min 30min 
HR Control 157 125 102 93 
(beats  
minute -1) 
Low 137 125 83 72 
 Medium 124 116 71 62 
 High 103 90 75 64 
SED within treatment 10.1 SED within time 13.8 
      
loge fR Control 2.3 (10) 2.0 ( 7) 1.9 ( 7) 1.8 ( 6) 
(breaths 
minute -1) 
Low 2.4 (11) 2.2 ( 9) 2.0 ( 7) 2.0 ( 7) 
 Medium 2.0 (  7) 2.0 ( 7) 1.7 ( 6) 1.8 ( 6) 
 High 2.3 (10) 2.2 ( 9) 1.9 ( 7) 1.9 ( 7) 
SED within treatment* 0.13 SED within time* 0.20 
      
SAP Control 103 103 96 104 
(mmHg) Low 114 117 110 107 
 Medium 114 105 103 111 
 High 134 118 110 108 
SED within treatment 7.2 SED within time 10.1 
      
DAP Control 83 79 74 77 
(mmHg) Low 89 80 87 76 
 Medium 89 77 75 80 
 High 102 76 72 76 
SED within treatment 5.4 SED within time 8.0 
      
MAP Control 96 100 83 85 
(mmHg) Low 99 97 91 86 
 Medium 97 93 83 91 
 High 113 97 86 88 
SED within treatment 4.3 SED within time 8.1 
      
PaCO2 Control 61 57 57 55 
(mmHg) Low 61 58 59 58 
 Medium 59 58 57 57 
 High 59 57 58 56 
SED within treatment 1.6 SED within time 2.5 
      
PaO2 Control 48 58 58 60 
(mmHg) Low 45 53 60 63 
 Medium 54 57 59 62 
 High 53 55 56 61 
SED within treatment 3.6 SED within time 4.1 
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A-a gradient Control 31 21 19 18 
(mmHg) Low 29 18 16 14 
 Medium 28 22 19 17 
 High 27 23 19 17 
SED within treatment 2.5 SED within time 3.0 
      
pH Control 7.28 7.32 7.35 7.38 
 Low 7.31 7.34 7.36 7.37 
 Medium 7.30 7.32 7.34 7.36 
 High 7.28 7.31 7.35 7.39 
SED within treatment 0.008 SED within time 0.016 
      
Temperature Control 39.2 39.6 39.7 39.5 
(ºC) Low 39.1 39.5 39.4 39.4 
 Medium 39.2 39.5 39.3 39.1 
 High 39.0 39.2 39.3 38.3 
SED within treatment 0.05 SED within time 0.31 
      
Lactate Control 5.20 4.46 3.06 1.89 
(mmol L-1) Low 3.44 2.41 1.25 0.77 
 Medium 3.85 3.03 1.98 1.14 
 High 4.50 3.57 1.86 1.03 
SED within treatment 0.273 SED within time 0.778 
      
* SEDs apply only to loge fR means 
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Table 8: Median and Inter Quartal Range (IQR) for all R-8-OH-DPAT treatment groups (0, 
0.005, 0.02 and 0.07 mg kg-1) for time to recumbence (in minutes), induction-, 
immobilisation- and recovery scores of blesbok (n = 6 animals with a total of 24 
immobilisations) and impala (n = 6 animals with a total of 24 immobilisations). Where scores 
were not parametrically distributed, difference amongst the treatment groups were analysed 
using the Friedman’s ANOVA test and p-values are quoted. All six animals of each species 
were immobilised with 0.09 mg kg-1 etorphine on four occasions as various dosages of R-8-
OH-DPAT were added to the mixture.  
 Time to 
recumbence  
Induction score Immobilisation score Recovery score 
Blesbok 
p-value 
3.46 (1.3),  
p = 0.334 
1 (0), 
p = 0 
3 (0.5), 
p = 0.656 
1 (0), 
p = 0 
     
Impala 
p-value 
3.6 (1.67),  
p = 0.615 
1 (0), 
p = 0 
4 (1), 
p = 0.902 
1 (0), 
p = 0 
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4.3.1 Blesbok 
There was no significant effect of treatment on the heart rate of blesbok. 
 
There was a significant linear treatment effect (p = 0.003) as well as a treatment by time 
interaction (p = 0.016) for respiratory rate. The overall mean respiratory rate of the medium 
dosage (26.7 ± 6.5 breaths minute-1) and high dosage (20.5 ± 5.0 breaths minute-1) group was 
higher than the control (11.5 ± 2.8 breath minute-1) (Figure 14). There was no difference 
between the low dosage treatment and the control at any time.  
 
There was no treatment effect on SAP and MAP. However, there was a significant treatment 
by time interaction for DAP (p = 0.014) caused by a larger drop of DAP in the control group 
and low dosage treatment (Table 7).  
 
There was a significant treatment by time interaction for arterial blood pH (p = 0.002). At 
five minutes, the pH values for the high dosage and medium dosage treatment groups were 
higher (7.49 and 7.48 respectively) than the low dosage treatment and the control treatment 
(7.44 and 7.44 respectively) (SED = 0.014). Although, this effect was not present after ten 
minutes.  
 
There was a significant nonlinear treatment effect (p = 0.021) as well as treatment by time 
interaction (p < 0.001) for PaCO2. From 15 minutes the high dosage treatment lead to 
significantly more severe hypercapnia than all other treatments. This difference persisted to 
the end of measurement when PaCO2 of the high dosage treatment measured 53 mmHg and 
the low dosage treatment measured 45 mmHg (SED = 1.8).  
 
There was significant linear treatment effect, irrespective of time on PaO2 (p = 0.036) 
indicating that hypoxia increased with dosage rate. The high dosage treatment led to 
significantly more pronounced hypoxia (overall mean = 68 mmHg) compared to when 
animals were treated with the control, low and medium dosage treatments (overall mean = 
74, 71 and 73 mmHg respectively) (SED = 1.6). 
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None of the treatments influenced A-a gradients and mean values for all treatment groups 
combined ranged from the lowest of 16 mmHg at 5 minutes (high dosage treatment) to the 
highest value of 24 mmHg at 30 minutes (medium dosage treatment) (SED = 1.2) 
 
 
Figure 14: Effect of R-8-OH-DPAT-treatment on respiratory rate of blesbok immobilised 
with etorphine (n = 6) over time (breaths minute-1). Control, low dosage (0.005 mg kg-1), 
medium dosage (0.05 mg kg-1), high dosage (0.07 mg kg-1). Respiratory rate values are 
retransformed from logarithms. Error bars are least significant differences (5 % LSD) at three 
levels of respiratory rate (10, 20 and 40). 
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4.3.2 Impala 
There was a significant linear treatment effect on the heart rate of this species (p < 0.001) 
whereby the heart rate was lower with the higher R-8-OH-DPAT dosages. Heart rate declined 
in a linear manner with all treatments over time. 
 
There was a significant treatment by time interaction for DAP (p = 0.032). At 5 minutes the 
high dosage treatment led to significantly higher DAP (102 mmHg) than all other treatments, 
but this difference was not present thereafter (SED = 8.0). Mean arterial pressure and SAP 
were not affected by the treatments but decreased with time in all treatment groups (p = 0.007 
and p = 0.028, respectively).  
 
At the five-minute time point the control and low dosage treatments led to worse hypoxia (48 
and 45 mmHg) compared to the medium and high dosage treatments (54 and 53 mmHg) 
(SED = 3.6). This difference, although clinically significant was not statistically significant 
and also not detectable at later time points. PaO2 with all treatments increased significantly 
over time (Figure 15). 
 
The A-a gradients determined at rectal temperatures of all treatment groups declined over 
time irrespective of treatment (p < 0.001). Mean values for all treatment groups combined 
ranged from the highest of 31 mmHg at 5 minutes (control treatment) to the lowest mean 
value of 14 mmHg at 30 minutes (low dosage treatment) (SED = 3.0). 
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Figure 15: Effect of R-8-OH-DPAT treatment on PaO2 (mmHg) of etorphine immobilised 
impala (n = 6) over time. Control, low dosage (0.005 mg kg-1), medium dosage (0.05 mg kg-
1), high dosage (0.07 mg kg-1). Error bars presented as least significant differences (5 % 
LSD). 
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4.4 Discussion 
There were significant cardiorespiratory effects of R-8-OH-DPAT on etorphine immobilised 
blesbok and impala (Table 7). Results of clinical interest that warrant further discussion 
include the R-8-OH-DPAT-related increase in respiratory rate in blesbok and the R-8-OH-
DPAT dosage-dependent changes in HR and PaO2 of impala.  
 
The medium and high dosage treatment of blesbok in this experiment developed the highest 
mean respiratory rates which differed significantly from the control group throughout the 
monitoring period (Figure 14). This is in accordance with Meyer et al. (2006) who reported 
that the IV administration of racemic 8-OH-DPAT (0.5 mg kg-1) in goats prevented 
respiratory depression caused by etorphine. However, this improved respiration in goats did 
not translate into improved ventilation as the goats were still hypercapnic. Meyer et al. (2006) 
also reported that despite this, the hypoxia in goats did improve due to an effect of 8-OH-
DPAT on the pulmonary circulation which improved oxygen diffusion. 
 
In contrast to the goats, the medium dosage treatment group of blesbok with the highest 
respiratory rate did not show any improved PaO2 values. Mean PaO2 was slightly lower than 
the control group. In addition, the high dosage treatment group developed the most severe 
hypercapnia and hypoxia out of all the treatment groups. It is therefore concluded that 
although the respiratory rate of blesbok increased when R-8-OH-DPAT was added, this did 
not translate into better ventilation. Equally, the addition of R-8-OH-DPAT did not appear to 
improve oxygen diffusion in the lungs as there were no clinical differences of PaO2 values 
between the treatment groups. The significantly increased respiratory rate of the medium 
dosage group can possibly be explained as an artefact (type II error) associated with the small 
sample size. Respiratory rate is highly influenced by environmental factors such as stress and 
induction time but also by the person counting the respiration. The model did not allow for 
the identification of panting animals This would have manifested as a higher respiratory rate 
but a lower tidal volume. 
 
It was previously speculated that the racemic 8-OH-DPAT and other serotonergic ligands 
improved pulmonary perfusion in goats and impala and thus facilitated better gas exchange 
(Meyer et al. 2006; Meyer et al. 2010). This improved gas exchange was illustrated by a 
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smaller A-a gradient (Herman et al. 2001; Meyer et al. 2010). R-8-OH DPAT had no effect 
on respiratory rate or the A-a gradient of impala in this experiment. The higher PaO2 values 
measured in impala with the medium and high dosage treatments at five minutes was 
unfortunately not of statistical relevance. This could also have been an artefact due to the 
small sample size (Figure 15, Table 7).  
 
PaCO2 values did not improve with any of the treatments. An explanation for a higher PaO2 
without improved ventilation or A-a gradient might be the reduction of the oxygen 
consumption through attenuation of the stress response due to the anxiolytic effects of R-8-
OH-DPAT (Carli and Samanin 1988; Picazo et al. 2000; Li et al. 2012; Żmudzka et al. 2018). 
Several studies have illustrated the beneficial effects of 8-OH-DPAT on the heart rate of 
laboratory animals (Ngampramuan et al. 2008; Vianna and Carrive 2009; Horiuchi et al. 
2011). In rats 0.05 to 0.1 mg kg-1 8-OH-DPAT reduced the sympathetic response and 
mitigated the tachycardia induced by restraint stress (Ngampramuan et al. 2008; Vianna and 
Carrive 2009).  
 
Evidence that the anxiolytic effect of R-8-OH-DPAT might have played a role in the 
cardiorespiratory events of impala at the start of the experiment, would be the alleviation of 
the initial etorphine-induced tachycardia. Tachycardia was most severe after 5 minutes with 
the control and low dosage treatments (157 and 137 beats minute-1 respectively) and less in 
the medium and high dosage treatments (124 and 103 beats minute-1  respectively; SED = 
10.1) (Table 7). Similar results were observed in a study on goats conducted by Meyer et al. 
(2006). When 8-OH-DPAT was injected with etorphine in goats, the heart rate (45 beats 
minute-1) was lower than when etorphine was injected on its own (55 beats minute-1) (Meyer 
et al. 2006).  
 
Goats treated with 8-OH-DPAT developed a higher MAP (140 mmHg) compared to goats 
treated with etorphine only (120 mmHg) within the first four to eight minutes after treatment. 
The MAP declined thereafter (Meyer et al. 2006). Similar results were observed in impala in 
the high dosage treatment with regards to mean values for DAP which differed significantly 
from the control group at the five minutes time point, but DAP of the control group declined 
thereafter. Despite the statistically significant blood pressure changes, it is probable that the 
range in which the changes occurred were not of clinical significance. 
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It is apparent that the effect of R-8-OH-DPAT on physiological variables during etorphine 
immobilisation differs between species. While R-8-OH-DPAT did not lead to any significant 
improvement of cardiovascular or blood gas variables in blesbok, the positive effects of this 
serotonin agonist on etorphine-induced tachycardia of impala from a dosage of 0.02 mg kg-
1and higher were apparent during the beginning of the immobilisation.  
 
4.5 Conclusion 
The addition of R-8-OH-DPAT did not influence induction, immobilisation or recovery of 
etorphine immobilised impala or blesbok. In this experiment, it became apparent that the 
beneficial respiratory effects of R-8-OH-DPAT during immobilisation with etorphine seem 
to be species-specific and cannot be generalised. This result, together with the possibility of 
serotonin toxicity at higher dosages, might not allow for the routine use of R-8-OH-DPAT 
during opioid-based wildlife immobilisations. 
 
Species-specific effects of serotonergic ligands, and the differences between the racemic 8-
OH-DPAT and its R-enantiomer on respiratory and cardiovascular physiology of wildlife 
warrant further investigation. 
 
Following these results, it made sense to further explore the possibility that the two most used 
opioids for immobilisation of African wildlife, etorphine and thiafentanil, have different 
physiological effects. One of the opioids might even be superior and preferably used 
compared to the other with regards to mitigation of respiratory depression and hypoxia. This 
led to the experiments described in the three following chapters. 
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Chapter 5: Comparison of etorphine and thiafentanil as 
immobilising agents for impala (Aepyceros melampus) 
 
This chapter is a modified version of the following submitted manuscript: 
 
Pfitzer S, Meyer L, Laubscher L, Warren K, Vaughan-Higgins R, Raath J.P, Laurence M. 
2019. Comparison of etorphine and thiafentanil as immobilising agents for impala 
(Aepyceros melampus), Veterinary Anaesthesia and Analgesia (undergoing second revision). 
 
5.1 Introduction 
Impala are small to medium sized antelopes found in the savannah woodlands of southern 
Africa. This antelope species is abundant and an important game ranching animal. Impala 
are regularly captured for trade and translocation as well as for research and clinical purposes. 
In South Africa, the increased popularity of colour-variants has meant that black, saddleback 
and white impala are specifically selected for, which makes some individuals very valuable 
as stud animals (Furstenburg 2016a). 
 
When darted with potent opioids, impala are prone to suffering from severe respiratory 
depression (Meyer et al. 2008a; Meyer et al. 2010; Zeiler and Meyer 2017a and 2017b; 
Pfitzer et al. 2019b). Common drugs used for darting impala in the wild are the potent opioids 
etorphine and thiafentanil, sometimes combined with ketamine or other sedatives and 
tranquillisers (Cheney and Hattingh 1987; Meyer et al. 2008; Lance and Kenny 2011; Kock 
and Burroughs 2012; Perrin et al. 2015; Zeiler and Meyer 2017a). Veterinarians usually have 
the full opioid antagonist, naltrexone, or an opioid agonist-antagonist such as butorphanol on 
hand for inducing emergency recovery or to alleviate respiratory depression as soon as 
possible if required (Meyer et al. 2010; Kock and Burroughs 2012; Zeiler and Meyer 2017b). 
While some individuals suffer from moderate respiratory depression and hypoxia, in others, 
this can be severe and cause death (Meyer et al. 2010; Zeiler and Meyer 2017a and 2017b).  
 
Impala are commonly exhibited in zoological institutions and are used as a model for 
antelope species during research. Various immobilisation protocols have been examined in 
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an attempt to find the best immobilising drug protocol for this species (Janssen et al. 1993; 
Meyer et al. 2008a; Perrin et al. 2015; Zeiler and Meyer 2017a). Most of these reports deal 
with opioid-based immobilisation protocols where the potent opioid is mixed with a sedative 
or tranquilliser. However, many veterinarians, when darting in field conditions, use 
thiafentanil as the sole immobilisation agent without addition of tranquillisers or sedatives 
into their darts (Kock and Burroughs 2012). The use of an opioid without addition of 
sedatives or tranquillisers for impala immobilisation has the advantage that it can be fully 
reversed with the opioid antagonist naltrexone and thus the impala can readily recover 
without residual sedative or tranquiliser effects. Animals are then better able to handle 
challenges such as predation or dominant herd counterparts shortly after reversal of the 
immobilisation.  
 
Thiafentanil was previously thought to be the superior drug for impala immobilisation when 
compared to etorphine as it is thought to achieve a faster induction and less respiratory 
depression (Meyer et al. 2008a; Lance and Kenny 2011; Kock and Burroughs 2012; Zeiler 
and Meyer 2017a).  
 
All previous studies comparing opioid immobilisation in impala had tranquillisers and 
sedatives added to the immobilisation mixtures when the two opioids were compared. These 
drugs may have interfered and masked effects caused by the opioids (Meyer et al. 2008a; 
Zeiler and Meyer 2017a). The aim of this study was to compare the immobilisation and 
physiological effects of etorphine and thiafentanil when used alone to immobilise impala. A 
further aim of this study was to determine which opioid is more suitable and safer to use for 
impala immobilisation. It is hypothesised that there will be clinically relevant differences of 
the drug effects with regards to the quality of immobilisation and physiological effects. 
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5.2 Materials and Methods 
The study was approved by the Murdoch University Animal Ethics committee (R3039/18) 
and the Wildlife Pharmaceuticals Animal Ethics Committee (WPAEC-2017-DPATBLES-
11-B). 
 
Eight wild captured female impala weighing 37 ± 4 kg were selected for this experiment 
which took place at the Wildlife Pharmaceuticals Wildlife Research Facility, South Africa 
(GPS: 25°31’25.2” S, 31°06’50.8” E). Research animals were chosen to be of same sex, 
similar size and in good health in order to minimise variability that could influence the 
results.  
 
Housing enclosures consisted of several compartments that were approximately six by eight 
metres in size and were constructed from sturdy gum tree poles. The impala were held in 
groups of four animals. After an initial adjustment period of two weeks after delivery and 
two weeks before the start of the actual research trial, the animals were chemically 
immobilised, marked and subjected to a veterinary health examination. At this occasion, the 
animals under immobilisation were weighed while lying in sternal position in a stretcher and 
lifted with a hand-held precision scale which was attached to a pole (Anyload OCSL Mini 
Crane Scale, Anyload Transducer Co. Ltd. Canada). 
 
The immobilising drugs etorphine (Captivon, 9.8 mg mL-1, Wildlife Pharmaceuticals (Pty) 
Ltd, South Africa) and thiafentanil (Thianil, 10 mg mL-1, Wildlife Pharmaceuticals (Pty) Ltd, 
South Africa) were administered IM via a remote injection by darting. Each animal was 
darted by means of a CO2 gas powered dart projector (X-Caliber, Pneu-Dart. Inc., 
Williamsport, PA, USA). The darts used were 1 ml P-type Pneudarts with 1.9 cm barbed 
needles (Pneu-Dart. Inc., Williamsport, PA, USA). Animals were darted on two separate 
occasions with a wash-out period of two weeks between each occasion. Each impala received 
both drug treatments which were initially allocated to animals at random in a cross-over 
design. Treatment 1 consisted of 0.09 mg kg-1 etorphine and treatment 2 consisted of 0.09 
mg kg-1 thiafentanil. The dosage to achieve immobilisation was determined from literature 
and in a previous study (Meyer et al. 2010; Pfitzer et al. 2019b). 
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The experiment was conducted during the cooler months of July and August between 08:00 
to 12:00 and 14:00 to 17:00 respectively to avoid hot ambient temperatures that occurred at 
midday. Four animals were processed per day. Monitoring of the animals was done outdoors 
in a shaded area. 
 
As soon as it became recumbent and was not able to rise at first approach, the darted impala 
was retrieved from the enclosure and placed onto a stretcher in sternal position. The head 
was held up with the nose pointing down to ensure patency of the upper airway. The animal 
was immediately blind-folded and cotton wool inserted into the ears to minimise external 
stimuli. It was carried to the monitoring table and kept in this position throughout the 
monitoring period. 
 
Recording of physiological variables began at five minutes after an animal became 
recumbent and was continued every five minutes until forty minutes post recumbence. 
Barometric pressure was measured by the EPOC portable blood gas analyser (EPOC Blood 
Analysis System, Epocal; USA) and the environmental temperature was measured by the 
Weather+ Bluetooth Sensor (Oregon Scientific, USA). Rectal body temperature was 
measured by means of a modified hand-held digital thermometer (Hanna Checktemp 1, 
Hanna Instruments (Pty) Ltd., USA). Respiratory rate was measured manually by means of 
visual observation of chest expansions and auscultation with a stethoscope for one minute 
(Littman Classic II SE; USA). The auricular (Arteria auricularis) or pedal arteries (A. 
digitalis) were catheterised using a 21 Gauge (G) catheter (Jelco IV catheter radiopaque; 
Smith Medical International, UK) to measure intra-arterial blood pressure and heart rate 
using the Deltran II pressure transducer (Utah Medical, Midvale, USA) connected to an 
IntraTorr blood pressure monitor (IntraTorr, IntraVitals, UK). Arterial blood was drawn 
anaerobically in a heparinised blood gas syringe (BD A-Line; Becton Dickinson & Co, UK) 
at times 5, 10, 15, 20 and 30 minutes after recumbence. The first 2 mL of blood were 
discarded to avoid contamination of blood from the catheter. Within five minutes after 
sampling, arterial blood was analysed using the EPOC portable blood gas analyser with 
EPOC BGEM test cards (BGEM smart cards; Epocal; USA), to determine blood gases and 
acid-base status. The A-a gradient was calculated as described by Meyer et al. (2010). 
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The immobilisation of all animals was reversed with an IV injection of naltrexone (Trexonil, 
50 mg mL-1, Wildlife Pharmaceuticals (Pty) Ltd, South Africa) injected at a ratio of 20 mg 
naltrexone to 1mg etorphine and 10 mg naltrexone per 1 mg thiafentanil as soon as the 40-
minute monitoring period was over (O’Dell et al. 2017). Immobilisation induction and 
recovery was assessed and scored subjectively in each animal. The induction score was based 
on speed and quality of induction and ranged from 1 to 5 with 1 = excellent and 5 = an animal 
that did not become recumbent. Immobilisation quality was scored at each sampling interval 
by assessing depth of CNS depression and movement on a scale of 1 to 5. A score of 1 = an 
animal that was conscious and mobile and needed to be re-dosed for safe handling and 5 = 
an animal that was anaesthetised too deeply and showed severe cardiorespiratory depression 
and no reflexes. The subjective recovery was scored based on the speed and smoothness of 
the recovery after the IV administration of naltrexone and ranged from 1 to 5 with 1 = an 
animal that got up within three minutes and had a smooth recovery and 5 = an animal that 
did not recover at all (Table 5). Time to recumbence was defined as time from dart injection 
to when the animal was recumbent and was unable to rise at first approach. 
 
5.2.1 Data analysis 
To determine whether there was a difference between the two opioids on the physiological 
variables of interest, analyses were performed with Genstat Version 19 (VSN International, 
UK). A linear mixed model was fitted to the data. The fixed model included the effects of 
the two drugs on the monitored variables, the effects of time after recumbence on the 
monitored variables as well as interaction between treatment and time effect. The random 
model included terms for animal number, animal number by treatment and animal number 
by treatment by minutes after recumbence. The residual variance or covariance model 
included correlations between measurements made on the same animal in the same trial and 
different variances for each animal. Non-significant random effects and co-variances were 
removed from the model before the significance of fixed effects was assessed. A p-value of 
less than 0.05 was considered significant. 
 
Heart rate in beats minute-1, ƒR in breaths minute-1, SAP in mmHg, DAP in mmHg, MAP in 
mmHg, arterial blood pH, HCO3 in mmol L-1, BE in mmol L-1, Agap in mmol L-1, lactate in 
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mmol L-1, PaCO2 at 37 °C in mmHg, PaO2 at 37 °C in mmHg, and A-a gradient at 37 °C in 
mmHg and RT in °C were statistically evaluated. 
 
Time to final recumbence between drug treatments was compared by means of one-way 
analysis of variance (ANOVA) in IBM SPSS Statistics for Windows, version 24 (IBM Corp., 
Armonk, NY, USA). Induction scores, immobilisation and recovery scores between drug 
treatments were analysed by means of Wilcoxon signed-rank test as the data were nominal. 
The significance level was set at p < 0.05. 
 
5.3 Results 
Ambient temperatures measured during treatment 1 were 20.7 ± 4.3 ºC and during treatment 
2, 21.9 ± 6.7 ºC. Barometric pressure measured during these experiments varied between 693 
and 706 mmHg. 
 
Mean time to recumbence was significantly (p = 0.007) faster with thiafentanil treatment 1.96 
minutes (SD = 0.81) compared to etorphine treatment 3.89 minutes (SD = 1.55). There was 
a significant difference for the median immobilisation scores which measured 2.59 with an 
interquartal range (IQR) of 0.73 with the etorphine treatment and 2.4 (IQR = 0.75) with the 
thiafentanil treatment (Z = -2.205, p = 0.027). However, after administration of the reversal 
agent naltrexone, the median recovery scores did not differ between treatments and all 
animals achieved a recovery score of 1 (IQR = 0) irrespective of the treatment. There was 
also a difference in induction scores using the Wilcoxon signed rank test (Z = -1.897, p = 
0.05). Median induction scores measured 1 for both treatments but the etorphine treatment 
had an IQR of 0.5 while the IQR of the thiafentanil treatment was 0. This effect was due to 
the fact that two of the eight impala when immobilised with etorphine, received an induction 
score of 2 as they stood up repeatedly after the initial recumbence.  
 
Significant difference between the treatments were detected for blood pressure. Heart rate, 
respiratory rate as well as blood gasses and acid-base variables showed a significant treatment 
by time interaction. Most physiological variables were also affected by time irrespective of 
the treatment (Table 9, Table 10).  
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Table 9: The significance (p-values) of treatment main effects, time main effects, and the 
treatment by time interaction for impala immobilised with etorphine and thiafentanil, 
respectively. Significant results (p < 0.05) are given in bold. 
Fixed term Treatment Time Treatment x time 
HR   0.392 <0.001 <0.001 
ƒR   0.844 <0.001   0.004 
SAP   0.005 <0.001   0.261 
DAP <0.001   0.376   0.133 
MAP <0.001   0.025   0.059 
PaCO2   0.402 <0.001 <0.001 
PaO2   0.635 <0.001 <0.001 
A-a grad   0.470 <0.001   0.087 
pH   0.282 <0.001   0.238 
HCO3-   0.837 <0.001 <0.001 
BE   0.571 <0.001 <0.001 
Agap   0.889 <0.001   0.002 
Lac   0.822 <0.001   0.931 
Temp   0.207   0.023   0.081 
Footnote: Physiological values evaluated were heart rate (HR), respiratory rate (fR), systolic arterial pressure 
(SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), arterial partial pressure of carbon 
dioxide (PaCO2), arterial partial pressure of oxygen (PaO2) and the alveolar-arterial oxygen gradient (A-a 
gradient) arterial blood pH (pH), arterial bicarbonate (HCO3-), arterial base excess (BE), anion gap (Agap), 
Lactate (Lac),rectal temperature (Temp). 
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Table 10: Mean physiological variables over time and standard error of differences (SED) in 
impala immobilised with 0.09 mg kg-1 etorphine and thiafentanil, respectively. 
   Time after recumbence of impala 
 
 
 Group 
 
5min 10min 15min 20min 30min 40min 
        
HR Etorphine 132  112 100  92 82 82 
(beats 
minute-1) 
Thiafentanil 113 111 107  111 110 107 
SED within treatment 6.3 SED within time 14.2 
        
fR Etorphine 13 13 12 14 13 12 
(breaths 
minute-1) 
Thiafentanil   7 11 13 15 15 16 
SED within treatment 1.5 SED within time 2.0 
        
Temperature Etorphine 38.8 38.9 38.9 38.9 38.8 38.5 
(ºC) Thiafentanil 38.9 39.0 39.2 39.2 39.3 39.2 
SED within treatment 0.10 SED within time 0.32 
        
SAP Etorphine 149 139 135 134 142 152 
(mmHg) Thiafentanil 179  160 158 158 159 165 
SED within treatment 4.3 SED within time 5.9 
        
DAP Etorphine 103  101  99  100  109  112  
(mmHg) Thiafentanil 134  125  123  129  125  126  
SED within treatment 5.0 SED within time 5.2 
        
MAP Etorphine 120  113  110  115  125  129  
(mmHg) Thiafentanil 151  141  133   146  141  141  
SED within treatment 5.7 SED within time 5.6 
        
pH Etorphine 7.30  7.32  7.34  7.36  7.39   
 Thiafentanil 7.26  7.31  7.33  7.35  7.38   
SED within treatment 0.008 SED within time 0.018 
        
HCO3- Etorphine 27.0  27.6  29.1  30.4  31.1   
 Thiafentanil 29.2  28.0  27.9  28.1  30.1   
SED within treatment 0.36 SED within time 1.41 
        
BE Etorphine 1.13  1.95  3.70  5.26  6.95   
 Thiafentanil 2.77  2.04  2.17  3.00  5.40   
SED within treatment 0.35 SED within time 1.02 
        
Agap Etorphine 12.79  13.07  10.70  10.84  10.59   
 Thiafentanil 11.10  12.68  12.41  11.45  10.98   
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SED within treatment 0.475 SED within time 0.959 
        
Lactate Etorphine 5.2  4.3  3.4  2.6  1.5   
 Thiafentanil 5.3  4.5  3.7  3.0  1.8   
SED within treatment 0.20 SED within time 0.90 
        
PaCO2 Etorphine 52  50  51  50  49   
(mmHg) Thiafentanil 61   54  51  48  47   
SED within treatment 1.6 SED within time 2.4 
        
PaO2 Etorphine 45  50  50  53  59   
(mmHg) Thiafentanil 37  52  59  60  59   
SED within treatment 2.3 SED within time 3.8 
        
A-a gradient Etorphine 39  36  34  32  28   
(mmHg) Thiafentanil 40  33  29  31  30   
SED within treatment 2.1 SED within time 2.6 
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There was a significant effect of time (p < 0.001) as well as a treatment by time effect (p < 
0.001) for mean values of heart rate. Heart rate with the etorphine treatment started higher 
and decreased within ten minutes to below the HR of the thiafentanil treatment. The 
difference of the HR between both treatment groups was only significant at the 30-minute 
time point. There was a large variation between animals, reflected in the large standard 
deviation (Figure 16, Table 10).  
 
The ƒR increased with time for the thiafentanil treatment but started out lower than with the 
etorphine treatment (Figure 16, Table 10). Panting was observed in one of the animals treated 
with etorphine. This animal took the longest time to final recumbence (7.46 minutes). Initial 
apnoea was observed in two animals treated with thiafentanil. Respiratory rates varied widely 
between individuals. 
 
There were significant effects of treatment for all three blood pressure parameters, namely 
SAP (p = 0.005), DAP (p < 0.001), as well as MAP (p < 0.001). All three variables were 
higher with the thiafentanil treatment compared to the etorphine treatment (Figure 17,Table 
10). While SAP and MAP changed over time, DAP did not significantly change over time 
(Figure 17, Table 9).  
 
The mean arterial pH increased over time for both treatments (Table 10). Mean arterial 
bicarbonate (HCO3-) increased over time with etorphine while it decreased initially and then 
increased after fifteen minutes with the thiafentanil treatment (Figure 18, Table 9, Table 10). 
The BE showed similar changes as HCO3- with the difference that the BE of thiafentanil-
treated animals started increasing after ten minutes already (Figure 18, Table 10). The Anion 
gap in contrast increased for both treatments during the first ten minutes after which it 
steadily decreased for both treatments (Figure 18, Table 10).  
 
Mean blood lactate significantly decreased over time irrespective of the treatment (Table 10).  
 
There was significant treatment by time interaction for PaCO2 (p < 0.001). The mean PaCO2 
decreased over time with both treatments. With the thiafentanil treatment it decreased from 
61 to 47 mmHg, while with the etorphine treatment, this parameter only decreased slightly 
from 52 to 49 mmHg (SED = 1.6) (Figure 19, Table 10). A significant treatment by time 
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interaction could also be observed for PaO2 (p < 0.001). Animals in both treatment groups 
were severely hypoxaemic. The thiafentanil treatment produced more severe hypoxaemia at 
the beginning of the monitoring period with mean values of 37 mmHg. The mean arterial 
PaO2 for both treatments increased however over time and despite initial differences, both 
treatments produced a PaO2 of 59 mmHg after 30 minutes (SED = 3.8) (Figure 19, Table 10).  
 
The alveolar arterial oxygen gradient (A-a gradient) of both treatments decreased over time 
irrespective of the treatment (Figure 19, Table 10). 
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Figure 16: Effects of treatment over time on heart rate (HR) / respiratory rate (fR) of impala 
immobilised with etorphine or thiafentanil. Error bars presented as least significant difference 
(5 % LSD). 
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Figure 17: Effects of treatment over time on systolic arterial pressure (SAP), diastolic arterial 
blood pressure (DAP) and mean arterial blood pressure (MAP) of impala after treatment with 
etorphine and thiafentanil. Error bars presented as least significant difference (5 % LSD). 
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Figure 18: Effect of treatment over time on the mean values for arterial bicarbonate (HCO3-
), base excess (BE) and anion gap (Agap) (y-axis in mmol L-1) of impala immobilised with 
etorphine and thiafentanil respectively. Error bars presented as least significant difference (5 
% LSD). 
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Figure 19: Effects of treatment over time on the mean values for PaCO2 and PaO2 and A-a 
gradient of impala immobilised with etorphine and thiafentanil respectively. Error bars 
presented as least significant difference (5 % LSD). 
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5.4 Discussion 
This study demonstrates that opioids alone in high dosages are suitable for the effective 
immobilisation of impala. A key difference between the effects of the two immobilising 
agents was the immobilisation induction. Time to recumbence was faster with thiafentanil 
treatment than with the etorphine treatment, as has been reported previously by Meyer et al. 
(2008a).  
 
Similar induction times have been reported by Janssen et al. (1993) who reported a time to 
recumbence of less than three minutes for impala darted with 0.08 mg kg-1 thiafentanil. 
Pfitzer et al. (2019b) reported an induction time of 4.0 ± 1.7 minutes for a dosage of 0.09 mg 
kg-1 etorphine in impala. When lower dosages of potent opioids were used on their own to 
immobilise impala, they took considerably longer to become recumbent and sometimes had 
to be physically handled in order to be subdued for anaesthetic monitoring (Cheney and 
Hattingh 1987; Janssen et al. 1993). The addition of sedatives or tranquilisers such as 
medetomidine or azaperone with thiafentanil does not appear to speed up the induction time 
when compared to results of the current study (Meyer et al. 2008a; Zeiler and Meyer 2017a). 
 
Rapid recumbence is desirable, especially in a field situation where impala could potentially 
run long distances during the induction period which could lead to complications such as 
failure to recover the animal, hyperthermia, injury, predation and death (Cheney and Hattingh 
1987; Janssen et al. 1993; Meyer et al. 2008a; Zeiler and Meyer 2017a). At the chosen high 
opioid dosage of 0.09 mg kg-1, all impala became recumbent without intervention. After 
impala had become recumbent and could be easily handled and positioned sternal for 
monitoring, they showed minor infrequent movements like chewing, tail flicking, ear 
twitching and sometimes limb movements. Similar movements have been observed by other 
authors when impala were immobilised with different drug cocktails (Janssen 1993; Meyer 
et al. 2008a; Zeiler and Meyer 2017a). The speed of induction alone lends weight to the 
argument that thiafentanil is the more suitable opioid for the immobilisation of wild impala.  
 
The degree to which the two opioids caused apnoea was notable. Although the initial apnoea 
was not reflected in the data of predicted means, it was observed with thiafentanil in this 
study in two of the eight animals (25 % occurrence). No such incidence was observed with 
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etorphine. This thiafentanil-induced initial apnoea has also been reported by Janssen (1993), 
Meyer et al. (2008a) as well as Zeiler and Meyer (2017a). In contrast to previous reports, 
both animals in this study quickly overcame this challenge. Quick recovery from apnoea 
might have been due to the fact that no sedative or tranquilliser was added to the immobilising 
mixture in this study and these may have potentiated respiratory depression caused by opioids 
in previous studies (Meyer et al. 2008a; Zeiler and Meyer 2017a).  
 
The normal ƒR of impala at rest has been reported as 20 ± 8 breaths per minute (Cheney and 
Hattingh 1987). In comparison, both treatments in the current study produced hypopnoea 
with ƒR of between 7 and 16 breaths minute-1 (Table 10). This hypopnoea contributed to 
respiratory depression which was also reflected by an increase in PaCO2 with values ranging 
from 49 to 52 mmHg with the etorphine treatment and from 47 to 61 mmHg with the 
thiafentanil treatment respectively. The primary cause of this hypercapnia was likely due to 
hypoventilation induced by the respiratory depressive effects of the opioids (Meyer et al. 
2015). This condition improved within the first 15 minutes of monitoring (Figure 19). Several 
attempts have been made to alleviate the respiratory depressive effects caused by opioids 
during wildlife immobilisation (Meyer et al. 2006; Meyer et al. 2010; Haw et al. 2016a and 
2016b; Pfitzer et al. 2019a and 2019b), but at this stage none of the compounds tested have 
been identified as suitable for clinical use in the field.  
 
Normal A-a gradients of 21 to 25 mmHg were reported in goats before opioid-immobilisation 
and increased to 33 to 40 mmHg post immobilisation (Meyer et al. 2006; Meyer et al. 2015). 
The A-a gradients of impala with both treatments in this study ranged from 28 to 40 mmHg 
and were highest at the beginning of the study. These large gradients indicate that 
hypoxaemia was not just caused by hypoventilation induced by respiratory depression but 
was also due to other disturbances that may have impeded the alveoli gas exchange of 
oxygen, or it was caused by the increased use of oxygen through increased tissue metabolism 
induced by catatonia or other drug-induced hypermetabolic effects (Heard et al. 1996; Meyer 
et al. 2010; Meyer et al. 2015; Buss et al. 2016). The decrease of the A-a gradients and 
improvement of hypoxaemia over time, points towards the fact that ventilation as well as gas 
exchange improved over time. 
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It is probable that with both treatments, respiratory acidosis was already partially 
compensated for at the first sample. This finding is indicated by slightly elevated levels of 
HCO3- as well as BE (Irizarry and Reiss 2009). Although lactate was moderately elevated at 
the beginning of the monitoring period and decreased quickly, the anion gap was within the 
normal reference range of 5-15 mmol L-1. The normal anion gap indicates that the acidosis 
was mainly of respiratory origin during the immobilisation and not mixed with a metabolic 
component as can often be expected when lactate values during capture are abnormally 
elevated (Bateman 2008; Irizarry and Reiss 2009).  
 
Blood pressures and HRs varied considerably not only between the treatment protocols but 
also between individual animals throughout the monitoring period. Based on reference values 
of similar sized animals, sheep and goats (Prothero 2015; Izwan et al. 2018), it could be 
concluded that the etorphine treatment produced only mild hypertension (mean MAP = 120 
mmHg). The thiafentanil treatment on the other hand, produced a moderate hypertension 
(mean MAP = 141 mmHg) throughout the monitoring period, although there was a slight 
decrease in blood pressure over time (SED = 1.50) (Table 10, Figure 17). Similar 
hypertensive effects in thiafentanil-treated impala were reported by Janssen et al. (1993) who 
reported a mean MAP of 130 to 140 mmHg during early measurements after recumbence 
after immobilisation treatment of impala with 29 and 76 µg kg-1 respectively. Persistent 
tachycardia and hypertension as observed in the thiafentanil-treated animals could stem from 
sympathetic nervous system activation by various factors such as by the opioids themselves, 
from hypoxia or hypercapnia or it could possibly also be stress-induced from the dart impact 
(Heard et al. 1990; Meyer et al. 2015; Buss et al. 2016). However, the fact that there was a 
significant difference between thiafentanil and etorphine indicates that the hypertension in 
this case was most likely predominantly drug- rather than stress-induced.  
 
Future studies should look into the origin of the cardiovascular changes such as tachycardia 
and hypertension as a result of opioid immobilisation. Apart from depression of central 
respiratory centres caused by opioids, cardiovascular and metabolic changes possibly 
contribute significantly towards the hypoxaemia of impala under opioid immobilisation 
(Meyer et al. 2015; Buss et al. 2018). If this is the case and these changes are due to 
sympathomimetic actions of opioids, or the acute fight and flight response as a result of 
darting and handling, drugs such as sympatholytics or anxiolytics might contribute towards 
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improvement of blood gas values of opioid immobilised impala (Köhnlein and Welte 2007; 
Dooley 2015). 
 
Although comparing various scientific reports on immobilisation of different species has its 
limitation, the wide individual variability in physiological response of impala following 
opioid-based immobilisation have been previously reported (Meyer et al. 2008; Zeiler and 
Meyer 2017a). Additionally, the physiological side-effects of the potent opioids appear to be 
more profound in impala than in other antelope species (Citino et al. 2002; Howard et al. 
2004; Cooper et al. 2005; Kilgallon et al. 2010; Dittberner et al. 2015). Phylogenetically, 
impala are not closely related to most African antelope species and this might explain their 
unique physiological reaction to opioids (Brashares et al. 1974; Hernandez Fernandez and 
Vrba 2005). The use of alternative species, which are phylogenetically more related as a 
model for opioid-immobilisation studies might be indicated for future drug experiments.  
 
5.5 Conclusions 
Immobilisation of impala with potent opioids is unpredictable because of the individual 
reaction of animals to the act of darting. Both potent opioids at a higher than normally 
recommended dosage of 0.09 mg kg-1 are suitable for the short-term immobilisation of 
impala. Thiafentanil has a significantly faster induction time. When free range animals are 
captured in the wild, this allows for easier and faster retrieval of the animals and could be of 
values despite the more severe cardiorespiratory side effects. On the downside, thiafentanil 
causes more severe hypertension and greater respiratory side effects, including possible 
apnoea, during the first ten minutes, which in some individual impala could be fatal. 
Therefore, etorphine might be the opioid of choice for impala if animals are captured in a 
more confined space. Care should be taken when combining thiafentanil with other sedatives 
or tranquillisers to use products that do not further compound hypertension. 
 
This study has shown that etorphine and thiafentanil have important different clinical and 
physiological effects and these effects need to be carefully considered to ensure the safety 
and welfare of animals immobilised under different conditions. 
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Chapter 6: Comparison of etorphine and thiafentanil as 
immobilising agents for blesbok (Damaliscus pygargus phillipsi) 
 
This chapter is a modified version of the following submitted manuscript: 
 
Pfitzer S, Meyer L, Laubscher L, Warren K, Vaughan-Higgins R, Raath JP, Laurence M. 
2019. Thiafentanil causes less respiratory compromise and less hypoxaemia than etorphine 
when used as an immobilising agent for blesbok (Damaliscus pygargus phillipsi), Veterinary 
Anaesthesia and Analgesia (revised draft submitted after second review) 
 
6.1 Introduction 
Blesbok (Damaliscus pygargus phillipsi) are medium sized antelopes endemic to southern 
Africa. Blesbok live in herds of 2 - 25 ewes with lambs and males as bachelor groups or as 
territorial rams. Both sexes have horns and are seasonal breeders. After a gestation period of 
approximately eight months, they give birth during the summer months of December to 
February. Blesbok prefer the grassland habitat of southern Africa and are very popular 
animals to be kept on game farms where they are utilised for ecotourism, meat production 
and hunting (Furstenburg 2016). Colour variations of blesbok are used for stud breeding in 
South Africa and fetch high auction prices (Furstenburg, 2016). Blesbok have to be captured 
and kept in temporary confinement regularly for translocation and trade purposes. Drug 
combinations commonly used for immobilisation of this antelope species contain potent 
opioid agonists such as etorphine or thiafentanil, in combination with the butyrophenone 
derivative azaperone or with an alpha-2 agonist (Kock and Burroughs 2012).  
 
There are very few studies on the effects of high dosages of opioids, used on their own, in 
wild animals. Generally studies like this, which are used to better determine the physiological 
effects of these opioids, are normally done in domestic ruminants such as goats, sheep and 
cattle (Harthoorn 1967; Heard et al. 1990; Heard et al. 1996; Meyer et al. 2015; Izwan et al. 
2018). Except for two recent trials in impala (Meyer et al. 2010; Pfitzer et al. 2019b), the 
experimental use of pure etorphine and thiafentanil has only been reported in a few studies 
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in impala and wildebeest, but these authors did not report on blood gas and acid-base changes 
(Harthoorn 1967; Cheney and Hattingh 1987; Janssen et al. 1993).  
 
The aim of this study was to compare the effects of immobilisation with etorphine or 
thiafentanil in blesbok in order to establish which one of the two opioids might be more 
effective and safer. The focus was on the respiratory system which is commonly depressed 
or compromised during opioid immobilisation. 
 
It is hypothesised that the two opioids would cause different times to recumbence, 
immobilisation quality and physiological effects during the immobilisation of blesbok. 
Insights into different effects to the two opioids will enable veterinarians to make better 
decisions regarding the safety and efficacy of the in-field use of these drugs.  
 
6.2 Materials and Methods 
The study was approved by Murdoch University’s Animal Ethics Committee (R3039/18) as 
well as Wildlife Pharmaceutical’s Animal Ethics Committee (WPAEC-2017-DPATBLES-
11-B). 
 
Eight wild captured, non-pregnant, adult female blesbok weighing 58 ± 2 kg were used for 
this study which occurred at the Wildlife Pharmaceuticals Wildlife Research Facility, South 
Africa (GPS: 25°31’25.2” S, 31°06’50.8” E). To minimise variability that could influence 
the results, research animals were chosen to be the same sex, of similar size and in good 
health. 
 
Blesbok were held in groups of four animals inside the research enclosures which were 
constructed from sturdy wooden poles. Horns of the animals were piped with plastic pipes to 
prevent horn injuries which are common in captive blesbok, especially at the beginning of 
confinement. The animals were allowed to adjust for two weeks after delivery. After this 
period, all blesbok were chemically immobilised, marked, examined to be in good health by 
a veterinarian and weighed while positioned inside a stretcher which was hooked to a 
precision scale (Anyload OCSL Mini Crane Scale, Anyload Transducer Co. Ltd. Canada).  
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A wash out period of one week was allowed before the actual experiments took place. For 
experiments, the immobilising drugs etorphine (Captivon 9.8 mg mL-1, Wildlife 
Pharmaceuticals (Pty) Ltd, South Africa) and thiafentanil (Thianil 10 mg mL-1, Wildlife 
Pharmaceuticals (Pty) Ltd, South Africa) were administered IM via remote injection 
(darting). Each animal was darted from a CO2 gas powered dart projector (X-Caliber, Pneu-
Dart. Inc., Williamsport, PA, USA). The darts used were 1 ml P-type Pneudarts with 1.9 cm 
barbed needles (Pneu-Dart. Inc., Williamsport, PA, USA). Animals were darted on two 
separate trial occasions with a wash-out period of one week between each occasion. Each 
blesbok received both drug treatments which were allocated to animals at random in a cross-
over design. Treatment 1 consisted of 0.09 mg kg-1 etorphine and treatment 2 consisted of 
0.09 mg kg-1 thiafentanil. The dosage to achieve immobilisation was determined in a previous 
study (Pfitzer et al. 2019b). 
 
Four to six animals were processed per day. All measurements were made outdoors in a 
shaded area between 08:00 to 12:00 and 14:00 to 17:00 to avoid hot ambient temperatures 
that occurred at midday. After darting, as soon as an animal became recumbent and could be 
approached, it was placed in sternal recumbence, with the head elevated and nostrils pointing 
downwards to ensure patency of the upper airways. To minimise external stimuli, it was then 
blindfolded, and cotton wool inserted into the ears. The animal was carried to the monitoring 
table on a stretcher and kept in this sternal position with the head elevated throughout the 
monitoring period. 
 
Recording of physiological variables began at five minutes after an animal became 
recumbent and was repeated every five minutes until forty minutes after recumbence. A 
modified hand-held digital thermometer (Hanna Checktemp 1, Hanna Instruments (Pty) Ltd., 
USA) was used to measure rectal body temperature. The EPOC portable blood gas analyser 
(EPOC Blood Analysis System, Epocal; USA) was used to measure barometric pressure. The 
environmental temperature was measured by the Weather+ Bluetooth Sensor (Oregon 
Scientific, USA). Visual observation of chest expansions and auscultation with a stethoscope 
(Littman Classic II SE; USA) over one minute served to measure respiratory rate. The 
auricular (Arteria auricularis) or pedal arteries (A. digitalis) were catheterised using a 21 G 
catheter (Jelco IV catheter radiopaque; Smith Medical International, UK) to measure intra-
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arterial blood pressure using the Deltran II pressure transducer (Utah Medical, UT, USA) 
which was connected to an IntraTorr blood pressure monitor (IntraTorr, IntraVitals, UK). 
The transducer was placed at the height of the scapulohumeral joint (near the heart base). 
This device also measured pulse rate. For blood gas analysis, arterial blood was drawn 
anaerobically in a heparinised blood gas syringe (BD A-Line; Becton Dickinson and Co, UK) 
at times 5, 10, 15, 20 and 30 minutes after recumbence. The arterial blood was analysed 
within five minutes after sampling using a portable EPOC blood gas analyser and EPOC 
BGEM test cards (BGEM smart cards; Epocal; USA) which determined blood gases, as well 
as acid-base status. The alveolar-arterial oxygen (A-a) gradient was calculated as described 
by Meyer et al. (2010). 
 
The immobilisation of all the animals was reversed as soon as the 40-minute monitoring 
period was over with IV naltrexone (Trexonil, 50 mg mL-1, Wildlife Pharmaceuticals (Pty) 
Ltd, South Africa) injected at a ratio of 20 mg naltrexone per 1 mg etorphine and 10 mg 
naltrexone per 1 mg thiafentanil (O’Dell et al. 2017). Induction, immobilisation and recovery 
was assessed and scored subjectively in each animal. The induction score was based on the 
speed and quality of induction ranging from 1 to 5 (with 1 = excellent and 5 = an animal that 
did not become recumbent). Immobilisation quality was scored at each sampling interval by 
assessing depth of CNS depression and movement on a scale of 1 to 5. A score of 1 = an 
animal that was conscious and mobile and needed to be re-dosed for safe handling and 5 = 
an animal that was anaesthetised too deeply and showed severe cardiorespiratory depression 
and no reflexes. The subjective recovery was scored based on the speed and smoothness of 
the recovery after the IV administration of naltrexone and ranged from 1 to 5 with 1 = an 
animal that got up within three minutes and had a smooth recovery and 5 = an animal that 
did not recover at all (Table 5). Time to recumbence was defined as time from dart injection 
to when the animal was in sternal or lateral recumbence and was unable to rise on first 
approach. 
 
6.2.1 Data analysis 
Analyses were performed with Genstat Version 19 (VSN International, UK)  
to determine whether there was a difference between the two opioids on the physiological 
variables of interest. A linear mixed model was fitted to the data. The fixed model included 
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the effects of the two drugs on the monitored variables, the effects of time after recumbence 
on the monitored variables as well as interaction between treatment and time effect. The 
random model included terms for animal number, animal number by treatment and animal 
number by treatment by minutes after recumbence. The residual variance or covariance 
model included correlations between measurements made on the same animal with the same 
treatment and different variances for each animal. Non-significant random effects and co-
variances were removed from the model before the significance of fixed effects was assessed. 
A p-value < 0.05 was considered significant. 
 
Physiological variables included in the statistical evaluation were RT in °C, HR in beats 
minute-1, ƒR in breaths minute-1, SAP, DAP and MAP in mmHg, arterial blood pH, HCO3- in 
mmol L-1, BE in mmol L-1, Anion gap in mmol L-1, lactate in mmol L-1, PaCO2 in mmHg at 
37 °C, PaO2 in mmHg at 37 °C and A-a gradient in mmHg at 37 °C. 
 
By means of one-way analysis of variance (ANOVA) time to final recumbence between drug 
treatments were compared in IBM SPSS Statistics for Windows, version 24 (IBM Corp., 
Armonk, NY, USA). A Wilcoxon signed-rank test was used to analyse induction, 
immobilisation and recovery scores between drug treatments as the data were nominal. The 
significance level was set at p < 0.05. 
 
6.3 Results 
Ambient temperatures measured during etorphine treatment were 24.9 ± 3.5 ºC and during 
thiafentanil treatment 24.3 ± 2.4 ºC (mean ± SD). Mean barometric pressure during these 
experiments was 698.5 mmHg. 
 
There was no difference (p = 0.116) between treatments for mean time to recumbence which 
was 2.48 ± 0.38 minutes for etorphine and 2.16 ± 0.37 minutes for thiafentanil (mean ± SD). 
Both treatments had seven animals with an induction score of 1 and one animal (not the same 
animal) with an induction score of 2. Recovery scores were 1 and were no different between 
treatments. Within three minutes after the IV injection of naltrexone all animals stood up and 
walked away. 
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Etorphine treatment induced a better (Z= -2.54, p = 0.012) quality of immobilisation 
compared to thiafentanil. The median immobilisation score of etorphine was 2.43 with an 
interquartile range (IQR) of 0.32 while the median immobilisation score of thiafentanil 
measured 2 (IQR = 0). Spontaneous movements such as chewing, tongue movements, ear 
and tail twitching and spontaneous limb movements were encountered in all animals during 
immobilisation and were more pronounced in the thiafentanil group.  
 
There was a significant effect of time on the majority of physiological variables for both 
treatments (Table 11). HR, ƒR, SAP, pH, PaCO2, PaO2 and the A-a gradient differed between 
the two treatments irrespective of time. SAP, DAP and MAP as well as the blood pH showed 
a treatment by time interaction (Table 11). 
 
Heart rate and ƒR were different between treatments (p = 0.013 and p = 0.034 respectively). 
The mean HR and ƒR was lower with etorphine treatment compared to thiafentanil (Figure 
20, Table 12). There was no change in heart rate over the monitoring period with either 
treatment, but, respiratory rate decreased significantly over time with etorphine (p = 0.021) 
(Figure 20, Table 12).  
 
There was no difference (p = 0.774) between mean rectal temperatures of the treatment 
groups. With both treatments, mean rectal temperature increased (p < 0.001) slightly over 
time with the lowest overall mean value being 39 ºC and the highest 39.2 ºC (Table 11, Table 
12). 
 
At all times after recumbence SAP was higher with the thiafentanil treatment compared to 
the etorphine treatment (p = 0.04; SED = 5.77) with the difference varying from 30 mmHg 
20 minutes after recumbence to 14 mmHg 40 minutes after recumbence. The mean arterial 
pressure and DAP did not differ between treatments (Figure 21).  
 
Mean PaCO2 was higher with etorphine immobilisation (p = 0.025, 45 mmHg) compared to 
the thiafentanil immobilisation (41 mmHg, SED = 1.5, Figure 22: ). Mean PaO2 was higher 
(p < 0.001) throughout the monitoring period with the thiafentanil treatment (64 mmHg) 
compared to the etorphine treatment (53 mmHg, SED = 2.4, Figure 22). The mean A-a 
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gradient was lower throughout the monitoring period (p = 0.003) when animals were treated 
with thiafentanil (29 mmHg), compared to treatment with etorphine (38 mmHg, SED = 2.3, 
Table 11, Figure 22).  
 
The mean pH value was lower (p = <0.001) with etorphine (7.43) compared to the thiafentanil 
(7.48) treatment. It increased (p = <0.001) over the monitoring period with both treatments 
(Table 1 and 2). There was no treatment effect on HCO3- or BE. The values of both variables 
decreased up to ten minutes and then increased over time thereafter (Table 11, Table 12). 
The anion gap was not influenced by treatment or time (Table 11, Table 12).  
 
Lactate concentrations did not differ between treatments but decreased over time (Table 11, 
Table 12). 
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Table 11: The significance (p-values) of treatment effects, effect of time and effect of 
treatment x time for blesbok treated with 0.09 mg kg-1 etorphine and thiafentanil respectively. 
Significant results (p < 0.05) are given in bold. 
Fixed term Treatment Time Treatment x time 
HR   0.013   0.067   0.797 
ƒR   0.034   0.021   0.074 
SAP   0.004 <0.001   0.002 
DAP   0.406 <0.001 <0.001 
MAP   0.156 <0.001 <0.001 
PaCO2   0.025 <0.001   0.195 
PaO2 <0.001   0.279   0.321 
A-a grad   0.003   0.278   0.066 
pH <0.001 <0.001   0.021 
HCO3-   0.466 <0.001   0.167 
BE   0.056 <0.001   0.198 
Agap   0.081   0.157   0.960 
Lac   0.150 <0.001   0.250 
Temp   0.774 <0.001   0.778 
Footnote: Physiological values evaluated were heart rate (HR), respiratory rate (fR), systolic arterial pressure 
(SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), arterial partial pressure of carbon 
dioxide (PaCO2), arterial partial pressure of oxygen (PaO2) and the alveolar-arterial oxygen gradient (A-a 
gradient) arterial blood pH (pH), arterial bicarbonate (HCO3-), arterial base excess (BE), anion gap (Agap), 
Lactate (Lac),rectal temperature (Temp). 
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Table 12: Mean physiological variables over time and standard errors of differences (SED) 
from blesbok immobilised with 0.09 mg kg-1 etorphine and 0.09 mg kg-1 thiafentanil 
respectively.  
   Time after recumbence of blesbok 
 
 
 Treatment 5min 10min 15min 20min 30min 40min 
        
HR Etorphine 42 37 36 36 36 37 
(beats minute-
1) 
Thiafentanil 45 41 42 42 43 43 
SED within treatment 2.0  SED within time 2.0 
        
ƒR  Etorphine 19 16 14 14 15 12 
(breaths 
minute-1) 
Thiafentanil 21 19 19 20 17 18 
SED within treatment 1.7  SED within time 2.7 
        
SAP Etorphine 156  153 145 144 145 150 
(mmHg) Thiafentanil 176 171 171 174 168 164 
SED within treatment 2.7  SED within time 6.3 
        
DAP Etorphine 116 108 106 103 104 108 
(mmHg) Thiafentanil 110 111 111 111 108 109 
SED within treatment 1.6  SED within time 3.4 
        
MAP Etorphine 137 132 126 123 123 126 
(mmHg) Thiafentanil 136 138 137 138 136 135 
SED within treatment 1.6  SED within time 6.2 
        
PaCO2 at 37 °C Etorphine 45 44 44 44 45  
(mmHg) Thiafentanil 43 39 40 41 41  
SED within treatment 0.9  SED within time 1.7 
        
PaO2 at 37 °C Etorphine 52 53 51 52 54  
(mmHg) Thiafentanil 61 68 66 64 64  
SED within treatment 2.6  SED within time 3.3 
        
A-a gradient at  Etorphine 39 39 41 37 37  
37 °C (mmHg) Thiafentanil 31 28 28 29 29  
SED within treatment 1.7  SED within time 2.8 
        
pH Etorphine 7.43 7.43 7.43 7.43 7.44  
 Thiafentanil 7.45 7.48 7.48 7.48 7.48  
SED within treatment 0.006  SED within time 0.007 
        
HCO3- Etorphine 31.7 31.5 31.8 32.1 32.6  
 123 
(mmol L-1) Thiafentanil 32.2 31.1 31.7 32.9 33.3  
SED within treatment 0.40  SED within time 0.51 
        
BE Etorphine 7.63 7.50 8.17 8.31 9.20  
(mmol L-1) Thiafentanil 8.36 8.00 8.56 9.69 10.57  
SED within treatment 0.376  SED within time 0.500 
     
Agap Etorphine 7.28 7.23 7.78 7.49 8.30  
(mmol L-1) Thiafentanil 8.01 8.11 8.28 7.86 8.72  
SED within treatment 0.551  SED within time 0.583 
        
Lactate Etorphine 1.2 0.9 0.9 0.8 0.8  
(mmol L-1) Thiafentanil 0.8 0.6 0.5 0.5 0.5  
SED within treatment 0.04  SED within time 0.21 
        
Temperature Etorphine 39.0 39.2 39.2 39.1 39.2 39.2 
(ºC) Thiafentanil 39.0 39.0 39.1 39.1 39.1 39.1 
SED within treatment 0.05  SED within time 0.23 
Footnote: Physiological values evaluated were heart rate (HR) in beats minute-1, respiratory rate (fR) in breaths 
minute-1, systolic arterial pressure (SAP) in mmHg, diastolic arterial pressure (DAP) in mmHg, mean arterial 
pressure (MAP) in mmHg, , arterial partial pressure of carbon dioxide (PaCO2) in mmHg, arterial pressure of 
oxygen (PaO2) in mmHg and the alveolar-arterial oxygen gradient (A-a gradient) in mmHg, arterial blood pH 
(pH), arterial bicarbonate (HCO3) in mmol L-1, arterial base excess (BE) in mmol L-1, anion gap (Agap) in 
mmol L-1, Lactate in mmol L-1, rectal temperature (°C). 
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Figure 20: Effect of treatment over time on the mean predicted values for respiratory ƒR 
(breaths minute-1) and heart rate HR (beats minute-1) of blesbok immobilised with etorphine 
or thiafentanil at 0.09 mg kg-1. Error bars presented as least significant difference (5 % LSD). 
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Figure 21: Mean systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and mean 
arterial pressure (MAP) over time of blesbok treated with etorphine or thiafentanil at 0.09 
mg kg-1. Error bars presented as least significant difference (5 % LSD). 
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Figure 22: PaO2, PaCO2 and A-a gradient (mmHg) over time in blesbok treated with 0.09 mg 
kg-1 etorphine or thiafentanil respectively. Error bars presented as least significant difference 
(5 % LSD). 
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6.4 Discussion 
This study demonstrates that blesbok can be safely immobilised with high dosages of both 
potent opioids without the addition of a sedative or tranquilliser. When antelope are 
immobilised, with potent opioids, a sedative or tranquiliser is usually added to the 
immobilisation mixture. Numerous reports exist that investigate the effects of opioids when 
mixed with sedatives and tranquillisers for use in wild ruminants. The addition of certain 
sedative and tranquillisers is said to act synergistically with opioids leading to faster 
induction times and fewer side effects, thus allowing for lower dosages of opioids to be used 
(Grootenhuis et al. 1976; Haigh 1990; Grobler et al. 2001; Citino et al. 2002; Cooper et al. 
2005; Meyer et al. 2008a). It is believed that opioids used on their own in high dosages 
increase blood pressure to unacceptable levels as has been reported in horses, zebras, 
rhinoceros and elephants (Harthoorn 1967; Hattingh et al. 1994 a and b; Buss et al. 2016). In 
African elephant (Loxodonta africana) darted with etorphine this high blood pressure was 
believed to be the cause of fatal lung oedema (Hattingh et al. 1994a). Blood pressure changes 
in medium sized antelope and small domestic ruminants as a result of etorphine treatment 
seem to be less dramatic than that seen in pachyderms and equids (Harthoorn 1967; Heard et 
al. 1990; Meyer et al. 2015; Izwan et al. 2018). According to Prothero (2015) the MAP of 
most healthy mammals (excluding giraffes) at rest measures 115 mmHg, irrespective of body 
size or species. Guided by this value, blesbok in this experiment, with MAPs of between 123 
and 138 mmHg can be assumed to be moderately hypertensive. The fact that hypertension 
was more severe with the thiafentanil treatment could be explained by the difference in 
receptor-affinity of the two opioids. Etorphine has non-specific affinity to mu, kappa as well 
as delta opioid receptors while thiafentanil is a selective mu-receptor agonist (Vardanya and 
Hruby 2014; Zeiler and Meyer 2017a). Opioid receptors can influence hemodynamic effects 
differently with presynaptic mu-receptors being predominantly involved in noradrenalin 
release modulation (Molina 2006). This new insight into the difference of the influence of 
thiafentanil and etorphine on blood pressure should be considered when selecting drugs for 
immobilising blesbok.  
 
Heart rate of blesbok at rest was reported by (Du Plessis 2018) as 104 beats minute-1. 
Consequently, animals in both treatment groups of the current study can be assumed to have 
been bradycardic throughout the monitoring period, despite the measured hypertension. 
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Bradycardia was also reported for goats with etorphine and carfentanil treatment (Heard et 
al. 1996).  
 
The ƒR of conscious blesbok lying down to rest, was reported to be 13 breaths per minute 
while standing blesbok had a respiratory rate of 20 breaths minute-1 (Du Plessis 2018). In this 
study, the respiratory rate was within this reported range. Although, opioid-induced 
bradypnoea, characterised by a reduced respiratory rate has been reported numerous times in 
many different species (Harthoorn 1967; Heard et al. 1996; Buss and Meltzer 2001; Pattinson 
2008; Izwan et al. 2018; Pfitzer et al. 2019b), bradypnoea did not occur in the etorphine- or 
thiafentanil-treated blesbok. A new insight provided by this study, is the difference in 
respiratory rates between treatments; respiratory rate was lower in etorphine- than 
thiafentanil-treated blesbok. Despite these differences, and even though these differences 
were also mirrored by differences in PaCO2, these animals were not suffering from 
hypoventilation as their PaCO2 values were within the upper expected normal range, which 
indicates adequate ventilation.  
 
The effects of the two drugs on respiration are best reflected in the blood gas values. These 
were arguably better when blesbok were immobilised with thiafentanil. Although the greater 
respiratory rate seen with the thiafentanil treatment, compared to etorphine, is mirrored by 
lower PaCO2 values and higher PaO2 values, the differing hypoxaemia resulting from these 
treatments was disproportionately large compared to the differences in the PaCO2 values. 
Thiafentanil treatment induced a moderate hypoxaemia (mean = 64 mmHg) compared to 
severe hypoxaemia (mean = 52 mmHg) induced by the etorphine, but the differences in mean 
PaCO2 were small (40.9 mmHg versus 44.7 mmHg, respectively). This disparity is also 
highlighted by the mean A-a gradients which were much lower throughout the monitoring 
period when animals were treated with thiafentanil (29 mmHg) compared to etorphine (38 
mmHg). Reference values for A-a gradients are not available for blesbok, but for similar 
sized animals, sheep and goats, it varies between 20 and 25 mmHg (Meyer et al. 2006; Izwan 
et al. 2018). Therefore, the A-a gradients for both treatments were most likely abnormally 
elevated. Elevated A-a gradients indicate reduced diffusion of oxygen across the alveoli 
membrane. The effects of etorphine on pulmonary pressure, and thus on gas exchange, have 
been documented and seem independent from its effects on systemic blood pressure (Heard 
et al. 1996; Izwan et al. 2018; Meyer et al. 2006, 2010, 2015). Therefore, the hypoxaemia 
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induced by both treatments was most likely caused by mechanisms, like opioid-induced 
pulmonary hypertension, that reduced gas exchange in the lungs.  
 
The arterial blood pH was within normal reference ranges of ruminants (Hagemoser and 
Lofstedt, 1981) and increased slightly during the monitoring period. The pH of the 
thiafentanil group was slightly higher than that of the etorphine group, possibly due to better 
ventilation.  
 
6.5 Conclusion 
Both potent opioids immobilised blesbok adequately and within an acceptable time frame, 
which is similar to when sedatives or tranquillisers are combined with these drugs. Both drugs 
caused hypertension, which could be classed as mild for etorphine and moderate for 
thiafentanil. The key difference between the two treatments was the better blood gas values 
when thiafentanil was used. Although thiafentanil in blesbok caused greater hypertension, it 
caused less severe hypoxaemia and respiratory compromise, therefore, is the safer drug to 
use for short immobilisation procedures. The use of oxygen supplementation is strongly 
advocated if etorphine is used for these procedures, or if either of the drugs are used for 
prolonged procedures.  
 
In the last two chapters of this thesis we could see how both antelope respond to the 
immobilisation with the two potent opioids. Some species differences also became apparent. 
It therefore stood to reason to carry out a thorough comparison of how immobilisation and 
physiological changes to opioid immobilisation between the two antelope species differed.  
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Chapter 7: Opioid immobilisation of antelope elicits species-
specific physiological responses 
 
This chapter is a modified version of the following manuscript: 
 
Pfitzer S, Meyer L, Laubscher L, Warren K, Vaughan-Higgins R, Raath JP, Laurence M. 
2019. Opioid immobilisation of antelope elicits species specific physiological responses, 
Journal of the South African Veterinary Association (in preparation). 
 
For this chapter, data generated during experiments described in chapter 5 and 6 were 
compared. Due to the modified statistical analysis, physiological variables in tables differ. 
 
7.1 Introduction 
When drugs are developed for the use in wild African ungulates, it is difficult to make broad 
recommendations with regards to dosage and side effects as there are many different species 
of wild African ungulates (Hernandez 2005). When investigating the physiological response 
to new drugs for wild ungulates, often domestic species have to be used as a first model 
(Harthoorn 1967, Heard 1990, Meyer et al. 2006, Meyer et al. 2015, O’Dell et al. 2017, 
Izwan et al. 2018, Pfitzer et al. 2019a). This is then usually followed by a selection of wildlife 
species that are used as representatives. The species most commonly used are impala as this 
species is kept in many zoo exhibitions, not classified as threatened and readily available in 
the wild as well as on intensive farming operations of southern Africa (Harthoorn 1967, 
Janssen et al. 1991 Meyer et al. 2008a, Perrin et al. 2015, Zeiler and Meyer 2017a and b, 
Pfitzer et al. 2019b). 
 
Impala are also considered a very challenging species to immobilise (Perrin et al. 2015, Zeiler 
and Meyer 2017a and b, Pfitzer et al. 2019b). Their flighty nature and fine body structure 
predispose to physical injury when darted, and their reaction to opioids seems unpredictable. 
Frequent deaths have been recorded due to their reaction to immobilisation drugs (Meyer et 
al. 2010, Perrin et al. 2015, Meyer and Zeiler a and b). Blesbok in contrast, seem to elicit a 
more predictable response to opioids and are considered a species that is fairly easy to 
immobilise (Pfitzer et al. 2019b). Similar to impala, they are also seasonal breeders, readily 
 131 
available in southern Africa and are not threatened in their conservation status (Furstenburg 
2016a). Blesbok also live in herds and can be hosted in groups as they are herd animals. As 
both sexes have horns, long term confinement can be a challenge (Pfitzer et al. 2019b), which 
may be the reason why blesbok are not as commonly kept in zoo exhibitions and thus also 
have not been used for ex situ wildlife research. Only recently have several research projects 
in South Africa been carried out with blesbok (Fitte 2017, Du Plessis 2018).  
 
Following ex-situ experiments under controlled and comparable conditions with blesbok, as 
well as with impala, the question arises, if either species should preferably be used as a model 
representing antelope species when carrying out investigations in anaesthesia or 
tranquillisation and how valid is the use of either species in order to extrapolate to other 
species? The aim of this experiment was to compare the physiological reaction of blesbok 
and impala to two potent opioids which are commonly used to immobilise wild antelope 
species. It was hypothesised that both drugs will have species-specific effects on the animals’ 
physiology. 
 
7.2 Materials and Methods 
The study was approved by the Murdoch University Animal Ethics committee (R3039/18) 
and the Wildlife Pharmaceuticals Animal Ethics Committee (WPAEC-2017-DPATBLES-
11-B). 
 
Eight wild captured female impala weighing 37 ± 4 kg (mean ± SD) and eight wild captured 
female blesbok weighing 58 ± 2 kg were selected for this experiment and held at the Wildlife 
Pharmaceuticals Wildlife Research Facility on Ngongoni Game Farm, South Africa 
(25°31’25.2” S, 31°06’50.8” E). This research was carried out according to a previously 
described protocol (Pfitzer et al. 2019b). Research animals were chosen to be of same sex, 
similar size and in good health in order to minimise variability that could influence the 
results. Horns of the blesbok were piped with plastic pipes to prevent horn injuries which are 
common in captive blesbok, especially at the beginning of confinement. 
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The enclosures consisted of several compartments that were approximately six by eight 
metres in size and were constructed from sturdy wooden poles. The animals were held 
separated per species and in groups of four animals. After an initial adjustment period of two 
weeks after delivery, the animals were immobilised, marked, weighed and subjected to a 
veterinary health examination.  
 
The immobilising drugs etorphine (Captivon, 9.8 mg mL-1, Wildlife Pharmaceuticals (Pty) 
Ltd, South Africa) and thiafentanil (Thianil, 10 mg mL-1, Wildlife Pharmaceuticals (Pty) Ltd, 
South Africa) were administered intramuscularly (IM) via remote injection by darting. Each 
animal was darted by means of a gas-powered dart projector (X-Caliber; Pneu-Dart. Inc., PA, 
USA). The darts used were 1 ml P-type Pneudarts with 1.9 cm barbed needles (Pneu-Dart. 
Inc., PA, USA). Animals were darted on two separate occasions with a wash-out period of 
two weeks between each occasion. Each antelope received both drug treatments which were 
allocated to animals at random in a two-way cross-over design. Treatment 1 consisted of 0.09 
mg kg-1 etorphine and treatment 2 consisted of 0.09 mg kg-1 thiafentanil. The immobilisation 
efficacy of these dosages was determined in a previous study (Pfitzer et al. 2019b). 
 
The experiments were conducted during the cooler months of April to August between 08:00 
to 12:00 and 14:00 to 17:00 respectively to avoid hot ambient temperatures of over 25°C at 
midday. Between four and six animals were processed per day. Monitoring of the animals 
was done outdoors in a shaded area. 
 
As soon as an animal became recumbent and could be approached, it was blind-folded and 
cotton wool inserted into the ears to minimise external stimuli. The animal was then placed 
onto a stretcher in sternal position with the head held up and nose pointing down to ensure 
patency of the upper airway. The animal was carried to the monitoring table and kept in this 
position throughout the monitoring period. 
 
Recording of physiological variables began at 5 minutes post recumbence and was continued 
every 5 minutes until 40 minutes post recumbence. Rectal body temperature was measured 
by means of a modified hand-held digital thermometer (Hanna Checktemp 1, Hanna 
Instruments (Pty) Ltd., NE, USA). Barometric pressure was measured by the EPOC portable 
blood gas analyser (EPOC Blood Analysis System; Epocal, ON, Canada) and the 
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environmental temperature was measured by the Weather+ Bluetooth Sensor (Oregon 
Scientific, OR, USA). Respiratory rate was measured manually by means of visual 
observation of chest expansions and auscultation with a stethoscope for one minute (Littman 
Classic II, 3MTM, MN, USA). The auricular (Arteria auricularis) or pedal arteries (A. 
digitalis) were catheterised using a 21 Gauge catheter (Jelco IV catheter radiopaque; Smith 
Medical International, UK) to measure intra-arterial blood pressure using the Deltran II 
pressure transducer (Utah Medical, UT, USA) connected to an IntraTorr blood pressure 
monitor (IntraTorr, IntraVitals, UK). The transducer was placed near the scapulohumeral 
joint (heart base) of the animal. This device also measured pulse rate. Arterial blood for blood 
gas analysis was drawn anaerobically in a heparinised blood gas syringe (BD A-Line; Becton 
Dickinson & Co, UK) at times 5, 10, 15, 20 and 30 minutes after recumbence. Within 5 
minutes post sampling, arterial blood was analysed using the EPOC portable blood gas 
analyser with EPOC BGEM test cards (BGEM smart cards; Epocal, ON, Canada), to 
determine blood gases and acid-base status. The alveolar-arterial oxygen (A-a) gradient was 
calculated as described by Meyer et al. (2010). 
 
The immobilisation of all animals was reversed with intravenous (IV) naltrexone (Trexonil, 
50 mg mL-1, Wildlife Pharmaceuticals (Pty) Ltd, South Africa) injected at a ratio of 20 mg 
naltrexone to 1 mg etorphine and 10 mg naltrexone per 1 mg thiafentanil as soon as the 40-
minute monitoring period was over (O’Dell et al. 2017). Time to recumbence 
(immobilisation induction) was monitored with a stopwatch and was defined as time from 
dart injection to when the animal was recumbent and was unable to rise on approach. 
 
The immobilisation score was taken repeatedly at each sampling interval. The immobilisation 
score referred to motor responses during the monitoring period from 1 to 5. A score of 1 = 
an animal that was conscious and mobile and needed to be re-dosed for safe handling and 5 
= an animal that was anaesthetised too deeply and showed severe cardiorespiratory 
depression and no reflexes (Pfitzer et al. 2019b). Each animal was subjected to a subjective 
recovery score (referring to speed and smoothness of recovery after the IV administration of 
naltrexone from 1 to 5 with 1 = an animal that got up within three minutes and had a smooth 
recovery and 5 = an animal that did not recover at all) (Pfitzer et al. 2019b).  
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7.2.1 Data analysis 
Analyses were performed with Genstat Version 17 (VSN International, UK) to determine 
whether there was a species-specific difference between the two opioids on the physiological 
variables of interest. A linear mixed model was fitted to the monitored physiological 
variables and immobilisation score. The fixed model included the species-specific effects, 
treatment effects, species-specific by treatment interactions, the effects of time after 
recumbence and interactions between time after recumbence and species and treatment. The 
random model included terms for animal, animal by treatment and animal by treatment by 
minutes after recumbence. The residual variance or covariance model included correlations 
between measurements made on the same animal for a specific treatment and different 
variances for each animal. Non-significant random effects and co-variances were removed 
from the model before the significance of fixed effects was assessed. A p-value of less than 
0.05 was considered significant. This data were reported as means with standard error of 
difference (SED) so that the reader can assess whether differences between means are 
statistically significant. The SEDs can be used to calculate a t-value and the least significant 
difference (LSD). The least significant difference was used to illustrate the difference of two 
means between the species in figures. Any difference larger than the 5% LSD is considered 
a significant result.  
 
Rectal temperature (RT) in °C, heart rate (HR) in beats per minute (beats minute -1), 
respiratory rate (ƒR) in breaths minute-1, systolic arterial pressure (SAP) in mmHg, diastolic 
arterial pressure (DAP) in mmHg, mean arterial pressure (MAP) in mmHg, arterial blood 
pH, bicarbonate (HCO3-) in mmol L-1, base excess (BE) in mmol L-1, Anion gap (Agap) in 
mmol L-1, lactate (Lac) in mmol L-1, arterial partial pressure of carbon dioxide (PaCO2) in 
mmHg at 37 °C, arterial partial pressure of oxygen (PaO2) in mmHg at 37°C, and alveolar-
arterial oxygen gradient (A-a gradient) in mmHg at 37°C, were statistically evaluated. 
 
Time to recumbence was analysed using a linear mixed model which included species-
specific effects, treatment effects and their interaction in the fixed model and animal by 
treatment effects in the random model. The residual variance model included different 
variances for each species. 
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7.3 Results 
Ambient temperatures during the blesbok experiments with etorphine were 24.9 ± 3.5 ºC and 
during thiafentanil treatment they were 24.3 ± 2.4 ºC. The mean barometric pressure was 698 
mmHg. For impala, ambient temperatures measured during the etorphine treatment were 20.7 
± 4.3 ºC and during thiafentanil treatment, 21.9 ± 6.7 ºC. The mean barometric pressure was 
697 mmHg. There was a significant species by treatment by time interaction (p < 0.001) for 
rectal body temperature. 
 
There was a significant species by treatment interaction for time to recumbence (p = 0.009). 
In blesbok, there were no significant differences between treatments for mean time to 
recumbence. The mean time to recumbence in blesbok immobilised with etorphine was 2.49 
(SE = 0.135) minutes and with thiafentanil 2.17 (SE = 0.135) minutes. This is in contrast to 
impala, where the mean time to recumbence was significantly faster with the thiafentanil 
treatment 1.96 (SE = 0.167) minutes compared to etorphine treatment 3.89 (SE = 0.194) 
minutes (Table 14, Figure 23).  
 
There was no species difference for immobilisation scores and recovery scores. 
Immobilisation scores. Overall Immobilisation scores varied from 2.03 to 2.77 and recovery 
scores were 1 for all animals. 
 
There was a significant interaction of species, treatment and time (p = 0.007) for HR. 
Blesbok, when treated with either opioid, developed a much lower heart rate (etorphine mean 
= 37; thiafentanil mean = 43 beats minute-1; SE = 1.4) compared to impala (etorphine mean 
= 98; thiafentanil mean = 109 beats minute-1; SE = 4.0) (Table 14). The HR of impala when 
treated with etorphine, started at 133 beats minute-1 at 5 minutes but dropped within 30 
minutes to 82 beats minute-1 (SE = 4.5) This large change over time was not present in 
blesbok the mean heart rate of which only differed between 44 and 35 beats minute-1 over 
time (SE = 2.5; Figure 24, Table 13). 
 
There was a significant species by treatment interaction (p = 0.036) as well as a species by 
time interaction (p < 0.001) for ƒR. Blesbok immobilised with thiafentanil had a higher ƒR 
(mean = 19 breaths minute-1; SE = 0.5) than blesbok immobilised with etorphine (mean = 15 
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breaths minute-1; SE = 0.5). Respiratory rate of blesbok immobilised with thiafentanil was 
also higher than ƒR of impala immobilised with thiafentanil (mean = 14 breaths minute-1; SE 
= 0.6) or etorphine (mean = 13 breaths minute-1; SE = 0.6). Blesbok immobilised with 
etorphine had a higher ƒR on average than impala immobilised with etorphine until 
approximately 15 minutes (Figure 25, Table 13). It was noted that 25 % of impala suffered 
from intial induction apnoea when immobilised with thiafentanil. 
 
There was a significant species by treatment by time interaction for MAP (p = 0.007).  
MAP was elevated in both species with either drug throughout the monitoring period. 
However, hypertension in both species was more severe when thiafentanil was used. In both 
species MAP decreased with the etorphine treatment in the first 15 minutes but then increased 
again. MAP with the thiafentanil treatment in impala decreased in the first 15 minutes while 
it stayed more consistent in blesbok (Figure 26, Table 13). 
 
There was a species by treatment by time interaction for PaCO2 (p = 0.027). For the mean 
PaCO2 a significant species difference could be observed in that PaCO2 values were higher 
in impala compared to blesbok with either treatment. PaCO2 values of impala treated with 
thiafentanil significantly decreased during the monitoring period from 60 to 48 mmHg. Mean 
PaCO2 values for blesbok were 44 and 41 mmHg for etorphine and thiafentanil respectively 
(SE = 0.5) while in impala mean PaCO2 values measured 51 mmHg with etorphine and 52 
mmHg with thiafentanil (SE = 1.3) (Figure 27, Table 13, Table 14). 
 
There was a significant species by treatment interaction for PaO2 (p = 0.006). While PaO2 
values differed significantly between species with thiafentanil immobilisation with means of 
64 mmHg (SE = 1.5) for blesbok and 53 mmHg for impala (SE = 1.7), this was not the case 
with etorphine. The mean PaO2 of both species with etorphine treatment was 53 mmHg. 
Thiafentanil treatment of impala elicited in the beginning an extremely low PaO2 of 38 
mmHg, which then improved within the first 10 minutes and reached 59 mmHg after 30 
minutes (SE = 2.3) (Figure 28, Table 13, Table 14).  
 
There was a species by treatment interaction (p = 0.009) for the A-a gradient. In blesbok, the 
A-a gradient was significantly lower when animals were treated with thiafentanil (mean = 28 
mmHg; SE = 1.0) compared to etorphine (mean = 37 mmHg; SE = 1.0). This difference 
between the two opioids could not be observed in impala (Figure 29, Table 13, Table 14). 
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There was significant species by treatment interaction for pH (p < 0.001). With either opioid 
treatment, blesbok had higher arterial pH values compared to impala. While the pH of 
blesbok with either treatment varied between 7.42 and 7.49 (SE = 0.005), impala especially 
at the beginning of each treatment suffered from acidaemia with pH values as low as 7.27. 
However, the pH of impala improved over the monitoring period with both treatments and 
reached the physiologically normal range of 7.39 with etorphine and 7.38 with thiafentanil 
treatment respectively (SE = 0.007). There was significant species by treatment interaction 
for pH (p < 0.001) as well as a significant species by time interaction (p < 0.001) (Figure 30, 
Table 13). 
 
There was a significant species by time interaction (p = 0.002) for lactate. Impala developed 
higher lactate values than blesbok, irrespective of the treatment. Mean lactate values of 
impala measured 3.30 mmol L-1 (etorphine) and 3.52 mmol L-1 (thiafentanil) respectively 
(SE = 0.26). In blesbok, mean lactate values measured 0.99 mmol L-1 (etorphine) and 0.84 
mmol L-1 (thiafentanil) (SE = 0.22). In both species, lactate values decreased over time but 
much more so in impala (Figure 31, Table 13, Table 14). 
 
There was a significant species difference for glucose (p < 0.001) in that with either opioid 
treatment, impala developed higher glucose values than blesbok. Mean glucose values in 
impala measured 7.20 mmol L-1 with etorphine and 8.69 mmol L-1 with thiafentanil 
respectively (SE = 0.31). Glucose decreased over time in impala with both treatments, but 
glucose values did not decrease in blesbok (Figure 32, Table 13, Table 14). 
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Figure 23: Time to recumbence (minutes) with error bars of blesbok and impala immobilised 
with 0.09 mg kg-1 etorphine (E) or thiafentanil (T). 
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Figure 24: Heart rate (HR) in beats minute-1 over time (minutes) of blesbok and impala 
immobilised with 0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD 
bar marks significant differences between the species. 
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Figure 25: Respiratory rate (ƒR) in breaths minute-1 over time (minutes) of blesbok and impala 
immobilised with 0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD 
bar marks significant differences between the species. 
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Figure 26: Mean arterial pressure (MAP) in mmHg over time (minutes) of blesbok and 
impala immobilised with 0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 
% LSD bar marks significant differences between the species. 
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Figure 27: PaCO2 in mmHg over time (minutes) of blesbok and impala immobilised with 
0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD bar marks 
significant differences between the species. 
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Figure 28: PaO2 in mmHg over time (minutes) of blesbok and impala immobilised with 0.09 
mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD bar marks significant 
differences between the species. 
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Figure 29: A-a- gradient in mmHg over time (minutes) of blesbok and impala immobilised 
with 0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD bar marks 
significant differences between the species. 
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Figure 30: pH over time (minutes) of blesbok and impala immobilised with 0.09 mg kg-1 
etorphine (E) or thiafentanil (T) respectively. The 5 % LSD bar marks significant differences 
between the species. 
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Figure 31: Lactate (mmol L-1) over time (minutes) of blesbok and impala immobilised with 
0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD bar marks 
significant differences between the species. 
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Figure 32: Glucose (mmol L-1) over time (minutes) of blesbok and impala immobilised with 
0.09 mg kg-1 etorphine (E) or thiafentanil (T) respectively. The 5 % LSD bar marks 
significant differences between the species. 
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Table 13: Species comparison of mean physiological variables over time and significant error 
of difference (SED) for immobilisation with etorphine 0.09 mg kg-1 of blesbok and impala 
respectively and for immobilisation with thiafentani 0.09 mg kg-1 of blesbok and impala 
respectively. Physiological values evaluated were heart rate (HR) in beats minute-1, 
respiratory rate (ƒR) in breaths minute-1, systolic arterial pressure (SAP) in millimetres 
mercury (mmHg), diastolic arterial pressure (DAP) in mmHg, mean arterial pressure (MAP) 
in mmHg, arterial partial pressure of carbon dioxide (PaCO2) in mmHg, arterial pressure of 
oxygen (PaO2) in mmHg, alveolar-arterial oxygen gradient (A-a gradient) in mmHg, arterial 
blood pH (pH), arterial bicarbonate (HCO3-) in mmol L-1, arterial base excess (BE) in mmol 
L-1, anion gap (Agap) in mmol L-1, lactate in mmol L-1, glucose in mmol L-1, rectal 
temperature (RT) in °C and immobilisation scores. 
Variable Species Time after recumbence with etorphine in minutes 
 
  5 10 15 20 30 40 
        
HR Blesbok 44 35 35 36 35 40 
 Impala 133 112 100 93 82 84 
SED within time 6.2  
        
ƒR  Blesbok 19 16 15 14 15 12 
 Impala 11 13 12 13 14 11 
SED within time 1.9    
        
SAP Blesbok 157 152 144 146 148 149 
 Impala 147 135 133 135 143 150 
SED within time 5.6 
        
DAP Blesbok 116 106 104 104 106 107 
 Impala 105 99 97 101 108 113 
SED within time 4.7 
        
MAP Blesbok 137 129 125 127 126 127 
 Impala 120 112 109 116 121 129 
SED within time 5.1 
        
PaCO2  Blesbok 46 44 44 44 44  
 Impala 52 50 51 50 50  
SED within time 1.6 
        
PaO2  Blesbok 52 53 51 52 54  
 Impala 49 52 51 55 58  
SED within time 3.8 
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A-a gradient Blesbok 36 38 41 35 36  
 Impala 39 36 35 33 29  
SED within time 2.2 
        
pH Blesbok 7.42 7.43 7.43 7.44 7.44  
 Impala 7.30 7.32 7.34 7.36 7.39  
SED within time 0.010 
        
Lactate Blesbok 1.4 1.1 1.0 0.9 0.7  
 Impala 5.2 4.2 3.2 2.5 1.5  
SED within time 0.47 
        
Glucose Blesbok 5.3 5.2 5.1 5.0 5.1  
 Impala 7.7 7.6 7.3 7.0 6.4  
SED within time         0.34       
        
RT Blesbok 39.0 39.2 39.2 39.1 39.1 39.2 
 Impala 38.9 39.1 39.0 39.1 38.8 38.7 
SED within time 0.16 
        
Immobilisation Blesbok 2.25 2.56 2.55 2.77 2.51 2.35 
 Impala 2.5 2.5 2.45 2.73 2.61 2.61 
SED within time 0.116 
        
Variable Species Time after recumbence with thiafentanil in minutes 
 
 Species 5 10 15 20 30 40 
        
HR Blesbok 43 41 42 42 44 44 
 Impala 115 111 106 110 109 108 
SED within time 6.1 
        
ƒR  Blesbok 20 18 19 19 17 17 
 Impala 9 11 13 15 15 16 
SED within time 1.8 
        
SAP Blesbok 174 173 173 176 168 165 
 Impala 174 161 160 158 157 164 
SED within time 5.6 
        
DAP Blesbok 108 111 112 112 108 109 
 Impala 134 125 122 128 124 125 
SED within time 4.7 
        
MAP Blesbok 136 137 137 139 136 135 
 Impala 150 141 133 144 140 140 
SED within treatment 4.9 
 150 
        
PaCO2  Blesbok 44 39 40 40 40  
 Impala 61 54 51 49 48  
SED within time 1.6 
        
PaO2  Blesbok 61 68 66 64 64  
 Impala 38 51 58 58 59  
SED within time 3.8 
        
A-a gradient Blesbok 29 27 28 29 30  
 Impala 40 33 29 32 32  
SED within time 2.2 
        
pH Blesbok 7.44 7.47 7.47 7.48 7.49  
 Impala 7.27 7.31 7.33 7.35 7.40  
SED within time 0.010 
        
Lactate Blesbok 1.2 0.9 0.8 0.7 0.5  
 Impala 5.3 4.4 3.5 2.7 1.7  
SED within time 0.47 
        
Glucose Blesbok 4.5 4.3 4.2 4.2 4.5  
 Impala 8.8 9.0 8.8 8.6 8.1  
SED within time        0.34       
        
RT Blesbok 38.9 39.1 39.1 39.1 39.1 39.0 
 Impala 38.8 38.9 39.0 39.0 39.2 39.2 
SED within time 0.16 
        
Immobilisation Blesbok 2.07 2.03 2.09 2.11 2.06 2.05 
 Impala 2.37 2.29 2.48 2.52 2.38 2.38 
SED within time      0.116 
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Table 14: Summary of physiological variables (means) and overall effect of time on the 
variables in blesbok and impala immobilised with 0.09 mg kg-1 etorphine and thiafentanil 
respectively. 
Variable (mean) Blesbok Impala 
 Etorphine Thiafentanil Etorphine Thiafentanil 
Time to recumbence  2.5 2.2 3.4 2.0 
Immobilisation score 2.5 2.1 2.6 2.4 
Recovery score 1 1 1 1 
HR (beats minute-1) 37 43 98 109 
HR effect none none decreasing decreasing 
ƒR (breaths minute-1) 15 19 13 14 
ƒR effect decreasing decreasing none Increasing 
MAP (mmHg) 128 136 119 140 
MAP effect decreasing none increasing decreasing 
PaCO2 (mmHg) 44 41 51 52 
PaCO2 effect none decreasing decreasing decreasing 
PaO2 (mmHg) 53 64 53 53 
PaO2 effect none none increasing increasing 
A-a gradient (mmHg) 37 28 35 33 
A-a gradient effect none none decreasing decreasing 
pH 7.43 7.47 7.34 7.33 
pH effect increasing increasing increasing increasing 
Lactate (mmol L-1) 0.99 0.84 3.30 3.52 
Lactate effect decreasing decreasing decreasing decreasing 
Glucose (mmol L-1) 5.1 4.3 7.2 8.7 
Glucose effect none none decreasing decreasing 
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7.4 Discussion 
Both species of antelope were successfully immobilised with high dosages of opioids without 
the addition of tranquillisers or sedatives.  
 
Although there were differences in ambient temperatures and a significant species by 
treatment by time interaction (p < 0.001) for rectal body temperature, these differences were 
not physiologically relevant; the rectal temperature differences at no point exceeded 0.5 °C 
(Table 1). The fact that the difference in environmental temperatures was not reflected in the 
body temperatures was not surprising as Meyer et al. (2008) reported that changes in body 
temperature of impala immobilised with various drug combinations was influenced 
predominantly by stress. It is reassuring for veterinarians working in field conditions to know 
that reasonably prolonged immobilisation (up to 0 minutes) does not result in hypothermia 
or hyperthermia in either species as long as the environmental temperatures are moderate. 
 
Time to recumbence is an important factor under field conditions. Faster time to recumbence 
reduces exposure to stressors and facilitates faster recovery of the animal. A fast time to 
recumbence also lessens the risk of animals disappearing or being attacked by herd members 
or predators while the drugs are taking effect. Therefore, the significantly faster time to 
recumbence measured in impala when immobilised with thiafentanil in this experiment is of 
great clinical relevance. It is an important factor to be considered and weighed up against 
adverse cardiopulmonary effects of this drug when a clinician has a choice of drugs they may 
use in the field. 
 
A further important difference from a clinical perspective between the two species was the 
HR. Heart rate of blesbok at rest was reported by Du Plessis (2018) as 104 beats minute-1. 
Blesbok in both treatment groups of the current study can be assumed to have been 
bradycardic throughout the monitoring period. Resting HR in impala are not known. 
However, in sheep and goats, which are similar in size to impala, resting HR is 70-110 beats 
minute-1 (Meyer et al. 2015; Sjaastad et al. 2016 , Izwan et al. 2018). Impala during the first 
10 minutes were tachycardic and showed a lot of variation of the HR between individuals as 
well as over time (Table 13). Species differences in domestic and wild ungulates with regards 
to the effects of opioids on the HR have been reported previously (Harthoorn 1967; Izwan et 
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al. 2018). In a comparative experiment between sheep and goats, sheep developed a 
significantly elevated HR with etorphine treatment, while the same treatment did not affect 
the HR of goats. At the same time, the stroke volume in sheep decreased and thus, the 
elevated HR did not result in changes with regards to cardiac output (Izwan et al. 2018).  
 
Both species developed hypertension with either opioid. Hypertension was more severe when 
thiafentanil was used with mean MAP values of 136 and 140 mmHg for blesbok and impala 
respectively. MAP of most healthy ruminants should measure around 115 mmHg, 
irrespective of body size (Prothero 2015). High blood pressure (> 180 mmHg) as a 
consequence of opioid immobilisation of pachyderms has been reported and resulted in fatal 
lung oedema in elephants (Hattingh et al. 1994a; Hattingh et al. 1994b). In a field setting HR 
and blood pressure are important variables as their changes could have serious consequences 
for the welfare of the animal. Thus, they may influence which sedatives or tranquillisers 
should be combined with an opioid for immobilisation. For example, it is common practice 
amongst wildlife veterinarians to combine etorphine with the butyrophenone derivative 
azaperone as it is a tranquilliser but also causes vasodilation and has anti-hypertensive effects 
(Kock and Burroughs 2012). The wisdom of using this drug combination in the presence of 
an opioid-induced bradycardia as found in blesbok needs to be questioned, because in the 
absence of an elevated cardiac output, peripheral vasodilation and bradycardia could 
potentially result in dangerously low blood pressure. Unfortunately, cardiac output was not 
measured in this experiment and therefore further investigations into the use of azaperone in 
combination with opioids in blesbok would be in order. The results of the current experiment 
provide the first evidence of the comparative difference in these two variables in different 
species immobilised with the same drugs, and further highlights the need to choose drugs 
according to species, rather than an assumed generalised effect. Furthermore, this study 
highlights that these drugs have profound cardiovascular effects that need to be studied in 
more detail to properly understand their effects and reveal their risks.  
 
The respiratory rate of blesbok lying down to rest, was reported to be 13 breaths minute-1 
while standing blesbok had a respiratory rate of 20 breaths minute-1 (Du Plessis 2018). The 
normal ƒR of impala at rest has been reported as 20 + 8 breaths minute-1 (Cheney and Hattingh 
1987). Interestingly, in this experiment blesbok treated with thiafentanil did not seem 
affected by opioid-induced respiratory depression, characterised by a reduced respiratory 
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rate. This finding is in contrast to impala which, especially at the start of the monitoring 
period, displayed a low respiratory rate with both opioid treatments. As a consequence, 
impala also suffered from hypercapnia and hypoxia (PaCO2 means = 51 and 52 mmHg; PaO2 
means = 53 mmHg) (Table 14)  
 
PaCO2 values of blesbok (means = 45 mmHg (etorphine) and 41 mmHg (thiafentanil) 
respectively) were within the upper normal physiological range reported in awake small 
ruminants (Ismail et al. 2010), indicating adequate ventilation during immobilisation. 
Despite adequate ventilation, blesbok suffered from hypoxaemia, which was greater during 
the etorphine treatment (Figure 28). 
 
Possible reasons for this hypoxaemia can be explained by an elevated A-a gradient. In the 
literature, resting A-a gradients for small ruminants were between 20 and 25 mmHg (Meyer 
et al. 2006; Izwan et al. 2018). Thus, the mean A-a gradients of the blesbok, as well as the 
impala, treated with etorphine should be considered elevated as they measured 37 and 35 
mmHg respectively (Table 14). This finding indicates that etorphine caused an elevated A-a 
gradient in both species, while thiafentanil caused a greater elevation in impala (mean = 33 
mmHg) compared to blesbok (mean = 28 mmHg), where it was mild. A ventilation-perfusion 
(V/Q) mismatch or right-left shunting of lung portions might have been the cause for 
inadequate oxygen diffusion indicated by the elevated A-a gradients (Meyer et al. 2015; 
Fahlman et al. 2016). Opioid-induced pulmonary vasoconstriction, resulting in pulmonary 
hypertension, might have also led to inadequate oxygen diffusion from pulmonary congestion 
and, or, oedema, or could have caused a faster blood flow which might have hindered gas 
exchange as capillary blood might have passed the alveoli too fast to enable effective oxygen 
diffusion (Hattingh 1994a; Meyer et al. 2015). 
 
Clearly, if respiratory rate was the only assessment of respiration, hypoxia in blesbok under 
etorphine immobilisation would have been overlooked. Blood gases, although expensive and 
not always practical to use, should not be underestimated as an important monitoring tool.  
 
In light of the magnitude of hypoxia and hypercapnia of the two antelope species it is not 
surprising that the pH was at all times higher in blesbok than in impala. Normal blood pH 
values of 7.3 to 7.5 were reported in healthy goats by Stevens et al. (1994). The pH values in 
 155 
both antelope species remained mostly within this reference range. The thiafentanil treated 
impala started with the lowest mean pH of 7.27 but improved quickly over time (Table 13). 
The initial pH values of impala were possibly not just influenced by respiratory acidosis but 
also by a subclinical metabolic acidosis associated with elevated lactate levels of 5.2 and 5.3 
mmol L-1 measured at the beginning of the monitoring period. Initially elevated lactate in the 
impala could possibly be associated with the initial stress response of these animals to the 
capture. This assumption is supported by elevated glucose and an initial tachycardia 
(Hattingh 1988), all of which improved over the 40-minute monitoring period. Impala seem 
to be more fractious in nature compared to blesbok and this stress response, coupled with a 
greater sensitivity to opioid-induced respiratory compromise, may explain why impala are at 
more risk and considered to be one of the more challenging species to immobilise. Not only 
are they a small and fragile target to dart but the severe respiratory disturbances, coupled 
with stress related physiological derangements, could be fatal if not immediately attended.  
 
In summary, both species developed different physiological derangements as a result of the 
opioid immobilisation. While in impala, these changes were more immediate, due to severe 
respiratory depression, inadequate pulmonary oxygen diffusion and a capture related stress 
response; in blesbok they were not quite as obvious. Opioid-induced bradycardia and 
disturbance of pulmonary oxygen diffusion leading to hypoxia are a concern in blesbok 
immobilised with etorphine. Therefore, hypoxia as well as blood pressure should be closely 
monitored and treated in the event of prolonged opioid immobilisation in both species. 
 
Impala, due to their availability, and presence in many zoos, have been mostly studied to 
understand the effects of immobilising drugs (Cheney and Hattingh 1987; Janssen et al. 1993; 
Bush et al. 2004; Meyer et al. 2008; Meyer et al. 2010; Perrin et al. 2015; Zeiler and Meyer 
2017a and 2017b). However, the response to immobilising drugs is probably not uniform 
across antelope species. Therefore, detailed monitoring and data analysis from various 
different antelope species immobilised during routine management procedures should be 
undertaken in the future in order to make more meaningful, species-tailored, 
recommendations on drugs used for immobilisation.  
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7.5 Conclusions 
This experiment confirms the initial hypothesis that significant species-specific physiological 
responses to opioid immobilisation exist in blesbok and impala. Some of these differences 
seem to be coupled to a species-specific stress response. Extrapolation of the results from 
one species to other ungulates is not recommended given the significant differences in the 
way these two species responded to the opioids. This research provides veterinarians, 
working in field conditions, with scientific evidence of how each species responds to 
etorphine and thiafentanil, and how these responses may affect the animals’ health and which 
drugs are better suited to particular conditions. 
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Chapter 8: General discussion and conclusion 
 
Wildlife immobilisation is commonly achieved with the use of potent opioids, namely 
etorphine and thiafentanil (Kock and Burroughs 2012). Both these drugs can have severe side 
effects, especially with regards to respiratory depression. According to publications on 
previous experiments with serotonin agonists, the serotonin 5-HT1A agonist R-8-OH-DPAT 
was evaluated as a drug which, if added to potent opioids for immobilisation, could 
potentially mitigate opioid-induced respiratory depression and hypoxia (Richter et al. 2003; 
Meyer et al. 2006, 2010).  
 
The focus of the first two investigations was to determine intramuscular bioavailability of R-
8-OH-DPAT and investigate the possibility of using this drug in conjunction with potent 
opioids to mitigate opioid-induced respiratory depression. Results of an IM bioavailability 
experiment in goats was promising. The mean bioavailability of R-8-OH-DPAT after IM 
injection in goats was 66 %. However, at a dosage of 0.1 mg kg-1, goats that were treated IV 
developed signs of serotonin toxicity. Goats were used as the model species for antelope and 
therefore, dosages chosen for the wildlife experiment, were chosen to be lower than 0.1 mg 
kg-1 to be safe. Two abundant antelope species, impala and blesbok, were chosen for the next 
experiment. Two species were chosen, in order to elucidate potential species-specific effects 
of R-8-OH-DPAT. Various dosages of R-8-OH-DPAT (0, 0.005, 0.02 and 0.07 mg kg -1) 
were combined with 0.09 mg kg-1 etorphine for immobilisation in both species. Six animals 
of each species were utilised for this four-way cross-over experiment. 
 
For wildlife research, the use of large numbers of animals in experiments is not usually 
feasible. The keeping of large numbers of antelopes is a logistical challenge and similar 
experiments in the past conducted by other researchers have used 6 to 10 animals (Huber et 
al. 2001; Howard et al. 2004; Sawicka et al. 2015). It is generally accepted that this number 
of animals yields significant findings in this type of research into the physiological impact of 
certain drugs. 
 
The addition of R-8-OH-DPAT did not influence induction, immobilisation or recovery 
scores in either of the species. It did also not significantly affect respiratory parameters or 
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blood gases in either species. The increased respiratory rate in blesbok had to be put down to 
a type II error associated with the small sample size. Initially improved PaO2 values were 
measured when impala were treated with the higher dosages of R-8-OH-DPAT. Although 
clinically significant, these were not statistically significant. Impala when treated with the 
two higher dosages of R-8-OH-DPAT did show significantly less opioid-induced 
tachycardia. Beneficial effects of R-8-OH-DPAT, if any, might therefore lie in the potential 
anxiolytic effects of the serotonin agonist rather than in its effects on respiration and blood 
gases, at least at the dosages that were investigated.  
 
Failure to reproduce the promising results reported when 8-OH-DPAT was used in goats 
(Meyer et al. 2006) could be due to species-specific effects of this serotonin agonist. It could 
also be due to the fact that in previous experiments the racemic mixture of the drug was used, 
while in this wildlife experiment, the R-enantiomer was used as this was considered to be 
good practice (Hadrava et al.1996; Yu et al. 1996a). Different effects of the racemic 8-OH-
DPAT and its R-enantiomer on respiratory and cardiovascular physiology warrant further 
investigation in the future. 
 
Although the aim of this first experiment was not to compare opioid immobilisation between 
the two antelope species, different physiological changes between the control groups of both 
species when immobilised with etorphine were apparent. Therefore, it made sense to further 
explore species-specific differences of antelope when immobilised with opioids. The two 
most commonly used opioids for immobilisation of African wildlife, etorphine and 
thiafentanil, were therefore explored for their different physiological effects. Although, both 
opioids are used interchangeably by most wildlife veterinarians, few reports exist with 
regards to different physiological effects between both opioids in African wildlife species 
(Meyer et al. 2008; Raath 2009; Kock and Burroughs 2012; Zeiler and Meyer 2017a). By 
choosing the right opioid for a specific species, respiratory depression might already be 
mitigated. This led to the experiments described in the three following chapters. 
 
The next two experiments on impala and blesbok were designed to compare the two opioids 
and to eventually allow for comparison of species-specific effects of the opioids. In both 
experiments a similar drug dosage (0.09 mg kg-1) for both drugs were used in the two species 
and the same methods were used.  
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The dosage of 0.09 mg kg-1 for both drugs, used in both species, was chosen as it achieved a 
reasonable time to recumbence (5 minutes) and safe immobilisation for 40 minutes without 
the addition of more drugs. It could be argued that instead of using the dosage based on the 
drug substance mass (mg kg -1), drug dosage should have been chosen and reported based on 
molecular mass of the active part of the drug as this would have been more accurate (mol kg-
1). Effectively, the dosage of etorphine was 12.9 % higher, if molar mass is taken into 
account. However, results of these experiments were aimed to serve wildlife practitioners, 
most of which usually work on drug substance mass. Most wildlife immobilisation protocols 
are still reported in this way in veterinary journals (Janssen et al. 1993; Cooper et al. 2005; 
Meyer et al. 2015; Meyer and Zeiler 2017a). 
 
The comparative drug experiments (etorphine versus thiafentanil) carried out separately with 
impala and blesbok showed clearly that both opioids illicit drug, as well as species-specific 
responses. Both species could be successfully immobilised with either opioid at a dosage of 
0.09 mg kg-1 without the addition of a sedative or tranquilliser. A dosage of 0.09 mg kg-1 is 
considered a high dosage (Kock and Burroughs 2012) and therefore the results also clearly 
give an indication for the wide safety margin of these opioids when they are not used in 
combination with other drugs. Despite the wide safety margin, hypoxaemia of various 
degrees was present in most cases and the use of oxygen supplementation should be 
advocated when either of the potent opioids is used, especially for longer procedures.  
 
Hypopnoea and bradypnoea were only diagnosed in impala but hypoxaemia was present in 
both species after opioid treatment. The effects of etorphine on pulmonary blood pressure, 
and thus on gas exchange, have been documented and seem independent from its effects on 
systemic blood pressure. Mechanisms, like opioid-induced pulmonary hypertension, that 
reduced gas exchange in the lungs could have been involved in causing hypoxaemia in both 
species and warrant further exploration (Heard et al. 1996; Meyer et al. 2006, 2010, 2015; 
Izwan et al., 2018; Buss et al., 2018). 
 
In impala, thiafentanil had a significantly faster induction time which in a field situation, 
allows for easier and faster retrieval. On the downside, thiafentanil in impala caused greater 
cardiorespiratory side effects, including apnoea and hypertension, during the first ten 
minutes, which in some individual impala can be detrimental.  
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In blesbok, there was no difference with regards to the induction time of either drug. In 
contrast to the impala, blesbok did not experience bradypnoea or apnoea with either 
treatment. However, thiafentanil caused less hypoxaemia and respiratory compromise and 
therefore could be considered as the safer drug for short procedures. 
 
Both opioids caused mild to moderate hypertension in both species, but hypertension was 
more severe when thiafentanil was used. Hypertension needs to be considered with regards 
to the use of thiafentanil in cardio-vascularly compromised animals and also with regards to 
the choice of drugs that are to be combined with the potent opioid. 
 
The wide individual variability in physiological responses of impala following opioid-based 
immobilisation has been previously reported and is part of what makes the chemical 
immobilisation of this species so challenging (Meyer et al. 2008a; Zeiler and Meyer 2017a 
and b). Individual variability like this was not observed in blesbok.  
 
In future it would be of importance to investigate species differences as these experiments 
also highlighted that even between similarly sized antelope species, there are clinically 
significant differences with regards to physiological responses to drugs. There are many 
different antelope species and therefore it is highly recommended that blood pressure as well 
as blood gases are recorded during routine management procedures whenever an opportunity 
arises. Data gathered from these activities should be collated and published in journals that 
are easily accessible for the veterinary profession. This research will enable wildlife 
practitioners to make more educated choices in future with regards to the best and more 
species-specific choice of immobilisation drugs. 
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8.1 Conclusion 
8.1.1 The suitability of R-8-OH-DPAT to be used routinely in opioid-based wildlife 
immobilisation 
Based on this thesis, we found that, the serotonin agonist R-8-OH-DPAT had a bioavailability 
of 66% after IM injection in goats. The drug did not negatively affect the quality of etorphine-
based immobilisation of impala or blesbok. Despite these positive properties, R-8-OH-DPAT 
turned out not be a suitable drug for routine use in wildlife immobilisation to combat opioid-
induced respiratory depression. The reason for this is that R-8-OH-DPAT did not show 
sufficient efficacy with any of the dosages tested in blesbok or impala. It was also established 
that the use of higher dosages of R-8-OH-DPAT could lead to serotonin toxicity and put the 
animals at risk. 
 
8.1.2 Differences between the two potent opioids, thiafentanil and etorphine with 
regards to time to recumbence, immobilisation quality and physiological variables, 
during immobilisation of blesbok and impala 
No matter which opioid is used, both cause hypoxaemia to a greater or lesser degree. Oxygen 
supplementation should be considered and further investigated for impala as well as for 
blesbok. 
 
Veterinarians should also be aware that in some species, such as impala, thiafentanil can 
achieve a faster time to recumbence than etorphine. However, this finding cannot be 
extrapolated across all species because in blesbok there was no significant difference between 
both drugs with regards to time to recumbence. In addition, time to recumbence has to be 
weighed against potential negative cardiopulmonary side-effects of the drug. 
 
Finally, our experiments reported that thiafentanil causes more severe hypertension 
compared to etorphine as well as induction apnoea and hypoxia in impala. This was a striking 
discovery and should influence the choice of drugs that veterinarians combine with opioids. 
It should also influence the choice of opioid if an animal might be compromised. In addition, 
the importance of blood pressure monitoring during immobilisation whenever feasible has to 
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be emphasised, especially when animals are immobilised for longer periods of time (> 20 
minutes). The potential for the development of severe hypertension caused by potent opioids 
should be of concern (Hatting 1994 a and b). Severe hypotension leading to the compromise 
of organ perfusion, should be of equal concern (Haskins 2015). Hypotension in white 
rhinoceros (Ceratotherium simum) has been reported by Buss et al. (2016) when azaperone 
was included with the etorphine immobilisation. 
 
This work clearly highlights the differences between both opioids. Veterinarians need to be 
aware of these differences and should not use etorphine and thiafentanil as interchangeable 
immobilisation products for ungulates. This work is a first step towards empowering 
veterinarians to make a scientifically based choice with regards to which opioid should be 
used for a certain species and situation. 
 
8.1.3 Species-specific differences with regards to immobilisation quality and the 
effects of both opioids on respiratory physiology of the two antelope species 
Results of this thesis for the first time clearly highlight that there are distinct species 
differences with regards to physiological effects of opioids during wildlife immobilisation. 
Therefore, one has to be very careful when extrapolating dosages and physiological effects 
from one species to another.  
 
Following results from these experiments, veterinarians should now be aware that 
thiafentanil in some species, such as blesbok, causes less respiratory compromise than 
etorphine. The same however, cannot necessarily be said when thiafentanil is used to 
immobilise impala. 
 
Further, blesbok do not show the same wide variability of physiological responses which can 
be expected when immobilising impala. Therefore, the immobilisation of blesbok is usually 
less eventful and blesbok do not suffer to the same degree of severe respiratory compromise 
as impala. 
 
While blesbok seemed to ventilate adequately, low PaO2 values and elevated A-a gradients 
showed that despite adequate ventilation, these animals were suffering from hypoxaemia, 
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possibly caused by reduced gas exchange. Under normal field immobilisation circumstances, 
this would not be diagnosed and once again highlights the importance of accurate arterial 
blood oxygenation monitoring and oxygen supplementation. 
 
To know species-specific differences will enable veterinarians to be adequately prepared and 
look out for the specific challenges that each species will present during immobilisation. This 
work can serve as a step towards a species-specific approach to immobilisation and 
immobilisation monitoring in order to reduce the risks associated with immobilisation and 
improve animal welfare. 
.  
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